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Mapatumumab kan zonder duidelijke toename van toxiciteit gecombineerd warden met 
gemcitabine en cisplatin-bevattende chemotherapie (dit proefschrift). 
Het toevoegen van de VEGF-receptor tyrosine kinase rem mer tivozanib aan de combinatie van 
FOLFOX (fluorouracil, oxaliplatin en leucovorin) geeft niet meer of ernstiger bijwerkingen dan 
FOLFOX of tivozanib a Ileen (dit proefschrift). 
Het combineren van tivozanib met oxaliplatin en fluorouracil geeft geen farmacokinetische 
interacties tussen deze middelen (dit proefschrift). 
Het is mogelijk tumorlaesies met 1111n-mapatumumab scintigrafie in beeld te brengen; de 
eventuele waarde hiervan voor de patient moet nader warden vastgesteld (dit proefschrift). 
Dezelfde biomarker kan zowel prognostisch als predictief zijn (dit proefschrift). 
Het intranasale Norwalk virus-like particle heeft een beschermende werking tegen de 
ontwikkeling van norovirus gastroenteritis en vaccinatie dient daarom te warden overwogen in 
de populatie met een hoog risico (Atmar et al, N Engl J Med 2011). 
7. Dat gletsjers veel langzamer smelten dan tot recent werd gedacht, betekent nog niet dat de 
achteruitgang in omvang niet dramatisch is (o.a. Jacob et al, Nature 2012). 
8. Gedurende een economische crisis wordt juist het onbetaalbare steeds waardevoller. 
9. Het is per definitie onmogelijk om aan te tonen dat iets niet kan (M. Bulnes). 
10. Bij homeopathische middelen is het geloof erin het enige werkzame bestanddeel {M. Houben). 
11. De eerste regel voor klussers 'bewaar alle onderdelen', is ook zeker van toepassing op het 
schrijven van een proefschrift {S. IJzer). 
12. Voor wie wacht komt alles steeds te laat (The Lau). 
Corina Oldenhuis, 18 april 2012 
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In the past four decades, the mainstay of anticancer treatment has been surgery, 
radiotherapy, and systemic therapy comprising antihormonal treatment, 
immunotherapy, targeted agents and chemotherapy. Despite improvement in these 
treatment modalities, still half of the patients die as a consequence of metastatic 
disease. For patients with metastatic solid tumors in general only systemic therapy 
remains an option. However, a major problem of systemic therapy is that the tumor 
often develops resistance for the applied drugs. 
Chemotherapy-resistant tumor cells, for example, are characterized by an intrinsic or 
acquired incapability of going into apoptosis as a consequence of defects in the 
intrinsic apoptotic pathway. One strategy to overcome this resistance might be 
targeting the extrinsic pathway. This pathway is activated by the endogenously present 
Tumor Necrosis Factor (TNF) Related Apoptosis-lnducing Ligand (TRAIL, or Apo2L). 
TRAIL can bind to five different receptors, but induces apoptosis only after binding to 
its two death receptors, TRAIL-Rl (DR4) and TRAIL-R2 (DRS). The other three 
receptors, TRAIL-R3 (DcRl), TRAIL-R4 (DcR2) and the soluble osteoprotegerin (OPG), 
act as decoys. The finding that TRAIL only induces apoptosis in several tumor cells and 
not in normal cells makes it a potentially attractive anti-cancer compound. A 
recombinant human (rh) form of TRAIL, targeting all TRAIL-Rs, and monoclonal 
antibodies that only target either TRAIL-Rl or TRAIL-R2 were proven safe as single 
agent in phase 1 and phase 2 trials. Moreover, numerous preclinical studies showed 
synergy when combining these TRAIL-receptor targeting agents with chemotherapy. In 
addition, many chemotherapy-resistant cell lines as well as xenograft models could be 
sensitized to chemotherapy by the addition of rhTRAIL or one of the TRAIL-Rl/TRAIL­
R2 antibodies. 
Another potential approach to treat malignancies is blocking angiogenesis, the 
formation of new blood vessels. Tumors require an adequate vascularization for 
obtaining oxygen and nutrients, thereby stimulating tumor growth and the 
development of metastases. An important proangiogenic protein is Vascular 
Endothelial Growth Factor (VEGF), known to be overexpressed by many tumor types. 
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VEGF binding to VEGF-receptors {VEGFR) present on endothelial cells can be prevented 
by drugs blocking VEGF directly or by inhibiting the tyrosine kinase activity of the 
receptors. 
TRAIL-R targeting agents and angiogenesis inhibitors are examples of targeted 
therapies, i.e. drugs acting against a specific tumor cell characteristic. Anticancer 
drugs, and typically targeted therapies, are beneficial in only a subgroup of patients. 
Better upfront patient selection before therapy or early selection of patients during 
treatment is needed to prevent unnecessary toxicity and time loss in non-responders. 
The aim of this thesis is to study the safety, tolerability and pharmacokinetics of novel 
targeted anti-cancer agents and to concurrently develop predictive biomarkers for 
better upfront and early selection of patients. 
Outline of the thesis 
In chapter 2, an overview of the available literature concerning the TRAIL pathway and 
its exploitation for use in the clinic is given. The current knowledge on the physiological 
and pathophysiological role of TRAIL and its receptors is described. Furthermore, 
preclinical and clinical studies with rhTRAIL and TRAIL-R antibodies are reviewed. In 
addition, studies on potential powerful combinations with chemotherapy and other 
targeting agents are highlighted for the chemotherapy-resistant glioblastoma models 
and the combination of rhTRAIL with bortezomib is presented as an interesting 
strategy. 
Chapter 3 focuses on the results of a phase 1 study combining the TRAIL-Rl antibody 
mapatumumab with chemotherapy. We administered escalating doses of 
mapatumumab to patients with advanced solid tumors in combination with standard 
doses gemcitabine and cisplatin. Toxicity and tolerability were closely monitored. In 
addition, pharmacokinetic interactions of the drugs were studied and preliminary hints 
of activity were assessed. 
Drugs solely targeting tumor cells are probably not sufficient to optimally treat 
malignancies. Increasingly, the critical role of the microenvironment in tumor 
development, migration and metastasis is acknowledged. A crucial role in the 
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microenvironment is played by angiogenic factors. Tivozanib is an orally available 
VEGF-Rl, VEGF-R2 and VEGF-R3 tyrosine kinase inhibitor that showed potent 
anticancer activity in vitro and in preclinical in vivo models. Tivozanib appeared to be 
safe as single agent in advanced solid tumor patients and in preclinical models 
synergistic effects were observed when combined with chemotherapy. These data 
have led to the phase 1 study, for which preliminary data are reported in chapter 4. In 
this dose escalation study, tivozanib was combined with the well known regimen for 
gastrointestinal tumors consisting of fluorouracil, oxaliplatin and leucovorin 
(FOLFOX6). Eligible were patients with advanced gastrointestinal malignancies. The 
safety of administering this combination was observed and pharmacokinetic profiles 
were studied. Additional patients at the highest dose level were enrolled to collect 
more robust safety, pharmacokinetic and efficacy data. 
Targeted therapies have in common that they act against a specific feature of tumor 
cells. Tumor heterogeneity is commonly present, even in patients with the same tumor 
type, and the target is not always expressed. It is a major challenge to select patients 
upfront or early during treatment who will benefit from these treatments, while 
correctly withholding it from patients who will not. Identification of, preferably easy 
obtainable, predictive biomarkers might help in this process. This is the focus of the 
second part of this thesis. First, in chapter 5, the confusing terminology of prognostic 
and predictive biomarkers is clarified. In this review examples of strong prognostic and 
predictive markers are provided and the progress in current biomarker development 
is described. Suggestions for future research are done as well. 
Of the common solid tumors, tumorigenesis is best understood for colorectal cancer 
(CRC). Approximately 5-10% of the CRCs are part of the well-characterized hereditary 
forms hereditary nonpolyposis colorectal cancer (HNPCC, or Lynch syndrome) and 
familial adenomatous polyposis (FAP). Since most of these patients develop CRC during 
their life, apart from screening strategies, treatment strategies are sought to prevent 
tumor development. Chemoprevention with non-steroidal anti-inflammatory drugs 
(NSAIDs) reduced the number of polyps in FAP patients, where its role in HNPCC is still 
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under debate. However, the exact mechanisms are incompletely understood. Previous 
studies indicated that NSAIDs seemed to be involved in apoptosis induction as well as 
in inhibition of proliferation. The NSAID sulindac showed in earlier studies upregulation 
of TRAIL-R2 in vitro and downregulation of anti-apoptotic proteins like Bel-XL. 
Furthermore, sulindac was found to be involved in the Wingless-int {Wnt) pathway. 
The Wnt signaling pathway plays an important role in neoplastic transformation of 
colonic epithelial cells. Mutations in the adenomatous polyposis coli (APC) or 6-catenin 
gene lead to accumulation and translocation of �-catenin to the nucleus. This results in 
activation of T-cell factor 4 and subsequently activation of carcinogenic genes. 
Moreover, active Wnt-signaling reduces p21 levels, allowing cells to proliferate instead 
of differentiate. Sulindac metabolites showed to decrease �-catenin expression and to 
induce p21 expression in colon cancer cells. In addition, sulindac induced p21 
expression in a mouse model. To gain further insight in the chemopreventive 
mechanisms of sulindac, we performed a biomarker study. This study is described in 
chapter 6. Biopsies of normal-appearing colonic mucosa obtained in two already 
publised studies in FAP and HNPCC patients before and after sulindac treatment were 
studied for apoptosis and expression of TRAIL-Rl, TRAIL-R2, p21 and �-catenin by 
immunohistochemistry. 
It is unknown if the TRAIL-Rl targeting agent mapatumumab actually reaches the 
tumor cells within a patient's tumor to display its anticancer efficacy. Also the effect of 
chemotherapy on mapatumumab binding to a patient's tumor is not clear, although 
upregulation of TRAIL-Rl after chemotherapy was seen in mice bearing human 
colorectal cancer tumor xenografts. Previously, indium-111 (1111n) radiolabeled 
mapatumumab was developed and prepared for clinical use. The tracer showed 
specific tumor uptake in high TRAIL-Rl expressing human xenografts in mice. In 
chapter 7 we give insight into the tumor uptake, pharmacokinetics and biodistribution 
of 1111n-mapatumumab in patients with advanced solid tumors, treated with 
gemcitabine, cisplatin and mapatumumab. Scans are performed at start of treatment 
13 
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and after 3 cycles of therapy, to elucidate also the effect of treatment on 
mapatumumab tumor uptake. 
The extrinsic apoptotic pathway is activated after ligand binding to TRAIL-Rl and/or 
TRAIL-R2. However, presence of the receptor is not sufficient to predict response to 
TRAIL-R targeting drugs. Mutations in death receptors or changes in expression of pro­
and anti-apoptotic downstream proteins might also play a role in insufficient apoptosis 
induction. Recently, the single nucleotide polymorphism {SNP) A683C in the 
TNFRSFlOA gene, encoding TRAIL-Rl, was identified. Cancer cell lines carrying the 
variant were resistant to TRAIL, in contrast to the wildtype carriers. In chapter 8 we 
analyzed the effect of SNP A683C in germline DNA samples of patients treated with 
gemcitabine, cisplatin and mapatumumab in the two previously performed studies 
described in chapter 3 and chapter 7. For this purpose we performed an analysis of the 
TRAI L-Rl polymorphism A683C in relation to disease outcome and toxicity. 
Finally, in chapter 9, the study results incorporated in this thesis are summarized and 
suggestions are made for future research. 
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Abstract 
The natural occurring tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) 
induces apoptosis following binding to the two TRAIL death receptors (DRs). Its 
recombinant form and monoclonal antibodies against the TRAIL DRs induce cell death 
in a wide variety of tumor cell lines and xenografts without causing toxicity to normal 
cells and are therefore potential attractive anticancer agents. These agents are 
currently in early clinical development. The phase 1 and 2 studies showed until now 
limited toxicity and tumor responses have been observed. Ongoing studies focus 
especially on combination of these agents with other targeted therapies or cytotoxic 
therapies. In this review, we summarize current knowledge on these agents and 
highlight their potential role in the intrinsically chemotherapy-resistant glioblastomas. 
In addition, we discuss the mechanisms to sensitize tumors cells to rhTRAIL by 




A major challenge in oncology remains the destruction of tumor cells while sparing 
normal cells. The natural occurring tumor necrosis factor {TNF) related apoptosis­
inducing ligand {TRAIL or Apo2L) induces apoptosis in a wide variety of tumor cell lines 
without causing toxicity to normal cells. Apoptosis is controlled via two major 
pathways: the intrinsic and extrinsic pathway {Figure 1). TRAIL activates the p53-
independent extrinsic pathway by binding to the death receptors {DRs) 4 {TRAIL-Rl) 
and DRS {TRAIL-R2/KILLER) at the cell surface. This has raised interest in the 
development of TRAIL receptor targeting drugs for anticancer treatment. 
Chemotherapy and radiotherapy initiate apoptosis via the intrinsic pathway. Frequent 
resistance towards these therapies occurs as a consequence of defects in the intrinsic 
pathway, for example, mutations in the tumor suppressor gene p53. Combination with 
agents targeting the TRAIL receptor might circumvent this resistance. 
In this review, we describe recent information on the physiological and 
pathophysiological role of TRAIL and its receptors. We give an update on preclinical 
and clinical oncological studies with the drugs recombinant human {rh) TRAIL and 
agonistic antibodies against the DRs. The potential role of these agents in the 
intrinsically chemotherapy-resistant glioblastomas is highlighted. In addition, we 
provide a scientific basis for the rationale of combining these compounds with other 
targeted therapies or cytotoxic therapies in the treatment of cancer, with specific 
emphasis on the combination of rhTRAIL and the proteasome inhibitor bortezomib. 
TRAIL and its receptors 
TRAIL is a type II transmembrane protein that forms a homotrimer that binds three 
receptor molecules on the surface of target cells. A zinc atom in the trimeric ligand is 
essential for its stability and optimal biological activity (1). The extracellular region of 
TRAIL can be cleaved from the cell surface by a cysteine protease to form a soluble 
ligand (2). Both the membrane-bound and soluble form can induce apoptosis in a wide 
variety of tumor cell lines, but not in most normal cells. TRAIL has five receptors. 
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Ligation of the membrane-bound receptors DR4 and DRS initiates the extrinsic 
apoptotic pathway (Figure 1). TRAIL binding to the two other membrane-bound 
receptors, decoy receptor 1 (DcRl/TRAIL-R3) and decoy receptor 2 (DcR2/TRAIL-R4), 
cannot induce apoptosis because they respectively lack an intracellular death domain 
or have a truncated intracellular death domain. The fifth, soluble receptor 
osteoprotegerin (OPG) inhibits TRAIL, but has a very low affinity for this ligand at 
physiological temperatures. 
Biological role of endogenous TRAIL and death receptors 
TRAIL plays an anti-inflammatory role. Recent data show that endogenous TRAIL 
induces apoptosis in hepatitis C virus infected hepatocytes and endogenous TRAIL 
limits the life span of activated leucocytes in a bacterial meningitis model in wildtype 
mice compared to TRAIL -/- mice (3,4). Moreover, there is growing evidence that TRAIL 
plays a role in autoimmunity. Blocking TRAIL in mice results in the exacerbation of 
experimental autoimmune encephalomyelitis, arthritis, and diabetes. In patients with 
active systemic lupus erythematosus (SLE) T cell membrane expressed TRAIL and 
soluble TRAIL concentrations as well as TRAIL gene expression in peripheral blood 
mononuclear cells are markedly elevated. T cell expressed TRAIL in mice results in 
more CD4+ Th cells that in turn enhances autoreactive B cells and consequently 
exacerbates SLE (5). Antitumor surveillance is another important property of TRAIL and 
its receptors (reviewed in (6)). TRAIL-receptor deficiency in mice promotes primary 
tumor development and results in the faster formation of lymph node metastases 
without the growth of the primary tumor (7,8*). 
Prosurvival role of TRAIL 
Recently, several studies indicated that there is also a prosurvival role for the TRAIL­
signaling pathway in normal as well as in tumor cells (2). In preclinical models, primary 
and secondary resistance to rhTRAIL-induced apoptosis does occur. In these cases, 
stimulation of the DRs results in alternative signaling with ultimate activation and 
nuclear translocation of NF-KB. This translocation leads to the activation of prosurvival 
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Figure 1. Intrinsic and extrinsic apoptotic pathway. 
Upon TRAIL homotrimer binding, the activated death receptors trimerize and recruit Fas-associated death 
domain (FADD) and the initiator caspase-8. In this death-inducing signaling complex (DISC), caspase-8 is 
autoactivated by proteolysis and released into the cytosol. This leads to activation of caspase-3 and 
subsequently apoptosis. FLICE-like inhibitory protein (FLIP) can block this activation. TRAIL can also trigger 
the intrinsic pathway through caspase-8-mediated cleavage of Bid. Cleaved Bid induces translocation of Bax 
and/or Bak into the mitochondria leading to cytosolic release of cytochrome c and SMAC/Diablo. 
Cytochrome c binds the adaptor proteins Apaf-1 and pro-caspase-9, consequently forming an apoptosome 
which activates caspase-9. This caspase activates caspase-3 resulting in apoptosis. Bcl-2 and Bel-XL can 
inhibit apoptosis by preventing cytochrome c release into the cytosol. The inhibitor of apoptosis proteins 
(IAPs) blocks caspase activation further downstream. SMAC/Diablo displaces these IAPs, thus promoting 
apoptosis. The intrinsic pathway can also be triggered after DNA-damage by chemotherapy or radiotherapy. 
19 
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and antiapoptotic genes. Human pancreatic cancer cells transplanted in severe 
combined immunodeficiency {SCID) mice showed a striking increase in volume and 
number of metastases after rhTRAIL treatment {9*). In addition, rhTRAIL induced cell 
proliferation in cultured small cell lung cancer cells {10). These data reflect a potential 
back side of TRAIL-receptor targeting agents as anticancer treatment. 
Antitumor effect of rhTRAIL and anti-DR4/anti-DRS antibodies 
Administration of rhTRAIL induces increased apoptosis in many cancer cell lines as well 
as in the inhibition of human tumor xenografts in mice. Moreover, rhTRAIL is nontoxic 
in nonhuman primates. RhTRAIL combined with chemotherapy, targeted therapies, or 
radiotherapy results in a synergistic antitumor effect and even restores sensitivity to 
other treatment modalities in resistant human tumor cells as well as mouse xenograft 
models. Next to rhTRAIL, several antibodies against the DRs are developed. While 
rhTRAIL binds all TRAIL receptors, the anti-DR4/anti-DRS antibodies selectively activate 
a specific DR. In addition, the serum half-life of rhTRAIL is, at 25 minutes in 
chimpanzees, much shorter than that of the DR-targeting monoclonal antibodies, 
which is around two weeks {11). Therefore, the antibodies have more favourable 
profiles. The preclinical tumoricidal effects seen with these antibodies in tumor cell 
lines and xenograft models are similar to that observed with rhTRAIL and are also 
potentiated when combined with other anticancer therapies {6,12). 
To select patients who might benefit from selected therapies, it would be very helpful 
to have predictive biomarkers. The 0-glycosylation status of DRs might be of interest. 
0-linked glycans regulate biochemical and functional properties of cell surface 
proteins, including apoptosis. 0-glycosyltransferase mRNA levels correlate with 
sensitivity for rhTRAIL in several tumor cell lines. Glycosylation of DRs results in 
increased TRAIL-induced clustering of DRs and consequently enhances caspase 8 
activation and apoptosis {13). However, apart from post-translational modifications in 




The prognostic value of DR expression was addressed in a study concerning 376 stage 
Ill colorectal cancer patients. As part of a randomized trial, these patients adjuvantly 
received chemotherapy. High DR4 expression was associated with a worse prognosis, 
with a worse disease-free as well as overall survival (15). 
Ongoing preclinical exploration: rhTRAIL in malignant gliomas 
Malignant gliomas are rapidly progressive brain tumors. Concomitant and adjuvant 
chemoradiotherapy with temozolomide has become the standard treatment for newly 
diagnosed glioblastoma resulting in significant, but moderate prolongation of survival. 
Treatment is still rarely curative and the prognosis of these patients remains dismal 
with a two-year overall survival of 27% (16). In recent years, research focused on the 
elucidation of molecular mechanisms underlying glioma development. Mounting 
evidence, suggesting a role for dysregulation of the apoptotic pathway, has therefore 
stimulated studies targeting the apoptotic pathway in this setting (17). Preclinical 
studies with rhTRAIL show induction of apoptosis in glioma cells (18). Efficient 
transfection of glioblastoma multiforme (GBM) cells with TRAIL-expressing adenovirus 
results in enhanced cell kill (19). However, resistance toward rhTRAIL-induced cell 
death is commonly observed in malignant glioma cell lines. To overcome this 
resistance, rhTRAIL has been combined with various cytotoxic chemotherapeutics and 
new biological agents. 5-Fluorouracil in combination with rhTRAIL in human 
glioblastoma xenograft bearing mice enhanced tumor apoptosis and resulted in a 
prolonged tumor growth delay (20). Moreover, the combination of temozolomide and 
rhTRAIL results in longer survival in a glioblastoma xenograft model than either agent 
alone (21). Several new biologicals might be potentially interesting to combine with 
TRAIL receptor targeting agents. These include heat shock protein inhibitors (HSPis) 
and histone deacetylase inhibitors (HDACis). HSPs are chaperone proteins that play a 
role in the regulation of cell growth through different client proteins and thereby have 
antiapoptotic properties. Downregulation of HSP90 by short-interfering RNA inhibits 
the recruitment of FLICE-like inhibitory protein (FLIP) and other antiapoptotic proteins 
to the death-inducing signaling complex (DISC), thereby sensitizing resistant glioma 
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cells to rhTRAIL-induced apoptosis (22*). HDACi induce apoptosis, tumor cell growth 
arrest, and differentiation. The HDACi vorinostat inhibits growth of GBM intracranially 
in mice and is currently evaluated in patients with recurrent GBM in a phase II study 
(23). Synergistic tumor cell death has been observed in a variety of other human 
cancer cell lines exposed to both rhTRAIL and HDACi (24). The combination of rhTRAIL 
with bortezomib is discussed below. It would be of interest to evaluate the 
combination of these targeted therapies in patients. 
Combinatorial TRAIL-receptor directed therapy with bortezomib 
Various antitumor agents have been combined with TRAIL to study their sensitizing 
effects. In particular, combinations with proteasome inhibitors have recently gained 
substantial interest. The first proteasome inhibitor to be granted approval was 
bortezomib, a selective and reversible inhibitor of the proteasomal degradation of 
proteins. 
The combination of rhTRAIL and bortezomib, has been studied in different cancer cell 
lines, such as non-small cell lung cancer (NSCLC), malignant glioma, hepatocellular 
carcinoma, colon, and pancreatic cancer (25-28). In many rhTRAIL-resistant cancer cell 
lines, bortezomib is able to sensitize these cells to rhTRAIL-induced apoptosis. 
Combined exposure to rhTRAIL and bortezomib results in the activation of caspase-8 
and caspase-3. Also caspase-9 can be activated indicating cross-talk between the 
extrinsic and intrinsic pathway (Figure 1) (26-28). Bortezomib enhances cell surface 
expression of DR4 and especially DRS (25-29). However, this mechanism can only 
partly explain the observed rhTRAIL sensitization (25-27). Sensitized tumor cells 
demonstrated stronger DISC formation upon rhTRAIL incubation, with increased Fas­
associated death domain (FADD) and caspase-8 recruitment (26). The effect of 
bortezomib on FLI P  levels, however, remains controversial. Some studies report no 




As stated before, rhTRAIL can activate the NF-KB survival pathway, which then 
contributes to rhTRAIL resistance. Bortezomib co-incubation is able to effectively 
inhibit TRAIL-induced NF-KB activation, thereby blocking this survival route (28} .  
No toxicity for either single agent rhTRAIL or bortezomib was found in primary human 
hepatocytes (PHHs), although combined administration results in some TRAIL-induced 
apoptosis in these cells. However, bortezomib and rhTRAIL induced apoptosis in 
hepatoma, colon and pancreatic cancer cell lines occurs at a more than 40-fold lower 
bortezomib concentration (25 nM} than in PHHs. This suggests a therapeutic window 
for combination therapy with bortezomib and rhTRAIL (26}. 
Next to rhTRAIL, agonistic DR antibodies are also studied in combination with 
bortezomib. These combinations enhance both the extrinsic and intrinsic pathways in 
non-Hodgkin's lymphoma (NHL} cell lines (29}. In mice bearing human lymphoma cell 
line xenografts, the combination of bortezomib and either DR-antibody shows a 
greater clearance of lymphoma cells from ascites and a trend to prolonged time until 
recurrence of lymphoma cells, indicating enhanced tumor cell death with the 
combination therapy (29}. Currently a phase 2 study is ongoing, combining the DR4 
antibody mapatumumab with bortezomib in multiple myeloma patients. 
Clinical application of rhTRAIL and anti-DR4/anti-DRS monoclonal antibodies 
RhTRAIL and several anti-DR4/anti-DR5 monoclonal antibodies have been evaluated in 
several clinical trials (Table 1). In phase 1 and 2 studies patients received rhTRAIL doses 
up to 15 mg/kg intravenous (i.v.) for five consecutive days. Preliminary results showed 
that rhTRAIL appeared to be well tolerated. The serum half-life is approximately 36 
min at 8 mg/kg. One partial response was seen in a patient with a chondrosarcoma. (R 
Herbst, abstract in J Clin Onco/ 2006, 24:3013}. In a phase lb study evaluating the 
safety of rituximab in combination with rhTRAIL in patients with NHL, three of five 
evaluable patients showed responses without apparent toxicity (L Yee, abstract in J 
Clin Oncol 2007, 25:8078). This combination is now further explored in a phase 2 study. 
At present, six agonistic monoclonal antibodies against the DRs are evaluated in clinical 
trials. Mapatumumab is the only one that specifically binds to DR4. In a phase 1 study 
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with this agent 49 patients received doses up to 10 mg/kg i.v. every two weeks. No 
significant toxicity was seen and the maximum tolerated dose has not been reached. 
However, the highest dose studied at present is far above the predicted effective dose 
of 6 mg/kg, on the basis of preclinical models. The mean terminal elimination half-life 
is 18.8 days, which make dosing every three weeks feasible (30*}. 
Subsequently, three phase 2 studies were initiated in patients with NHL, colorectal 
cancer, and advanced NSCLC. Among the 40 NHL patients, 1 complete and 2 partial 
responses were observed (A Younes et al., abstract 409, 47th ASH Annual Meeting, 
Atlanta, December 2005). In the NSCLC study 32, most heavily pretreated patients 
were enrolled at 10 mg/kg every 3 weeks. No responses were seen, however, up to 
29% had stable disease for on average 2.3 months (31}. Mapatumumab in combination 
with paclitaxel and carboplatin was considered safe in a phase lb study. 4/28 patients 
experienced a confirmed partial response, including 3 patients with NSCLC (L Chow, 
abstract in J Clin Oncol 2006, 24:2515). A phase 2 study with this combination in NSCLC 
patients has been initiated. In a phase lb study, mapatumumab could be administered 
safely up to 30 mg/kg every three weeks in combination with gemcitabine and 
cisplatin. No alterations in the pharmacokinetic profiles were observed. 11/45 patients 
experienced a partial response and 13/45 patients achieved stable disease more than 
18 weeks. (Oldenhuis et al., abstract 3540, 44th ASCO Annual Meeting, Chicago, June 
2008} 
One of the DRS-targeting antibodies, lexatumumab, was found to be safe and well 
tolerated at the maximum tolerated dose of 10 mg/kg. The average serum half-life in 
this study was 16.4 days. The best observed response was stable disease in 12 out of 
37 patients treated with a median duration of 4.5 months (32). Lexatumumab has also 
been evaluated in combination with several chemotherapy regimens. Reports of the 
other anti-DR agents summarized in table 1 are awaited. 
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Table 1. Overview of TRAIL receptor targeting agents in clinical evaluation. 
Agent (target) Clinical Combination 
development 



































































CRC: colorectal cancer; NHL: non-Hodgkin's lymphoma; NSCLC: non-small cell lung cancer; FOLFIRI :  
leucovorin, fluorouracil and irinotecan; FOLFOX: leucovorin,fluorouracil and oxaliplatin. 
(www.hgsi.com/hgs-etrl.html; www.clinicaltrials.gov; www.amgen.com/science/pipe.jsp; 
www.novartisoncology.com/research-innovation/pipeline.jsp) 
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Conclusions 
Interests in TRAIL, boosted by its unique property to selectively induce apoptosis in 
tumor cells, have resulted in the first clinical application of TRAIL-receptor targeting 
agents in the past years. Concerns about liver toxicity and autoimmune phenomena 
have been so far abrogated by clinical trials. Both rhTRAIL and TRAIL-receptor 
antibodies appear to be safe. Single agent response rates, however, are low. TRAIL­
receptor targeting agents do not appear to be potent enough and might need 
sensitizing agents to induce tumor cell apoptosis. TRAIL-receptor targeting agents are 
now being studied in combination with sensitizing cytotoxic therapies and other 
targeted therapies. Although combination of radiotherapy with DR-targeting 
antibodies have shown synergistic antitumor effects in xenograft mice, no clinical 
studies with this combination have been initiated till date (12). 
Little knowledge is available concerning the biodistribution of the TRAIL-receptor­
targeting agents in man and it is therefore not clear if these agents penetrate the 
tumor. In an attempt to visualize the tumor, a SPECT imaging study with the 
radioactively labeled DR4 antibody mapatumumab has commenced. 
Overall, however, future research will focus on combination strategies. Furthermore, 
incorporation of potential predictive biomarker analyses into clinical trials is needed. 
Together, this could guide patient-tailored therapy. 
Conflict of interest statement 
CNAM Oldenhuis and EGE de Vries performed a study with mapatumumab {Human 
Genome Sciences) and performed a study with LBY135 (Novartis). The University 
Medical Center Groningen receives the study drugs and financial support to perform 
the studies. 
Acknowledgment 
This research is supported by Grant 2006-3567 of the Dutch Cancer Society. 
26 
References and recommended reading 
Papers of particular interest have been highlighted as: 
* of special interest 
Chapter 2 
1 .  Hymowitz SG, O'Connell MP, Ultsch MH, Hurst A,  Totpal K,  Ashkenazi A,  de Vos AM, Kelley RF: A 
unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric 
Apo2L/TRAIL. Biochemistry 2000, 39:633-640. 
2. Malhi H, Gores GJ: TRAIL resistance results in cancer progression: a TRAIL to perdition? Oncogene 
2006, 25:7333-7335. 
3. Hoffmann 0, Priller J, Prozorovski T, Schulze-Topphoff U, Baeva N, Lunemann JD, Aktas 0, 
Mahrhofer C, Stricker S, Zipp F, Weber JR: TRAIL limits excessive host immune responses in 
bacterial meningitis. J.Clin.lnvest 2007, 117:2004-2013. 
4. Zhu H, Dong H, Eksioglu E, Hemming A, Cao M, Crawford JM, Nelson DR, Liu C: Hepatitis C virus 
triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. 
Gastroenterology 2007, 133:1649-1659. 
5. Rus V, Nguyen V, Puliaev R, Puliaeva I, Zernetkina V, Luzina I, Papadimitriou JC, Via CS: T cell TRA IL  
promotes murine lupus by  sustaining effector CD4 Th cell numbers and by  inhibiting CD8 CTL 
activity. J.lmmunol. 2007, 178:3962-3972. 
6. Duiker EW, Mom CH, de Jong S, Willemse PH, Gietema JA, van der Zee AG, de Vries EG: The 
clinical trail of TRAIL. Eur J.Cancer 2006, 42:2233-2240. 
7. Finnberg N, Klein-Szanto AJ, EI-Deiry WS: TRAIL-R deficiency in mice promotes susceptibility to 
chronic inflammation and tumorigenesis. J.Clin.lnvest 2008, 118:111-123. 
*8. Grosse-Wilde A, Voloshanenko 0, Bailey SL, Longton GM, Schaefer U, Csernok Al, Schutz G, 
Greiner EF, Kemp 0, Walczak H:  TRAIL-R deficiency in mice enhances lymph node metastasis 
without affecting primary tumor development. J.Clin.lnvest 2008, 118:100-110. 
The authors generated TRAIL-receptor deficient mice and subsequently initiated skin tumors. The 
number, rate of appearance and malignant transformation rate of benign papilloma did not differ 
between TRAIL-R-/- mice compared to TRAIL-R+/- and TRAIL-R+/+ mice. However TRAIL-R -/- mice 
developed earlier and significant more lymph node metastases, suggesting a protective role for 
the TRAIL-R in mice. 
*9. Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, Zorenkov D, Emme D, Roder C, Kalthoff 
H, Wajant H: TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 
2006, 25:7434-7439. 
In this paper, the authors inoculated SCIO mice with human pancreatic cancer cells overexpressing 
Bel-XL, thereby inhibiting TRAIL-induced apoptosis. Upon rhTRAIL treatment a 5.8-fold increase in 
the tumor volume and a significant increase in the number of liver metastases were found 
compared to saline-treated mice. 
10. Belyanskaya LL, Ziogas A, Hopkins-Donaldson S, Kurtz S, Simon HU, Stahel R, Zangemeister-Wittke 
U: TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on 
TRAIL-R2/DR5 expression in the absence of caspase-8. Lung Cancer 2008, 60:355-365 
11. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA: Preclinical studies to predict the 
disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: 
characterization of in vivo efficacy, pharmacokinetics, and safety. J.Pharmacol.Exp.Ther. 2001, 
299:31-38. 
12. Marini P, Denzinger S, Schiller D, Kauder S, Welz S, Humphreys R, Daniel PT, Jendrossek V, Budach 
W, Belka C: Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies 
HGS-ETRl and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth 
delay in vivo. Oncogene 2006, 25:5145-5154. 
13. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, van Goetz M, 
Yee SF, Totpal K, et al.: Death-receptor O-glycosylation controls tumor-cell sensitivity to the 
proapoptotic ligand Apo2L/TRAIL. Nat.Med. 2007, 13:1070-1077. 
14. Carlo-Stella C, Lavazza C, Locatelli A, Vigano L, Gianni AM, Gianni L: Targeting TRAIL agonistic 
receptors for cancer therapy. Clin.Cancer Res. 2007, 13:2313-2317. 
27 
Targeting TRAIL death receptors 
15. Van Geelen CM, Westra JL, de Vries EG, Boersma-van EW, Zwart N, Hollema H, Boezen HM, 
Mulder NH, Plukker JT, de Jong S, et al.: Prognostic significance of tumor necrosis factor-related 
apoptosis-inducing ligand and its receptors in adjuvantly treated stage I l l  colon cancer patients. 
J.Clin.Oncol. 2006, 24:4998-5004. 
16. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, 
Marosi C, Bogdahn U, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for 
glioblastoma. N.Engl.J.Med. 2005, 352:987-996. 
17. Lefranc F, Brotchi J, Kiss R: Possible future issues in the treatment of glioblastomas: special 
emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. 
J.Clin.Oncol. 2005, 23:2411-2422. 
18. Hao C, Beguinot F, Condorelli G, Trencia A, Van Meir EG, Yong VW, Parney IF, Roa WH, Petruk KC: 
Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res. 2001, 61:1162-1170. 
19. Wohlfahrt ME, Beard BC, Lieber A, Kiem HP: A capsid-modified, conditionally replicating oncolytic 
adenovirus vector expressing TRAIL leads to enhanced cancer cell killing in human glioblastoma 
models. Cancer Res. 2007, 67:8783-8790. 
20. Lee KC, Hamstra DA, Bhojani MS, Khan AP, Ross BD, Rehemtulla A: Noninvasive molecular imaging 
sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy. 
Clin.Cancer Res. 2007, 13:1839-1846. 
21. Saito R, Bringas JR, Panner A, Tamas M, Pieper RO, Berger MS, Bankiewicz KS: Convection­
enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic 
administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft 
model. Cancer Res. 2004, 64:6858-6862. 
*22. Panner A, Murray JC, Berger MS, Pieper RO: Heat shock protein 90alpha recruits FLIPS to the 
death inducing signaling complex and contributes to TRAIL resistance in human glioma. Cancer 
Res. 2007, 67:9482-9489. 
The authors show that high levels of the antiapoptotic protein FLIP alone are not sufficient enough 
to inhibit apoptosis. HSP90a is needed to serve as chaperone protein by recruiting FLIP to the DISC 
and inhibiting apoptosis in human glioma cells. 
23. Yin D, Ong JM, Hu J, Desmond JC, Kawamata N, Kanda BM, Black KL, Koeffler HP: Suberoylanilide 
hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma 
cells in vitro and in vivo. Clin.Cancer Res. 2007, 13:1045-1052. 
24. Fulda S: Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr.Cancer Drug Targets. 
2008, 8:132-140. 
25. Koschny R, Holland H, Sykora J, Haas TL, Sprick MR, Ganten TM, Krupp W, Bauer M, Ahnert P, 
Meixensberger J, Walczak H: Bortezomib sensitizes primary human astrocytoma cells of WHO 
grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. 
Clin.Cancer Res. 2007, 13:3403-3412. 
26. Koschny R, Ganten TM, Sykora J, Haas TL, Sprick MR, Kolb A, Stremmel W, Walczak H: 
TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis 
within a therapeutic window. Hepatology. 2007, 45:649-658. 
27. Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, Sun SY: The proteasome inhibitor PS-341 
(bortezomib) upregulates DRS expression leading to induction of apoptosis and enhancement of 
TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC 
cells. Cancer Res. 2007, 67:4981-4988. bb 
28. Voortman J, Resende TP, Abou El Hassan MA, Giaccone G, Kruyt FA: TRAIL therapy in non-small 
cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor 
bortezomib. Mal.Cancer Ther. 2007, 6:2103-2112. 
29. Smith MR, Jin F, Joshi I: Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced 
by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL­
Rl and TRAIL-R2. Clin.Cancer Res. 2007, 13:5528s-5534s. 
*30. Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, Hill M, Mays T, McCoy T, 
Fox NL, et al.: Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully 
human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis­
inducing ligand receptor-1. J.Clin.Oncol. 2007, 25:1390-1395. 
28 
Chapter 2 
A phase 1 dose escalation study was performed with a fully human monoclonal antibody targeting 
DR4. Initially, patients received a single dose. After the confirmation of safety, dose and frequency 
of administration were carefully increased to 10 mg/kg every 14 days. Most common and mild 
adverse events were fatigue, fever, and myalgia. The authors showed that this antibody could be 
administered safely up to 10 mg/kg i. v. every two weeks. 
31. Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G, Klein J :  Phase 2 study of 
mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the 
TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008, 61:82-
90. 
32. Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, Barrett M, Judson I, Kaye S, Fox NL, et al.: 
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. 
Clin.Cancer Res. 2007, 13:6187-6194. 
29 
Targeting TRAIL death receptors 
30 
CHAPTER 3 
Mapatumumab, a fully human agonistic monoclonal 
antibody that targets TRAIL-Rl, in combination with 
gemcitabine and cisplatin: a phase I study 
CH Mom 1, J Verwei/, CNAM Oldenhuis1, JA Gietema1, NL Fox3, R Miceli3, FALM Eskens2, 
WJ Loos2, EGE de Vries1, S Sleijfer2 • 
1Department of Medical Oncology, University Medical Center Groningen, The 
Netherlands; 2Department of Medical Oncology, Erasmus University Medical Center 
Rotterdam, The Netherlands; 3Human Genome Sciences, Rockville, MD, USA. 
Clinical Cancer Research. 2009;15:5584-90. 
Note: Presented in part at the AACR-NCI-EORTC International Conference on Molecular 
Targets and Cancer Therapeutics, Philadelphia, PA, Nov 14-18, 2005; EORTC-NCI-AACR 
International Conference on Molecular Targets and Cancer Therapeutics, Prague, 
Czech Republic, Nov 7-10, 2006; and the 44th Annual Meeting of the American Society 
of Clinical Oncology, Chicago, IL, May 30- June 3, 2008. 
Mapatumumab, gemcitabine and cisplatin: a phase I study 
Abstract 
Purpose: To evaluate the safety, tolerability, pharmacokinetics and antitumor activity 
of mapatumumab, a fully human monoclonal antibody targeting tumor necrosis factor­
related apoptosis-inducing ligand receptor 1 (TRAIL-Rl), in combination with 
gemcitabine and cisplatin. 
Experimental design: Patients with advanced solid tumors received gemcitabine 1250 
mg/m2 i.v. on days 1 and 8, and cisplatin 80 mg/m2 i.v. on day 1 of each 21-day cycle. 
Escalating mapatumumab doses were administered i.v. every 21 days. Toxicity was 
evaluated and pharmacokinetic analysis of plasma mapatumumab, gemcitabine, 2-
difluoro-2-deoxyuridine, unbound and total platinum was performed. TRAIL-Rl tumor 
expression was determined immunohistochemically. 
Results: 49 patients received mapatumumab (1 mg/kg (n=4), 3 mg/kg (n=7), 10 mg/kg 
(n=12), 20 mg/kg (n=13) or 30 mg/kg (n=13)). A median of 6 cycles (range 1-48) was 
administered. The adverse events most commonly observed reflect the toxicity profile 
of gemcitabine and cisplatin. Dose-limiting toxicities (DLT) were seen in 3/12 patients 
at 10 mg/kg, consisting of grade 3 transaminitis, neutropenic fever and grade 4 
thrombocytopenia. At 20 mg/kg 2/12 patients had Dl Ts, including grade 4 
thrombocytopenia and grade 4 fatigue. The maximum tolerated dose was not reached. 
Pharmacokinetic interactions have not been observed. 12 patients had a partial 
response, and 25 patients showed stable disease with a median duration of 6 months. 
Conclusions: Mapatumumab in combination with gemcitabine and cisplatin is safe and 





The Tumor Necrosis Factor (TNF)-related Apoptosis-lnducing Ligand (TRAIL) pathway is 
an attractive target for antitumor therapy, since activation of death receptors on the 
cell surface results in stimulation of the intracellular signaling routes leading to 
apoptosis. The naturally occurring ligand TRAIL is a member of the TNF superfamily 
which can bind to 5 different receptors, including TRAIL receptors 1 {TRAIL-Rl, DR4) 
and 2 (TRAIL-R2, DRS), through which TRAIL transmits its apoptotic signal (1,2). For yet 
unknown reasons TRAIL, in preclinical models, selectively induces apoptosis in tumor 
cells without toxic effects on normal cells. 
Mapatumumab (TRM-1, ETRl) is a fully human immunoglobulin Gl lambda {lgGlA) 
agonistic monoclonal antibody to TRAIL-Rl competing with TRAIL for binding to TRAIL­
Rl. Single agent mapatumumab induces apoptosis in a range of cancer cell lines and 
inhibits tumor growth in various human tumor mouse xenograft models (3). Expression 
of TRAIL-Rl is frequently observed in human tumors, including pancreatic, ovarian, 
colorectal, gastric, uterine, lung and breast carcinomas (4). 
In two phase I studies in patients with solid tumors, single agent mapatumumab was 
well tolerated and adverse events were generally mild to moderate in severity (5;6). 
The maximum tolerated dose (MTD) in these studies was not reached with 10 mg/kg 
every 14 days {6) and 20 mg/kg every 28 days (5). Pharmacokinetic (PK) results showed 
a mean terminal elimination half-life of 18-21 days. Additionally, in phase II studies 
with mapatumumab in patients with non-small cell lung cancer (NSCLC), colorectal 
cancer (CRC) and non-Hodgkin's lymphoma (NHL), a similar toxicity profile was 
observed (7-9). In the NSCLC and CRC studies, stable disease was the best observed 
response in 30% of the patients. Three patients with follicular lymphoma experienced 
a tumor response. 
Combination therapy may synergistically enhance antitumor activity because 
mapatumumab induces apoptosis via the extrinsic pathway, while chemotherapy 
results in cell death by activating the intrinsic pathway. Accordingly, the addition of 
mapatumumab to gemcitabine or cisplatin resulted in increased cytotoxicity in various 
human tumor cell lines. Furthermore, in a human NSCLC (H460) xenograft model, 
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combining cisplatin and mapatumumab showed increased tumor growth inhibition 
compared to either agent alone (10). We therefore performed a phase I study to 
evaluate the safety and tolerability of escalating doses of mapatumumab in 
combination with gemcitabine and cisplatin in patients with solid tumors. Secondary 
objectives were to determine plasma mapatumumab concentrations, to assess the 
influence of mapatumumab on plasma gemcitabine and cisplatin PK, to evaluate 
disease response and to assess TRAIL-Rl expression in tumors of participating patients. 
Patients and methods 
Eligibility criteria 
Eligible for the study were patients with a histologically or cytologically confirmed 
advanced solid malignancy for whom no standard therapy options were available or 
for whom the combination of gemcitabine and cisplatin was considered an appropriate 
treatment. Additional eligibility criteria included: age � 18 years; Eastern Cooperative 
Oncology Group (ECOG) performance status O or 1; estimated life expectancy � 3 
months; adequate bone marrow and renal function, AST and ALT =:; 2.5 fold upper limit 
of normal (ULN); no previous chemotherapy, immunotherapy, radiotherapy or 
hormonal therapy within 3 weeks; no treatment with monoclonal antibodies within 
previous 3 weeks (murine or chimeric) or 8 weeks (human or humanized); no 
investigational agents within 4 weeks. Specific exclusion criteria included: known 
positive human immunodeficiency virus status; known chronic or acute viral hepatitis; 
clinical signs of brain metastases; hearing loss requiring the use of a hearing aid; 
neuropathy grade � 2; myocardial infarction, cerebrovascular accident or � NYHA Class 
Ill congestive heart failure within 6 months prior to study entry. 
The study was approved by the local Ethics Committees and the competent regulatory 




A cycle was defined as 21 days. Mapatumumab was administered at escalating dose 
levels (1, 3, 10, 20 and 30 mg/kg). At each dose level 3-4 patients were enrolled 
initially. Patients were considered to be evaluable for toxicity if they had completed 
one full cycle. Dose escalation decisions were made based on the safety assessments 
of all patients in the dose cohort using the National Cancer Institute Common Toxicity 
Criteria for Adverse Events (NCI-CTCAE) version 3.0. Dose escalation was considered if 
< 33% of the patients experienced dose-limiting toxicity (DLT). If one of 3-4 patients 
experienced a DL T, the dose level was expanded to a total of 6 evaluable patients. If a 
DL T was observed in � 2 out of 6 patients in a cohort the maximum tolerated dose 
(MTD) was exceeded. To further characterize safety at a certain dose level, up to 12 
additional patients could be included. 
By the initial DLT criteria, electrolyte disturbances secondary to inadequate antiemetic 
therapy and chemotherapy-induced transient liver enzyme elevations were considered 
dose-limiting. The protocol was amended after inclusion of the 5th patient in the 10 
mg/kg cohort in order to consider only those events as DLTs that were at least possibly 
related to mapatumumab or to its interaction with gemcitabine and/or cisplatin. Dl Ts 
were thereafter defined as: grade 4 neutropenia lasting > 7 days, febrile neutropenia, 
grade 4 thrombocytopenia; and grade 3 or 4 non-hematologic adverse events, with the 
following qualifications: grade � 3 transaminase elevations that did not resolve to s 
grade 1 before cycle 2, grade � 3 nausea and vomiting despite optimal antiemetic 
treatment, persistent grade � 2 neuropathy, serum creatinine � 2 times ULN, and 
grade 4 fatigue. Electrolyte disturbances due to inadequately treated vomiting were 
not considered dose-limiting if this had resolved prior to cycle 2. All Dl Ts described in 
this article are Dl Ts according to the amended protocol. 
Patients could receive a maximum of 6 chemotherapy cycles. Thereafter, in the 
absence of disease progression, mapatumumab monotherapy could be continued. 
Patients were withdrawn from the study in case of disease progression, unacceptable 
toxicity or refusal of treatment. 
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Drug administration 
Mapatumumab {Human Genome Sciences Inc, Rockville, MD) was administered i.v. in 
250 ml 0.9% saline over 2 hours on day 2 of cycle 1 and on day 1 of cycles 2-6 after 
gemcitabine and cisplatin administration. 
Gemcitabine {Eli Lilly, Indianapolis, IN) 1250 mg/m2 was administered i.v. over 30 
minutes on days 1 and 8 of each cycle. Cisplatin {Pharmachemie, Haarlem, The 
Netherlands) 80 mg/m2 in 1000 ml of 0.9% saline was infused i.v. over 3 hours 
following gemcitabine on day 1 of each cycle. 
No dose modifications were allowed for mapatumumab. Chemotherapy doses were 
reduced for severe side effects considered to be at least possibly related to 
chemotherapy or for the patient's safety in the opinion of the investigator. At the 
beginning of each cycle the absolute neutrophil count {ANC) had to be � 1,500/µl and 
platelets � 100,000/µL. Treatment could be delayed up to 2 weeks for hematologic 
recovery. Chemotherapy doses were reduced when treatment was delayed for > 1 
week. The day 8 gemcitabine was omitted in case of ANC < 1,000/µl and platelets < 
75,000/µL. 
Pretreatment and follow-up studies 
Prior to therapy a complete medical history, physical examination, 
electrocardiography, chest X-ray, laboratory evaluations {including blood chemistry, 
hematology, and urinalysis), and CT scan or MRI for disease assessment were 
performed. Vital signs were taken prior to administration of the study agents, every 30 
minutes during mapatumumab administration and 1, 2, 3 and 4 hours following 
completion of mapatumumab. Patients were evaluated for toxicity and laboratory 
values before the start of every cycle, on days 5 ± 1, 8, 11 ± 1 and 15 of each cycle and 
on days 2 and 3 of cycle 1. Response was assessed after every 2 cycles by Response 
Evaluation Criteria in Solid Tumors {11). If patients continued on mapatumumab 
monotherapy, tumor evaluations were performed every 3 cycles. 
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Pharmacokinetics and immunogenicity 
Serial blood samples for plasma gemcitabine, cisplatin and mapatumumab 
concentration measurements were collected prior to dosing and over a 26 hour period 
following the start of the infusion of the respective agents in cycles 1 and 2. In 
addition, mapatumumab samples were collected on day 15 of cycle 2, days 1 and 15 of 
cycle 4 and 6, day 15 and 29 of the final cycle, and during mapatumumab monotherapy 
prior to dosing every third cycle. Serum samples for immunogenicity were also 
collected prior to each cycle to determine plasma mapatumumab concentrations and 
anti-mapatumumab antibodies (6). 
Plasma concentrations of gemcitabine and its inactive metabolite 2-difluoro-2-
deoxyuridine (dFdU) were measured using a validated HPLC with diode array 
detection, and analysis of unbound platinum and total platinum were performed using 
an atomic absorption spectrophotometer (12). To determine PK parameters, plasma 
concentrations of gemcitabine, dFdU, cisplatin-derived unbound and total platinum 
were subjected to non-compartmental analysis with WinNonlin Enterprise, version 
5.0.1 (Pharsight Corporation, Cary, NC) using nominal dose and actual times postdose 
according to standard methods (13). Differences in PK parameters between cycle 1 
(prior to mapatumumab treatment) and cycle 2 (with mapatumumab treatment) were 
assessed by a 95% Cl for each cohort. Plasma mapatumumab concentration results 
were compared to a predicted range of concentrations based on phase 1 study results 
in subjects with solid tumors who received mapatumumab as a monotherapy (5, 6). 
lmmunohistochemical staining of tumor tissue 
3 µm thick archival tumor tissue sections from patients were cut from paraffin blocks 
and deparaffinized in xylene. Slides were immunohistochemically stained for TRAIL-Rl 
(14). Thereafter, slides were reviewed by light microscopy and scored by two 
investigators (CO (deblinded for clinical outcome), JB (blinded for clinical outcome)). 
Intensity of TRAIL-Rl staining was scored in four categories (no, low, moderate, and 
strong). 
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Abbreviations: (A)CUP, (adeno)carcinoma of unknown primary; NSCLC, non-small cell lung cancer; SCLC, 
small cel l lung cancer. 





Patient characteristics are shown in Table 1. From November 2004 to 31 January 2009, 
49 patients received a total of 209 cycles of combination treatment (median 5, range 
1-6). Additionally, 15 patients received 124 cycles of mapatumumab monotherapy 
(median 6, range 2-42). The number of patients treated at each dose level is shown in 
Table 2. At 20 mg/kg one patient experienced a cerebrovascular accident on day 5 of 
cycle 1, most likely related to cisplatin. In the 30 mg/kg cohort one patient experienced 
an epileptic seizure due to prior unknown brain metastases and went off study on day 
8 of the first cycle. Both patients were replaced because the toxicity data for cycle 1 
were incomplete. 
Table 2. Mapatumumab dose levels and DLTs as a function of dose. 
Dose level No. of patients Median no. of cycles No. of patients with DLT 
(mg/kg) (range) 
1 4 6 {3-12) 0 
3 7 6 {3-18) 0 
10 12 6 {1-21) 3 
20 13 4 (1-48)* 2 
30 13 5 (1-15) 0 
Abbreviation: DLT, dose-limiting toxicity. 
*One patient is ongoing and received 48 cycles as of 31 January 2009. 
Toxicity 
The most frequent chemotherapy-related and/or mapatumumab-related adverse 
events are listed in Table 3. Nausea and vomiting was frequently observed. These are 
well known side effects of cisplatin and gemcitabine and were therefore considered 
most likely caused by the chemotherapy. Hematologic toxicity, including 
thrombocytopenia, neutropenia and anemia, were considered to be most likely related 
to cisplatin and gemcitabine, although anemia may also have been cancer-related. 
Hematologic toxicity caused treatment delays, dose reductions and/or omissions of 
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day 8 gemcitabine at all mapatumumab dose levels. The dose intensity of cisplatin and 
gemcitabine was maintained at the highest dose level of mapatumumab {Table 4). 
Grade 3 or 4 elevations of transaminases was observed in 8 patients {16%). Three of 
these were reported as adverse events at least probably related to gemcitabine; 1 of 
the 3 was also considered possibly related to cisplatin and mapatumumab. 
Table 3. Number of patients with study drugs-related* adverse events by MedDRA preferred term and 
maximum toxicity grade occurring in � 10% of all patients (n=49). 
Adverse event Mild Moderate Severe Life- All active 
threatening 
No. % No. % No. % No. % No. % 
Nausea 20 40.8 22 44.9 4 8.2 0 46 93.9 
Vomiting 18 36.7 18 36.7 3 6.1 0 39 79.6 
Fatigue 10 20.4 22 44.9 4 8.2 1 2.0 37 75.5 
Thrombocytopenia 2 4.1 5 10.2 12 24.5 7 14.3 26 53.1 
Neutropenia 0 4 8.2 12 24.5 9 18.4 25 51.0 
Tinnitus 10 20.4 12 24.5 1 2.0 0 23 46.9 
Anemia 0 17 34.7 4 8.2 0 21 42.9 
Leukopenia 0 6 12.2 11 22.4 3 6.1 20 40.8 
Alopecia 10 20.4 8 16.3 0 0 18 36.7 
Peripheral sensory 12 24.5 3 6.1 0 0 15 30.6 
neuropathy 
Diarrhea 7 14.3 4 8.2 1 2.0 0 12 24.5 
Dysgeusia 8 16.3 2 4.1 0 0 10 20.4 
Anorexia 9 18.4 0 0 0 9 18.4 
Stomatitis 9 18.4 0 0 0 9 18.4 
Hypomagnesemia 4 8.2 3 6.1 1 2.0 0 8 16.3 
Hypokalemia 3 6.1 0 2 4.1 0 5 10.2 
Paresthesia 4 8.2 1 2.0 0 0 5 10.2 
Abbreviation: MedDRA, medical dictionary for regulatory activities. 
*possibly, probably or definitely related to gemcitabine, cisplatin and/or mapatumumab. 
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Table 4. Dose intensity of gemcitabine and cisplatin. 
Map No. Median no. of No. of pts No. of administrations Relative dose 
dose of cycles (range) with delay with delay (due to intensity (%)
° 
level in pts (both gem hematologic recovery) 
mg/kg gem cis and cis) gem cis gem cis 
1 4 6 (4-6) 6 (3-6) 1 3 ( 1) 3 (1) 87.2 94.8 
3 7 6 (3-6) 6 (3-6) 4 7 (3) 6 (3) 77.1 86.9 
10 12 6 (1-6) 4.5 (1-6) 9 17 (15) 16 (14) 71.4 82.7 
20 13 4 (1-6) 4 (1-6) 6 12 (10) 12 (10) 68.4 92.3 
30 13 5 (1-6) 4 (1-6) 4 8 (7) 8 (7) 82.1 92.5 
All 49 5 (1-6) 4 (1-6) 24 47 (36) 45 (35) 75.5 89.4 
Abbreviations: map, mapatumumab; pts, patients; gem, gemcitabine; cis, cisplatin. 
Relative dose intensity = dose intensity in mg/m2 / planned dose intensity in mg/m2 x 100% 
Dose-limiting toxicity (Table 2) 
In the 1 mg/kg and 3 mg/kg cohort no DlTs occured. At 10 mg/kg one patient 
experienced a grade 3 Al T elevation. However, this patient had an elevated Al T > 2.5 
times UlN at baseline (88 U/l; UlN 30 U/l) and therefore did not meet the inclusion 
criteria. The grade 3 Al T elevation was regarded as probably related to gemcitabine 
and possibly related to mapatumumab. The 10 mg/kg cohort after expansion to 6 
patients showed no additional Dl Ts. During expansion of the 10 mg/kg cohort two 
additional patients experienced a DLT. One patient developed neutropenic fever; the 
other, grade 3 Al T and AST elevations, and grade 4 thrombocytopenia. Thus, 3 out of 
12 patients experienced a Dl T at 10 mg/kg. 
In the 20 mg/kg cohort Dl Ts were observed in 2 out of 12 evaluable patients. One 
patient had a grade 4 fatigue and one patient grade 4 thrombocytopenia. 
No Dl Ts occurred in the 30 mg/kg cohort. 
Pharmacokinetics 
Individual subjects' plasma mapatumumab concentrations for each cohort of this 
study, along with predicted concentrations based on phase I PK study results, are 
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illustrated in Figure 1. There was substantial overlap between the observed 
concentrations and the predicted concentration ranges, at all dose levels. 
The mean (± SD) plasma gemcitabine, dFdU, unbound platinum and total platinum 
concentration-time profiles, pooled from all cohorts, are shown in Figure 2. For each 
compound, concentrations for the 1st treatment cycle are virtually superimposable or 
within 1 SD of the respective mean for the 2nd treatment cycle. 
Mean (with 95% Cl) exposure in cycle 1 and 2 as measured by AUC0.oo, AUC0.6h, or 
AUCiast for gemcitabine, dFdU and cisplatin-derived unbound platinum are summarized 
by cohort in Table 5. The 95% Cl for each compound in cycle 2 overlapped the 95% Cl 
in cycle 1, within and across each cohort. Exposure for each agent was fairly constant 
within a cohort and maintained its consistency across cohorts. 
Anti-mapatumumab antibodies 
One, previously untreated, patient in the 10 mg/kg cohort tested positive for anti­
mapatumumab antibodies at day 29 of cycle 2. All mapatumumab plasma values 
observed for this subject were within the predicted concentration range. 
Tumor response 
Figure 3 shows reduction of target lesions in 26 of the 37 patients in whom target 
lesions were present. Confirmed partial responses were observed in 12 out of the 49 
patients. Stable disease after 2 cycles was seen in 25 patients. Median duration of 
stable diseases and of partial responses was 6 months (range 1-33). 
TRAIL-R1 expression 
Tumor tissue was available in 35 patients. All tumors showed at least low cytoplasmic 
TRAIL-Rl expression in the majority of tumor cells. Staining intensity appeared not to 
be associated with tumor response (Table 6). 
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Table s. Gemcitabine, dFdU and unbound platinum AUCs in the absence (cycle 1) and presence (cycle 2) of mapatumumab. 
Gemcitabine dFdU 
Cisplati n-derived Cisplatin-derived 
AUCo.- (µg·hour/ml) AUC1ast (µg•hour/ml) 
unbound platinum unbound platinum 
AUCo.&h (µg·hour/ml) AUC1ast(µg•hour/ml) 
Cycle 1 Cycle 2 Cycle 1 Cycle 2 Cycle l _ _ _J:ycle 2 C�le l __fycle 2 
N 4 4 4 4 4 4 4 4 
Mean 12.3 12.9 211 237 3.62 3.40 4.28 4.28 
95% CI 9.80-14.8 9.78-16 .1 179-242 182-292 2.82-4.42 1.97-4.84 2.81-5.76 2.01-6.55 
N 7 7 7 7 7 7 7 7 
Mean 11.4 11.8 206 199 3.28 3.02 3.84 3.54 
95% CI 9.19-13.6 10.4-13.3 164-247 175-223 2.86-3.69 2.67-3.38 2.94-4.73 3.02-4.07 
N 12 9 12 9 11 8 11 8 
Mean 11.7 10.8 199 207 3.67 3.55 4.36 4.83 
95% CI 10.4-13.1 8.2-13.3 177-220 189-225 3.23-4.11 2.97-4.13 3.61-5.11 3.89-5.77 
13 9 13 9 13 9 13 9 
Mean 11.4 10.7 194 194 3.71 3.69 4.59 4.76 
95% CI 9.91-13.0 9.4-12.0 169-220 172-217 3.35-4.07 3.27-4.12 3.98-5.20 4.05-5.46 
30 mglkg 
N 13 11 13 11 13 11 13 11 
Mean 11.3 11.3 187 187 3.52 3.54 4.25 4.42 
95% CI 9.82-12.7 10.2-12.4 168-206 170-205 3.34-3.70 3.21-3.87 3.89-4.61 3.85-4.99 
In cycle 1, gemcitabine was administered immediately prior to cisplatin and 24 hours prior to the 1st mapatumumab dose. In the 2nd cycle (21 days later), 
gemcitabine, cisplatin, and mapatumumab were admin istered on the same day in immediate succession. 
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Figure 1. Plasma mapatumumab concentrations observed for individual subjects following 1, 3, 10, 20, or 
30 mg/kg mapatumumab IV infusion doses given 21 days apart, with the expected minimum to maximum 
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Figure 2A. Mean (± sd) plasma gemcitabine and dFdU concentrations following 1250 mg/m2 IV gemcitabine 
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Figure 28. Mean (± sd) plasma unbound and total platinum concentrations following 80 mg/m2 IV cisplatin 
doses administered as 3 hour infusion every 21 days (available data are presented for all cohorts combined). 
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Figure 3. Maximum percent change in target lesions from baseline (black bars) and duration of response 
(transparent bars) per patient. 
Table 6. Staining intensity in number of patients (n=35) in relation to tumor response . 
Staining intensity Tumor response according to RECIST11 
PR SD PD NA 
No 0 0 0 0 
Low 5 6 0 1 
Moderate 1 4 0 3 





Abbreviations: RECIST, Response Evaluation Criteria in Solid Tumors; PR, partial response; SD, stable disease; 




This paper is the first full report on combining chemotherapy with a TRAIL-receptor 
targeting agent. In this study mapatumumab was combined with gemcitabine and 
cisplatin. This combination is safe and well tolerated. The side effects observed reflects 
the toxicity profile of the chemotherapeutic agents. There were no PK interactions 
observed between the study drugs. Partial responses as well as prolonged stable 
diseases were seen. 
TRAIL-Rl is known to be expressed by human hepatocytes and therefore liver 
functions were closely monitored in this study (15}. We observed transient and 
reversible grade 3 ALT and/or AST elevations in 8 patients. Single agent gemcitabine is 
known to induce transient grade 3-4 transaminase elevations in up to 25% of the 
patients (16-18). Nevertheless, a relation with mapatumumab cannot be completely 
ruled out. In a phase I study with single agent mapatumumab 2 patients at the highest 
dose level of 10 mg/kg every 14 days experienced DLTs consisting of grade 3 bilirubin 
and transaminase elevations that were considered to be probably related to 
mapatumumab (6). Other patients treated at 10 mg/kg experienced mild or moderate 
liver enzyme elevations, likely also partially related to liver metastases. However, in 
another phase I study with single agent mapatumumab, there was no evidence of 
hepatotoxicity (5). 
Hematologic side effects in this study included neutropenia and thrombocytopenia. 
Grade 3 and 4 neutropenia was observed in 43% of the patients, with 1 patient 
experiencing neutropenic fever. Grade 3 and 4 thrombocytopenia occurred in 39% of 
the patients. These side effects, as well as the nausea and vomiting experienced by the 
majority of patients, were considered to be related to cisplatin and gemcitabine, and 
occurred in a frequency that is common for this combination {19,20}. Other non­
hematologic adverse events included fatigue, tinnitus and alopecia, and were mainly 
mild to moderate in severity. 
Side effects did not influence the total amount of cisplatin and gemcitabine 
administered at the various dose levels of mapatumumab. As a result, the dose 
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intensity of cisplatin and gemcitabine was maintained throughout all mapatumumab 
dose levels explored. 
The difficulty of assessing toxicity in studies evaluating a combination of various agents 
lies in the attribution of side effects. In the current study toxicity may have been the 
result of either 1 of the 3 drugs or of the combination of chemotherapy and 
mapatumumab. This dilemma is exemplified by the protocol amendments we had to 
make with regard to the DLT criteria. According to the initial criteria 4 out of 12 
patients experienced a DLT at the 10 mg/kg dose level. One of these patients 
experienced a grade 3 hypokalemia due to cisplatin-induced vomiting; this is common 
and was unlikely to have been potentiated by mapatumumab. The protocol was 
amended during the 3rd cohort to consider only events related to mapatumumab or its 
interaction with gemcitabine and/or cisplatin as DLTs. According to the initial DLT 
criteria none of the patients at 1 mg/kg and 2 out of 7 patients at 3 mg/kg experienced 
Dl Ts. These 2 patients had liver enzyme elevations unrelated to mapatumumab, and 1 
also experienced hyponatremia due to cisplatin-induced vomiting. Further dose 
escalation to 20 mg/kg was pursued without major toxicities, and at the highest tested 
dose level of 30 mg/kg no DLTs occurred. 
Plasma mapatumumab concentrations were in agreement with the predicted exposure 
based on the previous phase I studies rendering it unlikely that co-administration of 
mapatumumab with gemcitabine and cisplatin has a meaningful impact on 
mapatumumab exposure (5;6). Furthermore, co-administration of mapatumumab did 
not affect exposure to gemcitabine, dFdU, or cisplatin. 
In this study doses up to 30 mg/kg are evaluated, where the maximum dose given in 
the single agent phase I studies was 20 mg/kg (5). We considered the evaluation of 30 
mg/kg safe, because administration of mapatumumab appeared to be well tolerated at 
dose levels up to and including 20 mg/kg in the (ongoing) phase I and II studies at that 
moment. In addition, the plasma mapatumumab concentrations in the subjects who 
received 20 mg/kg mapatumumab were consistent with the predicted exposures, and 
gemcitabine and cisplatin did not affect the mapatumumab plasma values. 
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Biological agents are often active at doses below the MTD, and the highest dose tested 
in clinical studies may exceed the effective dose by far. With lower mapatumumab 
doses maximum receptor occupation may have been reached already. In addition, 
there were no apparent differences in mapatumumab plasma concentrations between 
patients treated at 20 mg/kg compared to those receiving 30 mg/kg mapatumumab 
(Figure 1). Consequently, doses higher than 30 mg/kg mapatumumab are unlikely to 
yield higher plasma concentrations. However, in the absence of studies that determine 
the optimal biological dose, we recommend 30 mg/kg mapatumumab every 3 weeks 
for randomized studies evaluating the efficacy of gemcitabine, cisplatin and 
mapatumumab. 
Most tumors in the present study did express TRAIL-Rl. No association was found 
between baseline TRAIL-Rl expression and tumor response. It would be interesting to 
study TRAIL-Rl expression during therapy in relation to response since mapatumumab 
combined with cisplatin resulted in synergistic anti-tumor effects in vivo, possibly due 
to TRAIL-Rl upregulation by chemotherapy (21). In addition, it is not likely that TRAIL­
Rl expression solely is predictive of response to mapatumumab-containing therapy, as 
several downstream factors in the TRAIL signaling pathway can affect the apoptotic 
response (22}. This also points to the interest of combining mapatumumab with 
chemotherapy, as presumably optimal antitumor efficacy will be achieved by targeting 
more than one pathway (23). Moreover, the simultaneous engagement of both the 
intrinsic and extrinsic apoptotic pathway may result in the prevention of resistance to 
either drug. This is important because recently evidence has emerged that in TRAIL­
resistant cells activation of the TRAIL receptors can lead to activation of nuclear factor­
KB (NF-KB) which subsequently mediates proliferation, invasion and metastasis (24-26). 
To prevent such detrimental effects of TRAIL pathway directed therapy, the 
development of resistance to TRAIL receptor activating agents should be avoided. In 
tumor cell lines treatment with chemotherapy results in sensitization to TRAIL­
mediated apoptosis, even in TRAIL resistant cell lines (27;28}. 
In this study, 26 out of the 37 patients with measurable disease showed a decrease in 
tumor lesions, and 12 patients achieved a partial response (Figure 3). These response 
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numbers are interesting compared to a historical overview of response rates in 
oncology phase I trials, including combination therapy studies {29}. Moreover, stable 
disease was achieved in 51% of the patients and was markedly prolonged in a subset of 
patients, including several with tumor types that in general are marginally responsive 
to standard chemotherapy regimens such as biliary tract cancer and pancreatic cancer. 
However, the value of these findings is of course limited by the non randomized nature 
of the study. Furthermore, no patients were previously treated with gemcitabine and 
cisplatin. It is therefore difficult to assess the contribution of mapatumumab to the 
efficacy of this combination. 
In conclusion, mapatumumab can be safely administered in combination with 
gemcitabine and cisplatin in doses up to 30 mg/kg. The pharmacokinetics of 
gemcitabine and cisplatin are not influenced by mapatumumab and vice versa. 
Responses and durable stable disease were seen across dose levels and in high 
numbers. Therefore, further studies, in a randomized setting, that explore the efficacy 
of this combination are warranted. 
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A phase lb study of tivozanib and FOLFOX6 in patients with advanced gastrointestinal malignancies 
Abstract 
Purpopse: Tivozanib is a highly potent and selective tyrosine kinase inhibitor of all 
three VEGF receptors with additive antitumor activity to 5-fluorouracil (SFU) in 
preclinical models. In phase I and II studies, tiovozanib monotherapy showed anti­
tumor activity. This phase lb study was conducted to determine the maximum 
tolerated dose (MTD), dose-limiting toxicities (DLTs), pharmacokinetics (PK) and anti­
tumor activity of escalating doses of tivozanib and standard dose leucovorin, SFU, and 
oxaliplatin (FOLFOX6) in patients with advanced gastrointestinal tumors. 
Patients and methods: Patients with advanced gastrointestinal malignancies were 
eligible. Tivozanib was administered orally once daily for 21 days in 28-day cycles, with 
FOLFOX6 administered every 14 days. Blood for tivozanib, SFU and oxaliplatin PK was 
sampled during the first cycle. Toxicity was scored according to the National Cancer 
Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 3.0. 
Patients were allowed to continue tivozanib following discontinuation of FOLFOX6. 
Tumor response was assessed after every 2nd cycle by RECIST version 1.0. 
Results: So far, 30 patients, (18 male, 12 female, median age 58 years years (range, 40-
75) were assigned to tivozanib 0.5 mg (n=9), 1.0 mg (n=3) and 1.5 mg (n=18). DLTs 
consisted of one episode of reversible grade 4 AST and ALT elevation and one episode 
of reversible grade 3 diarrhea at tivozanib 0.5 mg. No Dl Ts occurred at tivozanib 1.0 
mg. At tivozanib 1.5 mg DLT consisted of one episode of grade 3 vertigo and one 
episode of grade 3 epileptic seizure during cycle 2. Other grade 3/4 adverse events 
(AEs) included hypertension (n = 11) , neutropenia (n = 6) and fatigue (n = 4). No PK 
interactions were observed. Of the 30 patients, 1 patient had a complete response, 8 
patients achieved a partial response and 12 experienced stable disease. Five patients 
had progressive disease and 5 patients were not evaluable for response. 
Conclusions: The combination of tivozanib and FOLFOX6 is feasible and safe with drug 
related AEs that did not appear to be more frequent or severe than known to occur 
with either FOLFOX6 or tivozanib alone The recommended dose for future 
combination studies is 1.5 mg/day. Observed clinical activity merits further exploration 




Angiogenesis, the formation of new blood vessels, is essential for tumor growth. 
Vascular Endothelial Growth Factor (VEGF) is the most prominent and potent 
proangiogenic factor. VEGF binds with high affinity to the endothelial VEGF receptors 
(VEGFRs) and this results in endothelial cell proliferation, cell survival and 
angiogenesis. Various tumors express high VEGF levels and this has been found to be 
correlated with poor clinical outcome (1). 
Tivozanib (AV-951, KRN951) is a potent and selective oral VEGFRl, -2 and -3 tyrosine 
kinase inhibitor active at subnanomolar concentrations with half maximal inhibitory 
concentrations (IC50) of 0.21, 0.16, and 0.24 nM, respectively (2). In preclinical models, 
tivozanib demonstrated profound anti-angiogenesis and anti-tumor activity. In a 
single-agent phase I study, 41 patients with advanced solid tumors were treated with 
tivozanib for 28 days followed by a 2 week rest period (3). The maximum tolerated 
dose (MTD) in this study was 1.5 mg with controllable hypertension as the most 
common, dose-related adverse event. Its serum half-life was 4. 7 days, whereas 
pharmacodynamic analysis revealed dose dependent changes in serum concentrations 
of both VEGF and sVEGFR2. Tumor shrinkage was observed in 35% of the patients. In a 
phase II randomized discontinuation study with single agent tivozanib, 272 patients 
with advanced renal cell carcinoma were treated (4). The overall response rate was 
30% and a median progression-free survival of 11.7 months was observed. 
Hypertension and dysphonia were the most frequent drug-related adverse events (AE) 
in this study. A phase Ill trial comparing tivozanib with sorafenib in advanced renal cell 
cancer has completed patient enrollment (NCT01030783). 
In the single agent phase 1 study, durable stable disease was observed among patients 
with gastrointestinal malignancies. In addition, the combination of tivozanib with 
fluorouracil (5FU) and other cytotoxic agents resulted in additional anti-tumor activity 
in the MX-1 breast cancer xenograft model (5). We therefore performed a phase lb 
study to evaluate safety, tolerability and maximum tolerated dose of tivozanib in 
combination with FOLFOX6 (leucovorin, 5FU, and oxaliplatin) in patients with advanced 
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gastrointestinal malignancies. Secondary objectives were to determine the 
pharmacokinetic profile of tivozanib and its influence on 5FU and oxaliplatin 
concentrations and to assess the antitumor activity of this combination. 
Patients and methods 
Eligibility criteria 
Patients with a histologically or cytologically confirmed, metastatic gastrointestinal 
malignancy for whom FOLFOX6 was considered an appropriate treatment were 
eligible. Other inclusion criteria included: documented progressive disease; age � 18 
years; measurable or evaluable disease by RECIST (6); no more than 2 prior 
chemotherapy regimens for metastatic disease; at least 3 weeks since prior systemic 
anticancer treatment; resolution of toxicities from prior treatment to :::; grade 1; 
Eastern Cooperative Oncology Group (ECOG) performance status :::; 2 and a life 
expectancy � 3 months. Key exclusion criteria included: central nervous system 
metastases; second malignancies; inadequate hematologic, hepatic and renal function; 
significant cardiovascular disease; active infection; surgery in the previous 6 weeks; 
unhealed wounds, ulcers or bone fractures; bleeding disorders; deep venous 
thrombosis, pulmonary embolus or cerebrovascular accident within 12 months prior to 
the start of treatment; need for anticoagulation treatment or local radiotherapy within 
2 weeks before the start of cycle 1. 
The local Ethics Committees approved the study. Written informed consent was 
obtained before study-related procedures were started. The study is registered under 
trial number NCT00660153. 
Study design 
A cycle was defined as 28 days. Patients received tivozanib orally at escalating dose 
levels in capsules of 0.5, 1.0 or 1.5 mg once daily for 3 weeks followed by 1 week off 
drug. Based on the phase 1 study, where 2.0 mg/day exceeded the MTD, 1.5 mg per 
day was the maximum dose that would be tested (3). FOLFOX6 was administered on 
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days 1 and 15 of a 28 day cycle. FOLFOX6 consisted of leucovorin 400 mg/m2 as a 2-
hour infusion, and concurrently given oxaliplatin 85 mg/m2 intravenously (iv) over 2 
hours, followed by bolus 5FU 400 mg/m2 iv over 10 minutes and a 46-hour continuous 
infusion 5FU 2400 mg/m2 • On days when both tivozanib and FOLFOX6 were co­
administered, tivozanib was taken 5 minutes prior to the start of FOLFOX6. Dose 
reductions were allowed for patients with � grade 3 adverse events related to 
tivozanib, except for hypertension. Hypertension was treated according to local 
protocols before dose reduction was considered. Tivozanib could be reduced in steps 
of 0.5 mg, to a minimum dose of 0.5 mg daily. 
A standard 3+3 phase I trial design was used (7). Three patients were enrolled at each 
dose level. If 1 of 3 patients experienced dose-limiting toxicity (DLT) during cycle 1, the 
cohort was expanded to 6 evaluable patients. If a DLT was observed in � 2 out of 6 
patients in a cohort the MTD was exceeded. If O of 3 or 1 of 6 patients experienced a 
DLT during cycle 1, dose escalation was pursued. Dose limiting toxicity was defined as: 
Any grade 4 nonhematological toxicity; neutropenia � grade 3 associated with fever or 
sepsis; grade 4 neutropenia during 5 days or longer; grade 4 thrombocytopenia or 
bleeding requiring transfusion of platelets; toxicity of any grade resulting in inability to 
complete cycle 1 or resulting in interruption of treatment for > 2 weeks and any grade 
3 nonhematologic toxicity lasting > 3 days despite optimal supportive care with the 
exception of alopecia of any grade, grade 3 controllable hypertension, grade 3 self­
limiting or medically controllable toxicity, grade 3 AST or ALT lasting � 1 week, grade 3 
oxaliplatin-induced neurotoxicity in patients with prior exposure to oxaliplatin, grade 3 
gastrointestinal toxicity lasting � 1 week. NCI Common Terminology Criteria for 
Adverse Events (CTCAE) version 3.0 was used to grade toxicities (8). Once the MTD was 
reached, 12 additional patients with measurable disease could be enrolled at that 
dose. 
Patients could receive combined treatment for up to 1 year. If FOLFOX6 was 
discontinued earlier due to unacceptable toxicity in the absence of disease 
progression, tivozanib monotherapy could be continued. Patients were withdrawn 
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from the study in case of disease progression, unacceptable toxicity or refusal of 
treatment. Response was assessed after every 2nd cycle using RECIST version 1.0 (6). 
Pharmacokinetic (PK)studies 
Patients received a single dose tivozanib at day -5 (± 2 days). PK sampling was 
performed pre-dose and 1, 2, 4, 8 and 24 hours following dosing. On days 1 and 15 in 
cycle 1, PK samples for determination of serum levels tivozanib and plasma 
concentrations SFU and unbound platinum were taken pre-dose, 5 minutes prior to 
the end of oxaliplatin bolus, immediately after 5FU bolus, 1 hour after start of the 
continuous SFU infusion, at 24 hours and 48 hours following the start of FOLFOX6 
(prior to tivozanib dosing), and 5 minutes before the end of continuous 5FU infusion. 
In addition, blood samples were collected on days 8, 21 (pre-dose and 1, 2, 4, 8 and 24 
hours following dosing) and 22 of cycle 1 and on day 1 of cycle 2. Serum tivozanib 
samples were stored at -20°C until analysis by a validated reversed-phase liquid 
chromatography tandem mass spectrometry {LC-MS/MS) method in the range of 0.100 
to 100 ng/ml, with KRN633 as internal standard. 
For 5FU analysis, 30 µL aliquots of human lithium heparinized plasma, or appropriate 
dilutions of the sample, were extracted after the addition of 10 µL internal standard 
(either 5-chlorouracil or 13C/15N2 labeled 5-fluorouracil) with 1.5 ml ethyl acetate. 
After evaporation of the organic phase and re-suspension of the residue in an aliquot 
of 100 µL of Ringer's solution, an aliquot of 50 µL has been injected into the LC-MS/MS 
system as described peviously (9). 
Plasma concentrations of unbound oxaliplatin-derived platinum were determined as 
described for cisplatin-derived platinum {10). In brief 500 µL aliquots of the plasma 
supernatant were mixed with 1.0-ml aliquots of ice-cold {-20°C) ethanol. Ethanolic 
supernatant was collected by centrifugation at 18,000 x g for 5 min after which the 
clear supernatant was stored at T < -70°C until analysis. On the day of analysis aliquots 
of 1000 µL of the ethanolic supernatant, or dilutions of the supernatant in blank 
ethanolic supernatant, were evaporated to dryness under nitrogen at T = 80°C, and the 
residue reconstituted in 200 µL diluent (i.e., water containing 0.2% (v/v) Triton X-100 
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and 0.06% (w/v) cesium chloride), from which subsequently aliquots of 20 µL, in 
duplicate, were injected onto the graphite furnace of a Perkin Elmer Model 4110 ZL 
atomic absorption spectrophotometer (Uberlingen, Germany). Platinum peak areas 
were measured at 265.9 nm with a lower limit of quantitation of 0.0300 µg/ml. 
Results 
General 
The results presented in this report are preliminary en incorporate data until 
November 1st 2011. Overall, 30 patients were enrolled (Table 1). Patient characteristics 
are shown in Table 2. These patients received 113 cycles of combination therapy 
(median 4, range 1-8). In addition, 13 patients received 103 cycles tivozanib 
monotherapy (median 6, range 1-20). Three patients are continuing to receive 
treatment. 
Table 1. Dose levels. 
Cohort Tivozanib FOLFOX6 No. of patients 
1 0.5 mg/day Standard 9 
2 1.0 mg/day Standard 3 
3 1.5 mg/day Standard 6 
MTD expansion 1.5 mg/day Standard 12 
MTD, maximum tolerated dose. 
Two patients in the first cohort received a higher than per protocol dose 5FU. The first 
patient revealed a grade 2 leucopenia and the second patient suffered from reversible, 
grade 3 diarrhea. Treatment was stopped and both patients were replaced. The third 
patient in the first cohort was replaced because of early progressive disease, which 
manifested during the first cycle. 
Safety and tolerability 
Tivozanib in combination with FOLFOX6 was in general well tolerated. Most common 
observed AEs were fatigue, peripheral sensory neuropathy and anemia (Table 3). 
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Grade 3 or 4 AEs were hypertension (n = 11), neutropenia (n = 6) and fatigue (n = 4). 
Hematologic toxicity and neuropathy were considered most likely related to FOLFOX6. 
Hypertension was considered most likely related to tivozanib. Hypertension was well 
controlled with antihypertensive medications in all patients. Neutropenia was not 
associated with fever. Neutropenia, thrombocytopenia and peripheral sensory 
neuropathy resulted in dose reductions of oxaliplatin and/or SFU and FOLFOX6 
treatment delays across tivozanib dose levels in 18 patients (60%}. 
Table 2. Baseline patient characteristics. 
Characteristic 
Median age (range), y 
Male sex, n (%) 





Small bowel adenocarcinoma 







In the 0.5 mg cohort, 1 patient experienced grade 4 AST and grade 3 ALT elevations on 
day 2 of the first cycle. All study medication was stopped, after which AST and ALT 
normalized. FOLFOX6 was restarted with 1 week delay and again resulted in reversible 
grade 4 AST and ALT elevations. This toxicity was regarded as definitively related to 
SFU and oxaliplatin and possibly related to tivozanib. Reversible grade 3 diarrhea was 
observed in another patient in this cohort. This patient received a higher than per 
protocol dose SFU and was considered not evaluable. The patient was replaced and 
dose escalation was pursued. In the 1.0 mg cohort no DLTs occurred. 
At 1.5 mg/day tivozanib one patient experienced reversible grade 3 dizziness during 
cycle 1. Another patient suffered from a grade 3 epileptic seizure. However, this event 
occurred in cycle 2 and was therefore not considered a protocol-defined DLT. No other 
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DLTs were observed in the first 6 patients at 1.5 mg tivozanib and therefore 12 
additional patients were enrolled. No Dl Ts occurred in this expansion cohort. 
Table 3. Observed adverse events (�15% of the patients). 
Adverse event All grades (n = 30) Grade 3 / 4 (n = 30) 
n % n % 
Fatigue 27 90 4 13 
Peripheral sensory neuropathy 25 83 0 0 
Anemia 24 70 0 0 
Nausea 21 70 0 0 
AST elevation 21 70 1 3 
Thrombocytopenia 20 67 1 3 
ALT elevation 19 63 1 3 
Leucopenia 19 63 4 13 
ALP elevation 18 60 0 0 
Diarrhea 17 57 2 7 
Hypertension 16 53 11 37 
Vomiting 16 53 0 0 
Neutropenia 15 so 6 20 
Stomatitis 15 so 0 0 
Hoarseness 11 37 0 0 
Proteinuria 6 20 0 0 
Abbreviations: AST, aspartate aminotransferase; ALT, a lanine aminotransferase; ALP, a lkaline phosphatase. 
Pharmacokinetics 
Results are available for the first 22 patients enrolled. The mean tivozanib serum 
concentrations at steady state do not appear to be influenced by FOLFOXG treatment 
and were comparable to levels observed in the tivozanib monotherapy studies (Figure 
1A). Unbound platinum and 5FU plasma concentrations were similar on days 1 and 15, 
indicating that increasing serum levels of tivozanib did not influence plasma 
concentrations of unbound platinum or 5FU (Figures 1B and le). 
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Figure 1. Concentration-time profiles depicting mean values (± SEM) for {A) serum tivozanib concentration, 
{B) unbound oxaliplatin plasma concentration and (C) 5-FU plasma concentration as a function of time post­




Of the 30 patients, 1 patient with metastatic duodenal carcinoma had a confirmed 
complete response, currently lasting 36 weeks, and 8 patients obtained a partial 
response. Another 12 patients experienced stable disease. Responses occurred in 
patients with oesophageal cancer (n = 4), pancreatic cancer (n = 2), colorectal cancer (n 
= 1), gastric cancer (n = 1) and small bowel cancer (n = 1). 
The median duration of treatment was 5 cycles (range 1-27+ cycles). Percentage 
change of target lesions was available for 15 patients. Thirteen out of these 15 patients 
showed shrinkage of the target lesions (Figure 2). Seven out of the 9 patients (78%) 
with a partial or complete response developed hypertension during the study versus 9 
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Figure 2. Waterfall plot of maximum tumor change from baseline for the 15 patients currently available per 
tivozanib dose. * Indicates patients who are still receiving treatment. 
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Discussion 
This paper is a preliminary report of an ongoing phase I study combining the novel, 
oral angiogenesis inhibitor tivozanib with FOLFOX6 chemotherapy in patients with 
gastrointestinal tumors. The combination was well tolerated. The observed AEs 
predominantly consisted of well known FOLFOX6-related toxicity and tivozanib 
induced, controllable hypertension. One complete response and partial responses 
were observed throughout the cohorts. 
The MTD of tivozanib in combination with standard FOLFOX6 was not reached at 1.5 
mg/day. We did not explore higher doses, as the MTD in the single agent tivozanib 
phase I study was exceeded when using the next dose step of 2.0 mg/day (3). Tumor 
responses were observed in that single agent study also on dose levels <2.0 mg/day. 
Therefore, 1.5 mg/day is considered to be an effective biological dose and the 
recommended phase II dose for further studies combining FOLFOX6 and tivozanib. 
The most common observed AEs in this study were fatigue, peripheral sensory 
neuropathy, anemia and nausea. Incidences of neuropathy and nausea were 
comparable to those seen with FOLFOX6 alone and are therefore considered most 
likely related to the chemotherapeutic agents (11,12). Fatigue may be chemotherapy, 
tivozanib or cancer related. The incidence of fatigue of any grade in this study was with 
90% remarkably higher compared to the 51% incidence rate in the single agent 
tivozanib phase I study (3). We consider this difference to be the consequence of the 
combination therapy. 
Thrombocytopenia and neutropenia were seen in respectively 67% and 50% of the 
patients during treatment with FOLFOX6. Neutropenic episodes were not associated 
with fever. However, thrombocytopenia and neutropenia resulted in delayed dosing 
and dose reductions in 18 patients. Moreover, several patients could not continue 
FOLFOX6 due to delayed recovery. In the final analysis of this study we will report if 
dose intensity was stable and sufficient throughout the cohorts. 
Hypertension is a well-known side effect of angiogenesis targeting agents and blood 
pressure was therefore carefully monitored in this study (13). In 53% of all patients 
hypertension developed, and 37% required antihypertensive treatment. Fortunately, 
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in all patients in whom treatment had to be started, hypertension turned out to be 
easily manageable and in no patient resulted in interruption or termination of study 
drug administration. In the single agent studies frequencies of 45-58% (all grades) 
were reported (3,4). Frequencies for other VEGF tyrosine kinase inhibitors vary from 1-
40% (14). 
The observed toxicity in our study was comparable to that seen in other studies 
combining a pan-VEGF-R tyrosine kinase inhibitor with FOLFOX chemotherapy (15-17). 
Hypertension is probably associated with improved clinical outcome in patients 
treated with VEGF-R tyrosine kinase inhibitors (18,19). Although not statistically 
significant, there was a trend toward a higher incidence of hypertension in the patients 
with a tumor response compared to the remaining patients in our study (78% versus 
43%). 
Serum tivozanib levels in this combination study were comparable to those observed 
in the single agent phase I study (3). Therefore, serum tivozanib levels seem not to be 
influenced by FOLFOX6 chemotherapy. Furthermore, plasma levels of unbound 
platinum and 5 FU were not affected by increasing tivozanib levels during the 
treatment cycle. 
As a result of excessive production of proangiogenic factors and downregulation of 
antiangiogenic molecules, structural abnormalities make tumor vessels 
hyperpermeable. VEGF-R targeting agents like tivozanib can potentially restore the 
disbalance between pro- and antiangiogenic factors and result in tumor vessel 
normalization, as was shown for this drug in several preclinical studies (20-21). As a 
consequence, interstitial fluid pressure may decrease and tumor perfusion may 
improve, making the tumor more accessible for cytotoxic chemotherapy. In theory, 
this might increase tumor response rates, without effecting chemotherapy induced 
toxicity. Efficacy in our study was indeed promising, with a decrease in tumor size in 13 
of the 15 patients (87%) with measurable lesions. One patient achieved a complete 
response and 8 patients a partial response. Furthermore, keeping in mind that 
documented progressive disease was one of the inclusion criteria for this study, it is 
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also noteworthy to mention that 6 patients, having stable disease as best response, 
were on treatment for � 6 cycles. 
In conclusion, the combination of tivozanib and FOLFOX6 is feasible and safe. The 
recommended tivozanib dose for future combination studies with FOLFOX6 is 1.5 
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Prognostic versus predictive value of biomarkers in oncology 
Abstract 
Numerous options are currently available for tumour typing. This has raised intense 
interest in the elucidation of prognostic and predictive markers. A prognostic 
biomarker provides information about the patients overall cancer outcome, regardless 
of therapy, while a predictive biomarker gives information about the effect of a 
therapeutic intervention. A predictive biomarker can be a target for therapy. Among 
the genes that have proven to be of relevance are well-known markers such as ER, PR 
and HER2/neu in breast cancer, BCR-ABL fusion protein in chronic myeloid leukaemia, 
c-K/T mutations in GIST tumours and EGFRl mutations in NSCLC. Several reasons for 
the difficult elucidation of new markers will be addressed including the involvement of 
cellular pathways in tumour biology instead of single genes and interference in disease 
outcome as a result of anticancer therapies. Future perspectives for the development 




With the availability and application of various treatment modalities, survival among 
cancer patients has improved over the past decades. However, there are still many 
patients who receive anticancer therapy from which they do not benefit while they do 
experience toxicity. In recent years, a widespread search for new, tumour biology 
driven therapeutics has started. This has raised intense interest in the elucidation of 
corresponding prognostic and predictive biomarkers in order to improve outcome by 
better patient selection for an anticancer treatment. A biomarker is defined as a 
characteristic that is objectively measured and evaluated as an indicator of normal 
biologic processes, pathogenic processes or pharmacological responses to a specified 
therapeutic intervention (1). Biomarkers can be determined in numerous ways, for 
example, in easy obtainable body fluids serving as surrogate biological assay, like 
plasma, serum or urine. But also more invasive techniques requiring tumour tissue for 
immunohistochemistry as well as DNA and RNA analyses are widely used. A prognostic 
biomarker provides information about the patients overall cancer outcome, regardless 
of therapy. The presence or the absence of such a prognostic marker can be useful for 
the selection of patients for a certain treatment, but does not predict the response to 
this treatment. Prognostic biomarkers can be separated in two groups: biomarkers 
that give information on recurrence in patients who receive curative treatment and 
biomarkers that correlate with the duration of (progression free) survival in patients 
with metastatic disease. According to a NIH Consensus Conference, a clinical useful 
prognostic marker must be a proven independent, significant factor, that is easy to 
determine and interpret and has therapeutic consequences (2). A biomarker with 
predictive value gives information on the effect of a therapeutic intervention in a 
patient. A predictive biomarker can also be a target for therapy. One can distinguish 
upfront and early predictive markers. The first can be used for patient selection and 
the second provides information early during therapy. 
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The current interest in marker determination is boosted by the discovery of genes that 
have proven to be of clinical relevance such as the oestrogen receptor (ER), the 
progesterone receptor (PR) and HER2/neu in breast cancer, BCR-ABL fusion protein in 
chronic myeloid leukaemia, c-K/T mutations in gastrointestinal stromal tumours (GIST) 
and epidermal growth factor receptor 1 (EGFRl) mutations in non-small cell lung 
cancer (NSCLC). These genes all seem to be key regulators of development, growth and 
proliferation in the respective tumour types. Euphoria is now somewhat tempered 
because the discovery of other so-called promising markers translates rather slowly 
into clinical applicability. One reason for this is the fact that the course of most of 
malignancies is the consequence of a number of essential alterations in tumour cells 
rather than a single mutation (3). In addition, the limited size of most studies and 
variable techniques used for marker determination plays a role. Often initially reported 
promising results are not reproducible. In an attempt to optimise biomarker studies, 
Hayes and colleagues proposed a tumour marker utility grading system (TMUGS). For 
each biomarker a grade of utility is assigned, accompanied by a level of evidence (LOE) 
that scores the quality of the research. The LOE categories range from I to V. Level V 
evidence is obtained from case reports and clinical experience and is considered weak, 
while level I evidence is derived either from at least one prospective randomised 
controlled trial specifically designed to test the marker or from a meta-analysis and/or 
overview of level II or Ill studies and is considered definitive (4). In addition, a 
consortium of the National Cancer Institute-European Organisation for Research and 
Treatment of Cancer (NCI-EORTC) reported in several journals a guideline for reporting 
tumour marker prognostic studies (REMARK) (5). 
In this review, the progress in the development of biomarkers in solid tumours will be 
addressed such as, involvement of cellular pathways in tumour biology instead of 
single genes and interference in disease outcome as a result of anticancer therapies. 
Examples of both well-known biomarkers and potential new discoveries (summarised 
in Table 1) will form the basis for a discussion below on the present knowledge and 
new avenues for the development of prognostic and predictive biomarkers. 
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ER/PR in breast cancer 
ER and/or PR expression is an independent prognostic factor in breast cancer. Patients 
with ER and/or PR positive tumours have a better survival than hormone receptor 
negative tumours, with a 5-year overall survival (all stages) of 83% in the ER+/PR+ 
group versus 69% in the double negatives (LOE Ill} (6). High cellular expression of ER 
and PR predicts benefit from endocrine therapy in the adjuvant and metastatic setting 
(LOE I} (7). Tumour hormone receptor status is, therefore, routinely assessed in breast 
cancer. It now also becomes clear that hormone receptor status in a patient can 
change during the course of the disease and may differ across lesions. For example, 
the ER status of metastatic disease is different from the primary tumour in about 20% 
of cases (8,9). In addition, PR expression is lost in 40% of previous positive tumours 
when they metastasise. Therefore, recently revised guidelines of the American Society 
of Clinical Oncology recommend measurement of both ER and PR in metastatic lesions 
if these results might influence treatment planning (10). A search for non-invasive 
techniques to predict response to treatment is ongoing. Studies with positron emission 
tomography (PET) for whole body ER imaging with [18F]fluoroestradiol (FES) suggest 
feasibility of such an approach (11). 
HER2/neu in breast cancer 
Another relevant biomarker in breast cancer patients is HER2/neu. The HER2/neu gene 
amplification leads to overexpression of its receptor on the cell membrane. This results 
in increased proliferation and angiogenesis, and inhibition of apoptosis. HER2/neu 
positive tumours are more aggressive and have, therefore, a worse prognosis 
compared to negative tumours. In this respect, HER2/neu in node positive breast 
cancer is of prognostic value (LOE II). For the node negative, HER2/neu positive group 
of patients this is less clear (12-17). HER2/neu is the target for the monoclonal 
antibody trastuzumab and the EGFRl and HER2 dual tyrosine kinase inhibitor (TKI} 
lapatinib. Patients with HER2/neu overexpressing tumours benefit from treatment 
with trastuzumab in the metastatic as well as in the adjuvant setting (LOE II) (18-20}. 
Interestingly, HER2/neu positive patients receiving adjuvant chemotherapy plus 
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trastuzumab showed the same recurrence-free survival as HER2/neu negative patients 
treated with chemotherapy alone {21). Thus, the prognostic value of HER2/neu 
overexpression is neutralised in this study by targeting the prognostic biomarker. 
Like ER expression, HER2/neu expression can change over time and can vary between 
lesions within a patient. Several reports suggest a conversion from negative into 
positive HER2/neu status when the disease did recur, although depending on 
technique, for a varying percentage {22-25). Instead of serial biopsies, SPECT or PET 
whole body radiolabelled trastuzumab scintigraphy would be more attractive. This 
approach was capable to detect HER2/neu expression in tumour lesions in the patients 
{26,27). 
Both primary and acquired resistance to trastuzumab occurs. In addition to absence of 
the receptor there are a number of other factors that can potentially explain 
resistance. For example, the presence of multiple truncated HER2/neu receptors at the 
tumour cell surface might play a role. The truncated p95HER2/neu receptor lacks the 
extracellular binding domain for trastuzumab, but has tyrosine kinase activity. 
Therefore, trastuzumab resistant tumours that express p95HER2/neu might benefit 
from treatment with lapatinib {28). 
Prognostic biomarkers for the relapse of breast cancer 
Decision making about adjuvant systemic treatment for breast cancer is based on 
nodal status, tumour grade, tumour size, tumour hormone receptor and HER2/neu 
status, age and co-morbidity. Prognostic biomarkers that could provide better 
information on risk of relapse could spare many patients chemotherapy toxicity 
without compromising survival. Among several initiatives Buyse and colleagues 
validated a 70-gene signature for node negative breast cancer patients that has 
independent prognostic value additive to clinicopathologic parameters {29). This 
approach is now tested in a prospective European study (MINDACT). 
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Table 1. Biomarkers of interest: overview of prognostic and predictive value. 
Biomarker Tumour type Prognostic value Predictive value 
LOE LOE Therapy 
ER/PR BRCA Yes I l l  Yes Endocrine therapy 
HER2/neu BRCA Yes II Yes II Trastuzumab 
c-KIT GIST Yes, II Yes, II lmatinib 
subgroup1 subgroup2 
EGFRl NSCLC No I l l  Yes, II Gefitinib, erlotinib 
subgroup3 
CRC No I l l  Yes IV Cetuximab, 
panitumumab 
Mutated NSCLC Yes II Yes I l l  Gefitinib, erlotinib 
K-ras 
CRC No Il l Yes IV Cetuximab, 
panitumumab 
TRAIL CRC Yes I I  NK RhTRAIL; TRAIL 
receptors receptor 
antibodies 
VEGF RCC Yes II No II Angiogenesis 
inhibitors 
LOE: level of evidence; ER: oestrogen receptor; PR: progesterone receptor; BRCA: breast cancer; GIST: 
gastrointestinal stromal tumours; EGFRl: epidermal growth factor receptor 1; NSCLC: non-small cell lung 
cancer; CRC: colorectal cancer; TRAIL: tumour necrosis factor (TNF)-related apoptosis-inducing ligand; NK: 
not known; VEGF: vascular endothelial growth factor; RCC renal cell carcinoma. 
1. c-KIT exon 11 mutation. 
2. c-KIT exon 9 mutation. 
3. EGFRl exon 18, 19 or 21 mutation. 
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c-KIT in GIST 
Several features are evaluated over the last few years to determine malignant 
behaviour of GISTs. Of known relevance are tumour size and mitotic index, which are 
used to classify the biologic behaviour of GIST (30). The majority of GISTs are 
characterised by mutations in either the proto-oncogene c-KIT or the platelet-derived 
growth factor receptor alpha (PDGFRa). Interestingly, patients with mutation in the c­
KIT-gene in exon 11 have a better prognosis as compared to those who lack a mutation 
or have another mutation (LOE II) (31-33). With the introduction of imatinib and 
sunitinib the outcome of GIST patients improved dramatically (34,35). lmatinib and 
sunitinib are small molecule TKls, which block signalling via c-KIT and PDGFRa. In 50-
55% of the patients with advanced disease imatinib results in a durable objective 
response, while another 25-30% have stable disease according to RECIST (36). During 
the course of treatment, however, most patients develop resistance to imatinib. A 
subgroup of these patients with progressive disease within a few months of imatinib 
treatment was characterised by bearing exon 9 activating mutations in c-KIT. In the 
two studies comparing an imatinib dose of 400 and 800 mg daily, the only difference 
was a better progression-free survival at the highest dose in patients with a tumour 
harbouring an exon 9 mutation (LOE II) (32). Exon 9 mutational status is, therefore, a 
negative predictive factor for response to imatinib and a positive predictive factor for 
benefit of 800 mg imatinib (37). Progression after an initial response or stable disease 
for at least 3 months is caused by secondary c-KIT mutations in exon 13, 14, 17 or 18 in 
50-70% of these patients (38). Secondary mutations can differ across lesions in an 
individual patient. Several studies explored the value of different mutations in c-KIT 
and PDGFRa in the light of predicting response to TKls (39). 
EGFRl and K-ras in NSCLC and colorectal cancer (CRC) 
In NSCLC and CRC, biomarkers of interest are EGFR1 and the K-ras oncogene. EGFR1 is 
overexpressed in multiple cancer types and is one of the targets in the treatment of 
NSCLC and metastatic CRC. The EGFR pathway plays a role in several cellular functions, 
76 
Chapter 5 
including regulation of cell proliferation, migration and differentiation {Figure 1) .  The 
prognostic value of EGFRl protein expression is extensively studied in NSCLC and CRC 
patients but no definitive association between EGFRl expression and prognosis was 
found {40,41). 
The K-ras oncogene controls cell growth via regulation of signal transduction 
pathways. K-ras mutation results in malignant transformation . In a meta-analysis 
including 28 studies assessing the correlation between K-ras mutation and survival in 
NSCLC patients, K-ras mutation appeared to be a biomarker of poor prognosis {42). A 
multivariate analysis including 3439 CRC patients failed to prove an association 
between mutant K-ras and disease outcome {43) .  
In recent years, two small-molecule EGFRl TKls (gefitin ib and erlotin ib) and two anti­
EGFRl monoclonal antibodies {cetuximab and panitumumab) were introduced in the 
clinic. Four phase Ill trials in previously untreated patients with advanced NSCLC 
combining two different chemotherapy regimens with and without gefitinib or 
erlotinib demonstrated no survival benefit. Subgroup analysis, however, identified four 
characteristics associated with benefit for the patient namely adenocarcinoma, female 
sex, Asian ethnicity and non-smoking {44). Over the last years, it became clear that a 
subgroup of NSCLC patients, especially consisting of non-smokers, have mutations in 
the tyrosine kinase domain {exons 18, 19, and 21) of EGFRl . These mutations are 
predictive for response to either gefitin ib or erlotinib {LOE I I )  {45-48). In contrast to 
EGFRl mutations being a predictive biomarker for a beneficial effect, mutations in K­
ras are most commonly observed in heavy smokers predicting for treatment failure on 
EGFRl TKls {49,50) . 
In metastatic CRC, a subgroup of patients benefits of EGFRl directed antibody 
treatment. However, EGFRl mutations are rare in CRC patients and do not predict 
benefit from anti-EGFRl therapy. In contrast, EGFRl gene amplification appears to be 
a predictive factor for response to anti-EGFRl antibody treatment in CRC, although the 
studied series are small and retrospective {LOE IV) {40). In CRC, there is also increasing 
evidence that mutations in K-ras are predictive of non-response to cetuximab and/or 
panitumumab {40,51,52). 
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A. EGFR1 pathway. EGFR1 forms homodimers after binding by its growth factor ligands. This results in 
stimulation of intrinsic tyrosine kinase (TK) activity. Subsequently, several downstream signal transduction 
pathways are initiated resulting in the cell proliferation and the cell survival. EGFR1 antibodies and TK 
inhibitors can block signalling by binding to the extracellular domain and the intracellular TK domain, 
respectively. AB: antibody. 
B. Mutations in the tyrosine kinase domain (exons 18, 19 and 21) of EGFR1 result in a better response to 
EGFRl TKls. 
C. Mutated RAS results in continuous signal l ing, independent of EGFR1 and EGFR1 targeting agents. 
TRAIL receptors 
Tumour necrosis factor {TNF)-related apoptosis-inducing ligand {TRAIL or Apo2L) 
induces apoptosis in a wide variety of tumour cell lines without causing toxicity to 
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normal cells and is, therefore, a potential attractive agent. TRAIL binds the death 
receptors TRAIL-Rl (DR4) and TRAII-R2 (DRS) and initiates the apoptotic pathway. DR4 
and DRS are expressed on most tumour cells. In contrast to, e.g., HER2 and EGFRl, this 
receptor has to be activated and not inhibited in order for cells to go into apoptosis. 
Several studies addressed the prognostic role of DR expression in malignancies. In 376 
stage Ill CRC patients receiving adjuvant chemotherapy as part of a randomised study, 
high DR4 expression was associated with a worse disease-free and overall survival (LOE 
II} (53). RhTRAIL and several agonistic antibodies targeting the TRAIL receptors are 
currently evaluated in the clinic (54). So far, very little is known about possible 
predictive factors, and only pre-clinical data are available. DR4 and/or DRS have to be 
available at the tumour cell surface to initiate the apoptotic pathway, but just their 
presence is not sufficient to predict response to TRAIL receptor targeting agents. 
Several downstream factors in the TRAIL signalling pathway, for example, defects in 
caspase 8 or loss of function of the pro-apoptotic proteins BAK or BAX determine 
apoptotic response to TRAIL (55). In addition, mutations in DRS are responsible for 
inhibition of apoptosis by blocking the signal after TRAIL binding (56). An interesting 
biomarker is the 0-glycosylation status of DRs. 0-linked glycans regulate biochemical 
and functional properties of cell surface proteins, including apoptosis. 0-
Glycosyltransferase mRNA levels correlated with rhTRAIL sensitivity in several cancer 
cell lines and DR 0-glycosylation resulted in the activation of caspase 8 via TRAIL 
induced clustering of DR4 and DRS (57). In an attempt to predict which patients might 
benefit TRAIL receptors targeting therapy, a SPECT imaging study with the 
radioactively labelled DR4 agonistic antibody mapatumumab is initiated. 
VEGF and renal cell carcinoma (RCC) 
Even very small tumours require angiogenesis to provide nutrients and oxygen for 
survival. There is a close interaction between tumour cells that produce pro-angiogenic 
growth factors, like vascular endothelial growth factor (VEGF) and PDGF, and 
endothelial cells expressing growth factor receptors. The stimulation of endothelial 
cells results in proliferation and migration and eventually in formation of new vessels. 
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Clear cell RCC provides a unique model for studying angiogenesis because of frequent 
somatic inactivation of the Von Hippe/ Lindau (VHL) gene. The VHL gene plays a key 
role in regulation of the oxygen-sensing pathway by targeting the hypoxia-inducible 
factor (HIF) for degradation in the proteasome. Impaired VHL function, therefore, 
results in high expression of pro-angiogenic growth factors. Targeting the VEGF 
pathway with TKI sunitinib and sorafenib, the mTOR inhibitor temsirolimus and with 
the VEGF targeting monoclonal antibody bevacizumab prolongs progression-free 
survival in metastatic clear cell RCC (58-62). 
Simple clinical parameters like performance score and number of metastatic sites are 
known powerful prognostic factors in cancer. Motzer and colleagues developed a 
scoring system for metastatic RCC patients consisting of five clinical parameters: 
performance score, time between diagnosis and metastasis, haemoglobin, serum 
calcium and lactate dehydrogenase (LDH) (63). With this system, developed 
retrospectively in patients receiving interferon, patients can be classified as having 
good, intermediate or poor prognosis (LOE II) (4). This classification has been used to 
design and stratify medical intervention studies and as a consequence is now widely 
used to guide therapy. 
Several other parameters like C-reactive protein, platelet count and HIF expression 
also have prognostic value in RCC but do not have a role in clinical decision making. 
A high baseline serum VEGF level is associated with shorter progression free and 
overall survival in 2 prospective studies (4,64). In a phase Ill study of sorafenib versus 
placebo in advanced RCC, baseline VEGF level is an independent prognostic factor for 
overall survival (LOE II). Baseline serum VEGF in 2 cytokine studies in RCC patients also 
found VEGF to be an independent prognostic factor for survival (LOE Il l). No predictive 
biomarkers have been found so far which predict patients' benefit from angiogenesis 
inhibitors (65,66). VEGF mRNA and protein levels in serum, plasma and tumour have 
been investigated extensively with disappointing results. Even in RCC, the role model 
for angiogenesis, a high serum VEGF level or a change after starting therapy does not 
predict response to anti-angiogenic treatment. In the sorafenib study, both patients 
with high and patients with low baseline serum VEGF benefited from sorafenib (64). 
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There is a growing list of candidate markers from pre-clinical studies, and multiple 
clinical trials are underway to assess predictive biomarkers for angiogenesis inhibition. 
Single molecular markers may not be able to predict the benefit because of the 
complexity of signalling routes and because of the cross talk between different 
signalling pathways. 
Functional imaging with MRI, CT and PET scans for the assessment of tumour 
vascularity and metabolic activity is under investigation for its ability to predict 
response to angiogenesis inhibitors earlier. In vivo imaging of VEGF by radiolabelled 
bevacizumab has been successful in a human ovarian tumour xenograft and is an 
interesting concept for early response prediction (67). 
Drug induced toxicity as a predictive biomarker 
Interestingly a number of studies showed that the effect of a drug on normal tissues 
can be used as biomarker. In both a phase II and a phase Ill study evaluating the 
antitumour activity of cetuximab in metastatic CRC, skin rash was strongly related to 
response and survival (68,69). Similar results were found for erlotinib in NSCLC (70). 
Toxicity might thus be used to titrate drugs to effective doses as is done in 
the EVEREST study in CRC patients. Patients with no or mild skin toxicity after 22 days 
of treatment with cetuximab and irinotecan were randomised between standard and 
escalating doses of cetuximab until the development of grade 3 toxicity. Preliminary 
data show that dose escalation improves tumour response to a rate comparable to the 
group with initial moderate to severe skin toxicity at the standard dose (71). 
In a small series of 40 metastatic RCC patients treated with sunitinib, grade 3 
hypertension was associated with a higher objective response (72). 
Discussion 
A confusing mix-up exists of the terms prognostic and predictive biomarkers. This is 
partially due to the fact that predictive and prognostic biomarkers are frequently 
exchanged. In addition, during therapy or as a result of therapy initial factors can vary 
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in their presence and actual levels, e.g. a strong prognostic factor can be neutralised as 
a consequence of treatment {HER2/neu). 
Despite a growing number of publications about biomarkers that give information on 
disease outcome, the best prognostic factors are still simple clinical parameters like 
performance status, number of metastatic sites, tumour grade and LDH level. 
Prognostic biomarkers might especially be useful for hypothesis testing for their 
relevance as predictive markers, as targets for therapy and for the selection of patients 
for adjuvant treatment. 
What we need is predictive biomarkers that can guide patient tailored therapy as with 
our increasing knowledge of biologic behaviour of malignancies it becomes more and 
more evident that great heterogeneity among tumours exists. Together with the 
development of new anticancer biologicals an explosive search for effective predictive 
biomarkers has been initiated. Most studies only contribute low levels of evidence due 
to retrospective data and small sample size. In addition, many reports lack sufficient 
information to be compared to other studies, and it is therefore difficult to form an 
opinion about usefulness of such markers in daily practice. A predictive factor is used 
upfront to predict response to therapy or is monitored during treatment to define the 
effectiveness of this treatment. When a biomarker is used repeatedly to evaluate 
response, it is important that it can be measured non-invasively and gives information 
on all tumour lesions. In this perspective, and also for the evaluation of biomarker 
conversion during the course of the disease, there might be a role for imaging 
techniques to quantify levels of biomarkers over time for certain therapies. 
Different tumour types can be treated by blocking the same pathway. Predictive 
biomarkers may be shared between tumour types, like the negative predictive value of 
K-ras mutations in CRC and NSCLC for benefit from EGFRl inhibition. However, EGFRl 
mutations do predict benefit from EGFRl directed therapy in NSCLC but not in CRC. 
Response to c-KIT and EGFRl targeting agents in GIST and NSCLC cannot be predicted 
by the expression of their respective receptors, only by analysing specific mutations in 
the genes encoding for these receptors. This research finally might pay off as it will 
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allow specific selection of patients that will benefit from the TKls at a certain dose­
level. 
For EGFR targeting agents and angiogenesis inhibitors we presented studies that 
indicate that apart from the tumour also drug effects on normal tissues can be used as 
a predictive factor (68-70,72). Preliminary data in CRC patients in which the dose of 
cetuximab was titrated to skin rash suggests improvement of tumour response rate 
(71). 
These findings show that toxicity caused by the drug can be an early predictive factor 
for response. This is of great interest, because such clinical phenomena are much 
cheaper, always available and may be easier to exploit than the previously discussed 
genes or their products. 
Biomarkers are in general based on single markers. However, given the fact that 
tumour biology is often dictated by several essential cellular alterations it may be idle 
to think that single factors will be enough as predictive or prognostic factors in 
oncology. Solutions are now sought by analysing multiple factors with multiple reverse 
transcriptase-polymerase chain reaction (RT-PCRs), RNA microarrays and tissue 
microarrays. Significant contributions have already been made in the area of breast 
cancer research. Paik and colleagues tested whether the results of a RT-PCR assay of 
21 prospectively selected genes in paraffin-embedded tumour tissue would correlate 
with the likelihood of distant recurrence in patients with node-negative, tamoxifen­
treated breast cancer who were enrolled in the National Surgical Adjuvant Breast and 
Bowel trial B-14. RT-PCR of the selected genes was significant in predicting recurrence 
and overall survival {73). Other microarray studies in breast cancer identified 
independent sets of genes that might have prognostic value {29,74-76). 
Until recently, analysis was directed at identifying major differences in the expression 
of separate genes. Currently, there is increasing interest in minor changes in related 
genes that are involved in particular signalling pathways. Elucidation of pathways that 
are dysregulated in a specific tumour may lead to rational treatment selection (77). 
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In conclusion, prognostic biomarkers for relapse after local treatment are needed for 
better patient selection for adjuvant treatment strategies. Discovery of prognostic 
factors in the metastatic setting may identify new therapeutic targets and new 
predictive factors. The need for more upfront predictive biomarkers to select patients 
for tailored therapy is clear. Clinical observations during treatment can contribute to 
the identification of upfront predictive biomarkers, like EGFRl-mutations in non­
smoking NSCLC patients. In addition, early predictive markers might be useful in dose 
selection and early response measurement, because classical response measurement 
by RECIST criteria underestimates the clinical benefit of the new biological agents. 
Progress is made, but there is still an urgent need for prospective data to validate all 
the small, hypotheses generating studies and it is therefore of great importance that 
biomarker analyses are incorporated in randomised clinical trials as a separate 
objective. 
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Abstract 
Sulindac reduces colorectal cancer risk in genetically susceptible humans and animals. 
The molecular mechanisms underlying these effects are incompletely understood. 
Many studies suggest an important role for induction of apoptosis involving the 
mitochondrial pathway and the death receptor pathway. Alternatively, mechanisms 
involving the APC-�-catenin-Wnt pathway have been suggested, possibly mediated by 
p21. We determined the effects of sulindac on apoptosis and expression of death 
receptor (DR)-4 and DRS, �-catenin, and p21 in normal-appearing colorectal 
epithelium. Biopsies were obtained before and after sulindac treatment during two 
chemoprevention studies. Patients (n = 18) with hereditary nonpolyposis colorectal 
cancer (HNPCC) received 150 mg sulindac bd for 4 weeks in a placebo-controlled 
crossover design. Patients (n = 6) with familial adenomatous polyposis (FAP) received 
150 mg sulindac bd for 6 months. Apoptosis was assessed by M30 staining and 
expression patterns of DR4, DRS, �-catenin, and p21 were studied 
immunohistochemically. In HNPCC patients, apoptotic indices were similar following 
placebo and sulindac. Also in FAP patients, apoptotic indices were not different after 
sulindac compared with pretreatment values. Expression of DR4 and DRS was 
observed in all samples with no consistent differences between placebo/baseline and 
sulindac. Intensity of membranous �-catenin staining was lower in HNPCC samples 
following sulindac compared with placebo (P < 0.001). Similar results were obtained in 
FAP samples (P < 0.01). p21 expressions before and after sulindac treatment were 
similar in both patient groups. In conclusion, sulindac inhibits �-catenin expression in 
normal colorectal epithelium from HNPCC and FAP patients without affecting 




Colorectal cancer is the second leading cause of cancer death in the Western world. 
Familial adenomatous polyposis (FAP} and hereditary nonpolyposis colorectal cancer 
(HNPCC} are well-defined conditions predisposing to colorectal cancer (1). Numerous 
studies have established the chemopreventive effects of nonsteroidal anti­
inflammatory drugs (NSAIDs) as sulindac (2-4) and celecoxib (5) in patients with FAP, 
whereas studies in HNPCC patients are ongoing (6). 
The precise mechanisms by which NSAIDs mediate their effects are incompletely 
understood, but likely involve induction of apoptosis (7-9). Apoptosis is controlled via 
two major pathways, one originating at the cell membrane, the extrinsic pathway, and 
one involving the mitochondria, the intrinsic pathway (10). Apoptotic pathways 
originating at the cell membrane involve death receptors like Fas, tumor necrosis 
factor receptor 1, death receptor (DR}-3, DR4, and DRS, which are activated on binding 
to their respective ligands (10). Recent reports reveal that the NSAID sulindac mediates 
apoptosis through the mitochondrial pathway in colon cancer cells, involving caspase 9 
and BAX (11). Sulindac-induced apoptosis has also been shown to involve DRS, as 
sulindac induced up-regulation of DRS mRNA and protein levels, but not of DR4, in 
vitro (12,13}. 
The initial event in the neoplastic transformation of normal colon epithelium is 
assumed to be the activation of the Wnt signaling pathway, caused by mutations in the 
APC or the 8-catenin gene (14}. This leads to cytoplasmic and subsequent nuclear 
accumulation of �-catenin. In the nucleus, �-catenin binds and activates the 
transcription factor T-cell factor 4 (TCF4}. Finally, activated TCF4 activates a genetic 
program presumed to be responsible for early adenoma formation (14). Several in 
vitro studies suggest that sulindac mediates its antineoplastic effect by inhibition of 
the Wnt pathway (15-17). This is supported by studies in APCmin mice {18} and in 
adenomas of FAP patients (15). Recent reports reveal that sulindac affects Wnt 
signaling by modifying expression of p21, a cyclin-dependent kinase inhibitor (19). 
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To provide further insight into the mechanisms involved in the chemopreventive 
action of sulindac, we investigated the effects on apoptosis and expression of DR4, 
DRS, �-catenin, and p21 in normal epithelium of FAP and HNPCC patients. 
Materials and methods 
Patient selection 
Recently, a chemoprevention biomarker study was done in proven or probable HNPCC 
patients at the University Medical Center Groningen (20}. Proven patients were 
carriers of a mutation in one of the mismatch repair genes (hMLHl, hMSH2, hMSH6}. 
Probable HNPCC patients had a family history meeting the revised Amsterdam criteria 
(21} and a medical history of an HNPCC-associated cancer, a colorectal adenoma at an 
early age (<40 years), or an adenoma with advanced neoplastic characteristics. 
Individuals with prior colorectal surgery were enrolled when the estimated length of 
the remaining colon exceeded 50% of the original length. In this randomized double­
blind placebo-controlled crossover study, patients were assigned to receive sulindac 
150 mg orally twice daily or an identically appearing placebo for 4 weeks. Both were 
produced by the Pharmacy Department of the University Medical Center. After a 
washout period of 4 weeks, patients crossed over to the alternative treatment for 
another 4 weeks. Full colonoscopy was done at 4 and 12 weeks. Biopsies were taken of 
macroscopically normal mucosa with a standard biopsy forceps at four locations: 
ascending, transverse, and sigmoid colon, and rectum. Samples were formalin fixed, 
embedded in paraffin, and coded to disguise the subjects' treatment assignment. The 
local medical ethical committee approved the study. Reasons for exclusion from the 
study were use of a NSAIDs in the 3 months before the study, pregnancy, or a history 
of peptic ulcer disease or gastrointestinal bleeding. 
For the present study, sufficient residual material was available from 18 patients (12 
men, 6 women; mean age, 44.6 years). Nine of these patients were proven carriers of a 
mutation in the mismatch repair gene hMSH2 (n = 6) or hMLHl (n = 3). Samples from 
FAP patients were obtained from a study in which FAP patients had been treated with 
sulindac 150 mg twice daily during 9 months, as described previously (2, 22}. From six 
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patients, tissue sections were available from normal-appearing rectal mucosa before 
and after 6 months of treatment. These six patients had adenomas at baseline and 
showed regression of adenomas after treatment with sulindac. 
lmmunohistochemistry for apoptosis, DR4, DRS, 8-Catenin, and p21 
For immunohistochemistry, 3 µm thick sections were cut from paraffin blocks and 
deparaffinized in xylene. Apoptosis was determined using the murine monoclonal 
antibody M30 (Boehringer Mannheim, Mannheim, Germany) directed against cleaved 
cytokeratin-18 that is expressed during early apoptosis (23). Staining procedures for 
M30, DR4, and DRS were done as previously described (23, 24). For f3-catenin staining 
(1:1,000; clone 14, Transduction Laboratories, Lexington, KY), antigen retrieval was 
carried out by microwave treatment for 8 minutes at 700 W in 0.01 mol/L citrate 
buffer (pH 6.0). For p21 staining (1:50; clone WAFl, Oncogene Research, Darmstadt, 
Germany), antigen retrieval was done by heating slides thrice for 5 minutes at 115°C 
with 5-minute cooling in between in maleate buffer in a preheated autoclave (Presto 
deluxe, Presto, Eclaire, WI). After blocking of endogenous peroxidase with 0.3% 
hydrogen peroxide for 30 minutes and incubation with avidin and biotin blocking 
solutions (Vector Laboratories, Burlingame, CA), primary antibodies were applied for 1 
hour at room temperature. After washing with PBS, slides were incubated with 
appropriate secondary and tertiary antibodies. Slides were counterstained with 
hematoxylin. As negative controls, slides were stained in absence of the primary 
antibody. As positive controls, sections of normal human liver (DR4 and DRS) and 
colorectal cancer (f3-catenin, p21, and M30) were included. For each antibody, slides 
were stained in one batch. 
Evaluation of staining 
Slides were independently evaluated by light microscopy by two investigators in a 
coded fashion. For M30 and p21, positive cells were expressed as percentage of the 
total number of cells counted (apoptotic and p21 indices, respectively). Only complete 
longitudinal crypts and at least 500 cells were counted. Intensity of DR4, DRS, and f3-
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catenin staining was semiquantitatively graded using a scale from 1 to 3 (1, weak 
staining; 2, moderate staining; 3, intense staining). For f3-catenin, staining was 
separately recorded as membranous, cytoplasmic, or nuclear. To assess changes in 
staining intensity as a consequence of treatment, intensities were compared in paired 
slides and scored as increased, decreased, or unchanged. When the observers' scores 
differed, cases were re-evaluated using a multiheaded microscope and the final grade 
was reached by consensus. 
Statistics 
For statistical assessment of changes in apoptotic indices, p21 indices, and cumulative 
DR4, DRS, and f3-catenin expression scores following sulindac treatment versus 
placebo, the Wilcoxon rank sum test for paired samples was used. Changes in 
distribution of staining intensities of DR4, DRS, and f3-catenin were assessed using chi­
square tests. To determine differences between various colonic regions in HNPCC 
patients, Mann-Whitney tests for continuous variables and chi-square tests for 
discontinuous variables were conducted. Differences between proven and probable 
HNPCC patients were assessed using Mann-Whitney test for continuous variables and 
chi-square tests for discontinuous variables. Reported P values were two tailed and 
significance was assumed at P < 0.05. SPSS for Windows software (SPSS, Inc., Chicago, 
IL) was used for all statistical analyses. 
Results 
To assess changes in apoptosis, DR4, DRS, f3-catenin, and p21 expression following 
placebo and sulindac, samples were analyzed pairwise, comparing staining results in 
biopsies from the same patient in the same colonic region. The analysis of sample pairs 
was hampered by the problem of limited availability of material. In case one in a pair 
of samples contained insufficient material to allow evaluation, it meant that these 
samples were not evaluated. Not all biopsies obtained in HNPCC patients were of 
sufficient quality, limiting the number of sample pairs analyzed to 55 for apoptotic 
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indices, 64 for DR4, 67 for DRS, 48 for �-catenin, and 63 for p21 expression .  The 
number of sample pairs analyzed from FAP patients was six for all sta ining procedures. 
Apoptosis 
When comparing cumulative apoptotic indices between placebo and sul indac 
treatment ( in HNPCC} and between pretreatment and posttreatment with sulindac (in 
FAP), no statistically significant differences were observed (Table 1, left panel) . G iven 
the predi lection for the proximal colon in the development of colorectal neoplasia in 
HNPCC, apoptotic indices were compared in different colonic regions in HNPCC 
patients. For each region, apoptotic indices were not significantly different fol lowing 
sulindac compared with placebo a lthough in biopsies from the proximal colon there 
was a trend towards lowering of apoptotic ind ices fol lowing sul indac. 
DR4, DRS, and 8-catenin expression following placebo (HNPCC} and at baseline {FAP) 
I n  a l l  patient samples, cytoplasmic stain ing of DR4 and DRS was observed. For DR4, 
the immunoreactivity of epithelial cells increased gradual ly from the crypt base to the 
luminal surface. DRS immunoreactivity was seen a long the entire crypt axis. �-catenin 
expression was membranous in a l l  investigated samples ( i .e., no cases of cytoplasmic 
or nuclear sta ining were seen).  In HNPCC patients, DR4, DRS, and �-catenin sta ining 
intensities were similar in al l  four investigated regions of the colon. No differences 
were seen between proven carriers of MLH l  or MSH2 gene mutations and patients 
without an established mutation. Also, no d ifferences in expression patterns were 
observed between M LH l  and MSH2 mutation carriers. 
Changes in DR4, DRS, and 8-catenin expression following sulindac {HNPCC and FAP) 
Alterations in expression patterns of DR4, DRS, and �-catenin were ana lyzed, studying 
the distribution of sta ining intensities and changes in absolute and cumulative sta ining 
intensity scores. To assess whether changes in staining intensities were consistent in  
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Table 1. Mean apoptotic and p21 indices in sample pairs from normal colon mucosa following sulindac 
compared with placebo (HNPCC) and baseline values (FAP). 
n Apoptotic index* (%) n P21* (%) 
HNPCC Placebo Sulindac Placebo Sulindac 
Cumulative 55 0.76 ± 0.12 0.70 ± 0.09 63 38.1 ± 1.1 39.7 ± 0.9 
Ascendens 14 0.81 ± 0.13 0.67 ± 0.18 16 36.9 ± 3.0 42.7 ± 2.4 
Transverse 16 1.03 ± 0.39 0.69 ± 0.11 17 38.2 ± 2.2 38.7 ± 1.2 
Sigmoid 14 0.56 ± 0.11 0.94 ± 0.25 17 36.8 ± 2.5 36.2 ± 1.2 
Rectum 11 0.57 ± 0.11 0.43 ± 0.11 13 40.4 ± 2.2 41.9 ± 2.0 
FAP Baseline Sulindac Baseline Sulindac 
Rectum 6 0.88 ± 0.25 0.38 ± 0.31 6 17.7 ± 0.5 31.6 ± 12.4 
*Data expressed as mean ± SE. 
HNPCC patients, cumulative scores were calculated for each patient by adding the 
respective intensity scores in the samples from different parts of the colon. Cumulative 
scores were calculated when at least two sample pairs per patient were available. 
Table 2 summarizes changes in the distribution of staining intensities of DR4, DRS, and 
�-catenin expression following sulindac compared with placebo (HNPCC) and baseline 
(FAP). For DR4 and DRS, staining scores were similarly distributed following sulindac 
compared with placebo in HNPCC patients and compared with baseline values in FAP 
patients. For �-catenin, staining scores were distributed differently following sulindac 
compared with placebo in HNPCC (P < 0.001) and compared with baseline values in 
FAP samples (P < 0.01; Table 2), with lower scores in both patient groups after 
sulindac. In sample pairs, the intensity scores of DR4 staining were not consistently 
different following sulindac compared with placebo in HNPCC: higher in 26/64 pairs, 
lower in 27 /64 pairs, and unchanged in 11/64 pairs (not significant). For DRS, similar 
results were obtained: higher in 19/67, lower in 20/67, and unchanged in 28/67 pairs 
(not significant). The intensity scores of membranous �-catenin staining following 
sulindac compared with placebo were higher in 7 /48, lower in 26/48, and unchanged 
in 15/48 pairs (P < 0.05}. In paired FAP samples, DR4 and DRS staining intensities were 
similar between baseline and sulindac in all six samples. For membranous �-catenin, 
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staining intensities were lower following sulindac in three of six and unchanged in 
three of six FAP pairs {not significant}. In cases with lower staining intensity of 
membranous '3-catenin following sulindac, no apparent increase in cytoplasmic or 
nuclear staining was seen. With respect to cumulative staining intensity scores in 
HNPCC, scores were similar for DR4 and DRS following placebo and sulindac {data not 
shown}. However, for '3-catenin, cumulative intensity scores were significantly lower 
following sulindac compared with placebo {P < 0.01; Fig. 1}. 
Table 2. Distribution of DR4, DRS, and B-catenin staining intensities in sample pairs from normal colon 
mucosa following sulindac, compared with placebo (HNPCC) and baseline values (FAP). 
HNPCC FAP 
Staining score* Placebo Sulindac Baseline Sulindac 
n/n tested (%)t n/n tested (%) 
DR4 1 5/64 (8%) 6/64 {9%) 0/6 1/6 
2 31/64 (48%) 32/64 {50%) 5/6 4/6 
3 28/64 {44%) 26/64 (41%) 1/6 1/6 
DRS 1 10/67 (15%) 9/67 (13%) 4/6 3/6 
2 36/67 {54%) 39/67 (58%) 2/6 3/6 
3 21/67 {31%) 19/67 (28%) 0/6 0/6 
13-catenin 1 4/48 (8%) 9/48 (19%):j: 0/6 2/6 $ 
2 24/48 {50%) 33/48 (69%) 4/6 3/6 
3 20/48 (42%) 6/48 {12%) 2/6 1/6 
*Assessed as described in the Materials and Methods section. 
tNumber of samples investigated varied in patient groups as a consequence of limited availability of slides. 
=l=Distribution of staining intensities of h-catenin in HNPCC following placebo versus sulindac, P < 0.001. 
$Distribution of staining intensities of 13-catenin in FAP at baseline versus sulindac, P < 0.01. 
p21 
Mean percentages of p21-positive cells following placebo and sulindac are shown in 
Table 1 {right}. After placebo, p21 indices were comparable in different colon regions 
in HNPCC patients. p21 indices were not significantly different between HNPCC and 
FAP patients. Following sulindac, p21 indices were similar compared with placebo 
{HNPCC) and baseline {FAP} values. 
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Figure 1. Cumulative �-catenin intensity scores in paired samples from HNPCC patients (n = 12) following 
placebo (1) and sulindac (2). 
Discussion 
The efficacy of chemopreventive agents in the colorectum is routinely assessed by 
measuring one or more end points: biomarker modulation in the at-risk mucosa, 
adenoma regression, adenoma suppression, or adenoma prevention (25). Our 
biomarker modulation study evaluated changes in apoptosis and expression of DR4, 
DRS, 13-catenin, and p21 occurring in normal-appearing mucosa following treatment 
with sulindac in HNPCC and FAP patients. Although, in general, few conclusions can be 
drawn from biomarker studies, they provide an opportunity to identify mechanisms of 
action of chemopreventive agents. In particular, quantitative measurements of 
apoptosis are considered a sensitive index of the biological effects of nonsteroidal anti­
inflammatory drugs (6). Whereas several biomarker modulation studies are available in 
FAP patients, our placebo-controlled crossover study is one of only a few in HNPCC 
patients. We found that sulindac did not alter the apoptotic index in normal colorectal 
mucosa from HNPCC and FAP patients compared with placebo (HNPCC) or baseline 
(FAP). As anticipated from these null results, no changes were seen in expression of 
the death receptors DR4 and DRS. However, reduced membranous 13-catenin 
expression patterns were observed following sulindac in both patient groups, 
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suggesting an inhibiting effect of sulindac on the APC-(3-catenin-Wnt pathway. Sulindac 
is one of the most extensively studied NSAIDs in the setting of chemoprevention of 
colorectal cancer (7). An important mechanism behind the chemopreventive effect of 
sulindac seems to be the induction of apoptosis (7). Sulindac is a prodrug that is 
converted into sulindac sulfide and then sulindac sulfone by colonic bacteria {26). In 
vitro, both metabolites induce apoptosis in colon cancer cells (7,11,27), including 
mismatch repair-deficient cells {28). In APCMin mice, a mouse model of FAP, sulindac 
had an antitumor effect and was associated with induction of apoptosis {29). Also in a 
mismatch repair-deficient APCmin mouse model, carrying genetic features of both FAP 
and HNPCC, sulindac inhibited intestinal adenoma development {30). Whether this 
effect was mediated by induction of apoptosis was not studied. In normal rectal 
mucosa of FAP patients with adenomas, an increase or change of apoptosis has been 
observed following sulindac therapy {8,31). We did not find a significant effect on 
apoptosis in our FAP material, but this may be due to the limited number of cases. 
Interestingly, in presymptomatic, phenotypically unaffected FAP patients, no changes 
in apoptosis were seen on sulindac treatment {32). In accordance with these data, 
sulindac did not have a preventive effect on the development of adenomas in these 
phenotypically unaffected patients {33). There is no data on the efficacy of 
chemoprevention in HNPCC patients, although studies are ongoing (6, 34). Taken 
together, the chemopreventive action of sulindac in FAP patients seems to be 
mediated by induction of apoptosis, but limited to the stage when adenomas have 
already developed. 
Recent studies have suggested that (3-catenin is a target for the chemopreventive 
action of NSAIDs {16, 35, 36). In vitro, NSAIDs, including sulindac, prevented nuclear 
accumulation of (3-catenin (16, 35). Oncogenic activation of the Wnt signaling pathway 
resulting in nuclear translocation of (3-catenin is considered critical for the initiation in 
intestinal epithelial neoplastic transformation {37). A recent report reveals that 
adenomas from FAP patients showed less nuclear (3-catenin staining after sulindac 
treatment (15). Similar results were obtained in APCMin mice, in normal intestinal 
mucosa {38) as well as in adenomas {39). Our results in normal colon mucosa, with a 
99 
Effects of sul indac on normal colon in HNPCC and FAP 
reduction in membranous expression of 13-catenin following sulindac, are consistent 
with these data. Whether this phenomenon is limited to subjects with a predisposition 
for colorectal adenoma development or also applies to the general population remains 
unknown. Finally, we assessed whether changes in 13-catenin expression were 
associated with alterations in p21 expression. Recent data indicated that active Wnt 
signaling decreases p21 concentrations, preventing cells from entering Gl arrest or 
differentiation, thereby allowing cells to proliferate (40). In a previous study of three 
patients treated with sulindac, p21 expression increased in two compared with 
pretreatment values in rectal biopsy specimens (41). Our results in a larger patient 
group do not confirm these data. Although we recently postulated that sulindac could 
mediate its effect on intestinal adenoma formation by modifying p21 expression (19), 
the present study does not support such a mechanism. 
In summary, in normal colorectal mucosa from HNPCC and FAP patients, sulindac had 
an inhibiting effect on 13-catenin expression without affecting apoptotic indices and 
DR4, DRS, and p21 expression. Our data provide further support for inhibition of the 
Wnt signaling as a contributing mechanism of chemoprevention by sulindac. Whether 
this effect is universal or limited to patients genetically predisposed to colorectal 
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Serial 111 1n-mapatumumab scintigraphy in cancer patients 
Abstract 
Purpose: To visualize tumor lesions by serial 111 1n-mapatumumab scintigraphy and 
determine 1111n-mapatumumab pharmacokinetics in patients with advanced solid 
tumors at the start and during treatment with the TRAIL-Rl targeting antibody 
mapatumumab plus gemcitabine and cisplatin. 
Experimental design: Patients with advanced solid tumors received mapatumumab 20 
mg/kg iv and cisplatin 80 mg/m2 iv on day 1 and gemcitabine 1250 mg/m2 iv on days 1 
and 8, every 21 days. Patients received 150 MBq 1111n-mapatumumab in cycle 1 and 
cycle 3. Thirty minutes and at day 1, 3 and 6 after the first and second tracer injection 
planar whole body imaging and single-photon emission computed tomography (SPECT) 
were performed. SPECT images were fused with CT. TRAIL-Rl tumor expression was 
assessed immunohistochemically. Pharmacokinetic analysis of 1111n-mapatumumab 
was executed in both cycles. 
Results: In 5 of the 12 patients, 11 out of 18 tumor lesions known by CT were 
visualized with 1111n-mapatumumab SPECT. A large heterogeneity was seen in 1111n­
mapatumumab uptake between these patients. Two melanoma patients showed 
remarkable intense tracer uptake. In 3 patients all lesions were visualized. SPECT 
results in cycle 3 were comparable to the first SPECT series. Three of the 4 patients 
having positive 111ln-mapatumumab scintigraphy and tumor tissue available showed at 
least low cytoplasmic TRAIL-Rl expression. Intensity of staining did not correlate with 
positive 1111n-mapatumumab scintigraphy or tumor response to treatment. 
Conclusions: The 1111n-mapatumumab tumor uptake in this group of patients was 
variable and the value of tumor imaging in upfront patient selection for 




Achieving tumor cell death is an ultimate goal in anticancer treatment. The naturally 
occurring Tumor Necrosis Factor (TNF}-Related Apoptosis Inducing Ligand (TRAIL} 
induces apoptosis via activation of the TRAIL receptors (TRAIL-Rl and TRAIL-R2} are 
present on a broad range of tumor cells at variable expression levels. Moreover, TRAIL 
induces apoptosis in cancer cells, but not normal cells. These findings have raised 
interest in inducing tumor apoptosis via TRAIL-Rl and TRAIL-R2 targeting. 
Mapatumumab (HGS-ETR1, TRM-1} is a fully human TRAIL-Rl agonistic monoclonal 
antibody (mAb}. Single agent mapatumumab showed no major toxicities in two phase I 
studies in patients with advanced solid tumors or non-Hodgkin's lymphomas (1,2}. The 
mean terminal elimination half-life of mapatumumab ranged from 14 to 28 days (1,2}. 
Three phase II single agent studies have been conducted in patients with non-small cell 
lung cancer, non-Hodgkin's lymphoma or colorectal cancer, respectively (3-5}. In the 
non-small cell lung cancer and colorectal cancer studies, the best observed response 
was stable disease and in the non-Hodgkin's lymphoma study two complete and one 
partial tumor responses were reported. 
Mapatumumab combined with gemcitabine and cisplatin resulted in increased 
cytotoxicity in human tumor cell lines and mouse xenograft models. In a phase I study 
patients with solid malignancies were treated with this combination (6}. This 
combination with maptumumab up to 30 mg/kg every 3 weeks was well tolerated and 
safe. No alterations in the pharmacokinetic profiles of the drugs were observed. Partial 
responses were observed in 12 patients across dose levels and stable disease was seen 
in 25 patients. 
At the moment little is known about the tissue biodistribution of mapatumumab. It is 
unknown whether mapatumumab reaches the tumor in sufficient levels to be effective 
against tumor cells. Interestingly, in mice bearing human colorectal tumor xenografts, 
TRAIL-Rl was upregulated by chemotherapy and antitumor activity was markedly 
enhanced (7). It is unknown whether upregulation of TRAIL-Rl in the tumor occurs in 
patients as a result of concomitant chemotherapy. 
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We hypothesized that radiolabeled mapatumumab can help to visualize high TRAIL-Rl 
expressing tumor lesions and support future selection of patients that may benefit 
from this treatment. We therefore developed indium-111 {111 1n) radiolabeled 
mapatumumab suitable for clinical use. In high TRAIL-Rl expressing human xenografts 
in mice specific 1111n-mapatumumab uptake was shown (8). 
The aim of this study was to evaluate tumor lesion visualization (targeting) by serial 
111 1n-mapatumumab scintigraphy in patients with advanced solid tumors at the start 
and during treatment with mapatumumab plus gemcitabine and cisplatin. 
Furthermore, the biodistribution of 1111n-mapatumumab was studied, including 
calculation of pharmacokinetic parameters. 
Patients and Methods 
Eligibility criteria 
Eligibility criteria for this study were similar to inclusion criteria in the preceding phase 
I study (6). Eligibility criteria included: patients with histologically or cytologically 
confirmed advanced solid malignancies for whom no standard therapeutic options 
were available or for whom gemcitabine and cisplatin was considered an appropriate 
treatment; Eastern Cooperative Oncology Group (ECOG) performance status O or 1; 
age � 18 years; a life expectancy � 3 months; adequate bone marrow, hepatic, and 
renal function; no other anti-cancer treatment within previous 3 weeks. Excluded were 
patients with known positive human immunodeficiency virus status; known chronic or 
acute viral hepatitis; clinical signs of brain metastases; hearing loss requiring the use of 
a hearing aid; neuropathy � grade 2; myocardial infarction, cerebrovascular accident or 
� NYHA class I l l congestive heart failure within 6 months. 
The study was approved by the local medical ethical committee and is registered under 
trial number NTR2103. All patients provided written informed consent. 
Treatment 
Patients were treated as in the previous phase I study (6). Gemcitabine (Eli Lilly) 1250 
mg/m2 iv on days 1 and 8 and cisplatin (Pharmachemie) 80 mg/m2 intravenously (iv) on 
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day 1 were administered. In addition, patients received mapatumumab (provided by 
Human Genome Sciences Inc) 20 mg/kg iv in 2 hours on day 2 of cycle 1 and 3 and on 
day 1 of cycles 2 and 4-6. Cycles were repeated every 3 weeks for a maximum of 6 
cycles. 
Chemotherapy doses were reduced according to the phase I study protocol (6): when 
treatment was delayed for > 1 week, in the case of severe toxicity (,2: grade 3 according 
to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 
3.0) considered to be at least possibly related to chemotherapy or for the patient's 
safety in the opinion of the investigator. Cycle delays up to 2 weeks were permitted for 
hematologic recovery. A baseline CT scan was performed within 28 days before the 
start of cycle 1. CT-response was assessed after 3 and 6 cycles by Response Evaluation 
Criteria in Solid Tumors (RECIST version 1.0) (9). In the absence of disease progression 
after 6 cycles, continuing mapatumumab monotherapy was allowed. 
111/n-mapatumumab production and scintigraphy 
Clinical grade 1111n-mapatumumab was produced as described earlier {10). In short, 
reconstituted mapatumumab was conjugated with the chelator 2-{4-
isothiocyanatobenzyl)-diethylenetriaminepentaacetic acid {p-SCN-Bn-DTPA, 
Macrocyclics), purified by ultrafiltration and stored at -80°C. GMP-produced 1111nCl3 
{Covidien) was used to radiolabel the conjugate. Quality control was performed to 
ensure antigen binding capacity {> 80%}, stability and {radio)chemical purity {> 95%}. 
Size-exclusion chromatography {SE-HPLC), thin-layer chromatography {TLC) and 
BIAcore analysis were performed as described earlier (8, 10). 
Patients received 150 MBq 1111n-mapatumumab {10 mg), iv 1.5 hours after the start of 
the unlabeled mapatumumab infusion in cycle 1. If, after entering the first 4 patients in 
the study, tumor lesions were not adequately visualized with this treatment scheme, 
possibly due to TRAIL-Rl saturation by therapeutic mapatumumab dose, 150 MBq 
1111n-mapatumumab would be administered 7 days before the unlabeled 
mapatumumab infusion in cycle 1. On day 2, cycle 3, the 150 MBq 111 1n-mapatumumab 
was administered 1.5 hours following the start of the therapeutic dose mapatumumab 
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for both imaging schemes. All patients were monitored for infusion related reactions 
the first 4 hours after mapatumumab infusion. 
Planar whole body imaging and single-photon emission computed tomography (SPECT) 
was performed at 30 minutes and on days 1, 3 and 6 after the first and second tracer 
injection. Planar whole body imaging was performed using a two-headed gamma­
camera (Ecam or MultiSpect 2, both Siemens), equipped with parallel-hole medium­
energy all purpose collimators, at a scan speed of 10 cm/minute (at 30 minutes and 1 
day post-injection) or 5 cm/minute (at 3 and 6 days post-injection) and stored digitally 
in a 256x1024 matrix. SPECT images were acquired of pre-defined tumor regions, using 
180 degrees of sampling with 32 projections per head, 45 seconds acquisition time per 
projection and a 128 x 128 matrix size. 
Image and data analysis 
Non-scatter corrected SPECT images were reconstructed iteratively with an ordered 
subset expectation maximization algorithm (8 iterations, 16 subsets). A 9.00 mm 
Gaussian filter was applied. Whole body and SPECT reconstruction images were 
analyzed by two investigators (AB and CO) for 111 1n-mapatumumab uptake in possible 
tumor lesions. SPECT images were fused with conventional computed tomography (CT) 
images (obtained before start and after 3 cycles of treatment for response assessment) 
to validate regions of increased tracer uptake as tumor lesions, using a LEONARDO 
e.soft workstation (Siemens). 
Dosimetry 
The radiation-absorbed whole body and organ dose was estimated using the 
conjugated views counting technique with partial background subtraction and 
correction for attenuation and physical decay, as described previously (11, 12). Briefly, 
regions of interest (ROI) were drawn on the anterior and posterior whole body images 
of organs of interest that showed tracer uptake. Residence times were calculated using 
the SPRIND software package (13). Subsequently, OLINDA software was used to 
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calculate the organ radiation-absorbed doses and the effective dose, according to 
ICRP60 {14). 
111In-mapatumumab uptake in tumor lesions was assessed using the day 3 scan which 
showed the best image quality. 3D volumes of interest {VOis) were drawn around 
tumor lesions and normal muscle in the fused SPECT /CT images. 111In-mapatumumab 
accumulation was quantified as the mean and maximum counts per voxel, using a 
threshold of 40% of the maximum value. AMIDE Medical Image Data Examiner 
software {version 0.9.2, Stanford University {15)) was used as described previously 
{16). Tumor to normal muscle tissue ratios were calculated, to al low inter patient 
comparison. 
111 ln-mapatumumab pharmacokinetics 
Venous blood samples in heparin col lection tubes were obtained prior to, after 10 and 
30 minutes, 1 and 4 hours and 1, 3, 6 and 13 days following the first and second 111In­
mapatumumab injection. Urine {24 hours) was col lected during the first 4 days after 
tracer injection. Total radioactivity in the whole blood, plasma, and urine samples was 
determined using a calibrated gamma counter {wel l type LKB-1282-Compu-gamma 
system, LKB Wal lac). 
Pharmacokinetic parameters were derived using the Bayesian ITS module {KINPOP) of 
MW/PHARM {version 3.50, MediWare) for 111 In-mapatumumab blood clearance. The 
data from plasma, blood and urine were analyzed in a 1-, 2- and 3-compartment model 
to determine the best fit. 111In-mapatumumab blood clearance was calculated using 
non-linear regression analysis. Based on the blood curves, the area under the curve 
{AUC) half life {T ½) during distribution {a) and elimination {�) phase, total clearance 
{CL), volume of distribution {V1) and steady-state volume {V55) were determined. 
Statistics 
Associations between parameters were assessed with Pearson correlation coefficients. 
Differences between pharmacokinetic data were calculated using the non-parametric 
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Mann Whitney U-test in SPSS 16.0 (SPSS Inc.). Two-sided P-values � 0.05 were 
considered statistically significant. 
lmmunohistochemistry 
For immunohistochemistry, pretreatment tumor tissue was used. Slides of 3 µm were 
cut from paraffin blocks and stained immunohistochemically for TRAIL-Rl as described 
previously (17). They were scored for TRAIL-Rl staining intensity into four categories 
(no staining, low, moderate, and strong) by two investigators (CO, not blinded for 
clinical outcome, and JB, blinded for clinical outcome). Sections of normal human liver 
served as positive controls. 
Results 
Patients 
Twelve patients were enrolled. Patient characteristics are summarized in Table 1. One 
patient was taken off study after one treatment cycle because of severe nausea and 
vomiting. Two patients discontinued the study after 1 and 2 cycles because of early 
disease progression. These 3 patients therefore did not undergo the second imaging 
series. One melanoma patient was treated with 22 cycles before progressive disease 
was observed. The best response in this patient was stable disease. 
The treatment was in general well tolerated. The observed toxicity was comparable to 
the previous phase I study and consisted mainly of nausea, vomiting, and fatigue (6). 
Three patients discontinued cisplatin prematurely, two because of nausea and 
vomiting, despite optimization of antiemetic treatment after 2 and 5 cycles 
respectively and in one patient asymptomatic decrease in glomerular filtration rate 
occurred after the day 1 treatment of cycle 1. 
Of the 9 evaluable patients, 8 showed stable disease. One patient with pancreatic 
cancer had a confirmed partial response after 3 cycles. 
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No infusion related anaphylactic reactions or other adverse events were seen upon 
111 In-mapatumumab administration. Twelve patients underwent the first imaging 
series. Visual analysis of the SPECT scans showed retained 111In-mapatumumab blood 
pool activity during the scan sequence in all patients ( Figure 1). This was confirmed by 
the calculated long 111In-mapatumumab elimination half-life of approximately 13 days 
(Table 2). In addition to the blood pool, highest 111In-mapatumumab uptake was seen 
in liver, spleen, and kidneys. The 111In-mapatumumab mean effective whole body dose 
determined in this study was 0.20 mSv/MBq (Table 3). The calculated radiation 
absorbed dose for normal organs did not differ significantly after the first and second 
111In-mapatumumab injection (Table 3). 
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The first 4 evaluable patients showed limited tumor visualization. Therefore, in the 
next patients, 1111n-mapatumumab was administered 7 days before the mapatumumab 
infusion in cycle 1. 
Table 2. Pharmacokinetic parameters after 10 mg 1111n-Mapatumumab-injection (mean ± SD). 
Urinary 
AUC T'/2,a T'/2,13 CL Vl Vdss 
excretion 
(h*mg/L) (d) {d) (ml/d/kg) (ml/kg) (ml/kg) 
{% 1D/d) 
N = 17 956.0 ± 314.4 1.0 ± 0.6 12.7 ± 4.2 4.3 ± 1.1 44.0 ± 6.8 70.2 ± 19.7 1.4 ± 0.01 
Abbreviations: SD, standard deviation; AUC, area under plasma concentration-time curve; T½,a and T ½.�, 111 1n­
mapatumumab half-life during distribution phase and elimination phase respectively; CL, total clearance; Vl, 
volume of distribution for the central compartment; Vd,,, volume of distribution at steady state; %1D/d, 
percentage of the injected dose/day. 








Effective dose (whole body; mSv/MBq) 
Abbreviation: SD, standard deviation. 
Scan 1 (n = 9) 
Mean ± SD (mGy/MBq) 
0.34 ± 0.04 
0.26 ± 0.03 
0.36 ± 0.07 
0.25 ± 0.03 
0.14 ± 0.01 
0.32 ± 0.07 
0.14 ± 0.01 
0.20 ± 0.01 
Scan 2 (n = 7) 
Mean ± SD (mGy/MBq) 
0.34 ± 0.03 
0.23 ± 0.04 
0.36 ± 0.07 
0.25 ± 0.02 
0.14 ± 0.00 
0.32 ± 0.09 
0.14 ± 0.00 
0.21 ± 0.01 
The optimal time for the SPECT represents a balance between good tumor/non-tumor 
ratios and sufficient radioactive signal. The best tumor to background ratio was 
obtained 3 days post-tracer injection. The scans performed at day 6 were of inferior 
image quality as a consequence of insufficient counting statistics. 
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30 minutes dayl day3 day6 
Figure 1. Coronal and transversal SPECT images of the chest and upper abdomen 30 minutes and 1, 3 and 6 
days post-injection of 1111n-mapatumumab. Physiological 1111n-mapatumumab uptake is seen in 
predominantly the heart, the descending aorta and the liver. No tumor lesions are visible in these images. 
Figure 3. Coronal, transversal and sagittal CT images and 1111n-mapatumumab SPECT/CT fusion images of two 
melanoma patients, 3 days post-injection. (A) Tumor lesions in the upper abdomen and the left lower pelvic 
region show 1111n-mapatumumab uptake. (B) Intense 1111n-mapatumumab uptake in a tumor lesion in the 
abdominal wall. Arrows indicate tumor lesion. 
In 2 of the 12 patients, strong 111 1 n-mapatumumab uptake in tumor lesions was 
detected when the whole body scintigraphy and SPECT reconstructions were visually 
analyzed. After fusion of CT and SPECT images, tumor lesions were visible in 3 
additional patients. I n  these 5 patients, 11 out of 18 tumor lesions known by CT were 
imaged. Tracer uptake in these 11 lesions was variable. 
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The relation between mean and maximum 1111n-mapatumumab uptake was linear 
{r2=1.00, P < .00001). Further analysis was therefore performed using the maximum 
uptake value, which is not influenced by individual drawing of VOis. Quantification 
showed a 1111n-mapatumumab tumor to muscle ratio of median 3.3 {range, 2 .2-8.0) 
{Figure 2). 
Out of the 5 patients with 111 1n-mapatumumab tumor uptake, 2 patients showed 
markedly intense visualization of metastases {Figure 3) .  Both patients were diagnosed 
with metastatic melanoma. One melanoma patient showed optimal 1111n­
mapatumumab uptake in tumor lesions on the day-3 scan. In the other melanoma 
patient, the tumor lesion was already visible immediately after injection and continued 
to show on subsequent scans with the same intensity. In these 2 melanoma patients, 4 
out of the 6 metastases positive in the first scan were also visualized in the second 
imaging series. One lesion not detected during the first imaging series, showed 111 1n­
mapatumumab tumor uptake during the second series. One of these melanoma 
patients discontinued the study after 3 cycles because of disease progression, the 
other melanoma patient was treated for 22 cycles before the disease progressed. 
In the remaining 3 patients, visual analysis of images showed 1111n-mapatumumab 
tumor uptake in the identical lesions in both the first and second imaging series. 
CT evaluation after the second scan in the 5 patients with 111 1n-mapatumumab tumor 
uptake showed no difference in size of the individual tumor lesions if compared to 
baseline. No new tumor lesions were found with both CT scan and 1111n­
mapatumumab scintigraphy at the time of the second scan {cycle 3) .  
There was no significant difference in 1111n-mapatumumab pharmacotherapeutic 
parameters between the first and second group of patients {P = 0.53) and between the 
first and second imaging series {P = 0. 70). Data were therefore pooled {Table 2). In 
total 5 out of 22 datasets were excluded because of insufficient numbers of samples to 
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Figure 2. Tumor to normal muscle tissue ratios for the patients with mln-mapatumumab uptake in their 
tumor lesions (muscle uptake denoted as 1). Pt, patient. 
lmmunohistochemistry 
Sufficient tumor tissue was available for immunohistochemical analysis in 9 patients. 
Pretreatment tumor tissue was used in 8 patients (obtained 2-9 months before 
enrollment). In 1 patient a tumor sample was obtained 20 months after completion of 
the study treatment. Eight patients showed at least low cytoplasmatic TRAIL-Rl 
expression in tumor cells. In 4 out of 5 patients with 1111n-mapatumumab uptake in 
tumor lesions, tumor tissue was available. Three of these patients showed at least low 
cytoplasmatic TRAIL-Rl expression in their tumor cells. In the remaining patient no 
TRAIL-Rl in tumor cells was detected. No membranous staining was seen. Intensity of 
staining did not correlate with positive 1111n-mapatumumab scintigraphy or tumor 
response to treatment. 
Discussion 
This study showed that 1111n-mapatumumab scintigraphy is feasible and can identify 
tumor lesions in advanced solid tumor patients. Tracer uptake in tumor lesions 
occurred in 5 out of 12 patients. In patients showing tumor uptake, not all tumor 
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lesions detected by CT scan were visualized. The most intense uptake was seen in 2 
patients diagnosed with metastatic melanoma. This is the first proof that a TRAIL-R 
targeting monoclonal antibody can show preferential uptake in known sites of tumor 
in a subgroup of patients. 
Mapatumumab was wel l-tolerated and can be administered repeated ly, in some cases 
for several years without apparent adverse effects (6). In the phase I studies, the 
maximum tolerated dose was not reached and the observed toxicity was mild when 
combined with chemotherapy. As single agent activity has been seen in lymphoma (5), 
it is possible that the drug might play a role in combination therapy. Proper patient 
selection of those that might benefit from this antibody is critical. Nuclear imaging may 
contribute to selecting the appropriate patients for the drug by visualizing specific 
uptake that accumulates in the tumor, as a potential predictor of efficacy of the 
therapy is sufficient drug reaching the target. 
1111n-mapatumumab showed long blood pool circulation, indicated by the extended 
elimination half-life. This reflects a distribution which is general ly seen for intact 
radiolabeled monoclonal antibodies (18). The long 1111n-mapatumumab circulation 
al lows sufficient time for the 1111n-mapatumumab to accumulate in tissues during the 
time-frame of the imaging. 
Large heterogeneity was seen in 1111n-mapatumumab uptake between the various 
patients with known metastases by CT. Given the heterogeneity of tracer uptake 
observed in this study, 1111n-mapatumumab scintigraphy could potential ly identify 
patients that can benefit from mapatumumab-containing therapy. 
Patients showing tumor tracer uptake in the first imaging series, also showed uptake in 
the second imaging series. This indicates that target saturation has not been reached, 
despite the fact the patients at that time had already received 3 therapeutic dosing 
cycles of 20 mg/kg each. This is likely explained by the high TRAIL-Rl receptor turnover 
that is seen after TRAIL-Rl endocytosis induced by TRAIL-Rl targeting (19). In our study 
we performed 111 1n-mapatumumab scintigraphy before the start as wel l  as during 




The 111In-mapatumumab tumor uptake was highest in the 2 melanoma patients. A 
microarray study showed a higher TRAIL-Rl expression in 546 melanomas than in their 
benign nevi (20). Similar results were obtained in a study including 80 melanoma 
patients by immunohistochemical staining for TRAIL-Rl (21). In the current small study 
TRAIL-Rl expression was however not predictive for visualization of tumor lesions. The 
use of archival tumor tissue in this study may not represent the TRAIL-Rl expression 
status of the tumor at the time of imaging, as receptor status of tumors can change 
over time. A future larger study in patients with different tumor types will be needed 
to establish if high 111In-mapatumumab tumor uptake is typical for patients with 
metastatic melanoma. The fact that one of the melanoma patients was treated for 22 
cycles before the disease progressed may indicate that high 111In-mapatumumab 
uptake may be predictive for at least disease stabilization following mapatumumab 
containing treatment. 
In human colorectal cancer bearing mice treated with 60 mg/kg paclitaxel iv TRAIL-Rl 
expression levels increased 20-fold and 111In-mapatumumab uptake was increased 1 .4 
fold (7). The current clinical trial with 111In-mapatumumab scans before and after 3 
cycles of chemotherapy did not indicate that this uptake increased following 
mapatumumab combined with gemcitabine and cisplatin. 
111In-mapatumumab differs from a number of other radiopharmaceuticals visualizing 
cell membrane receptors, as its target, TRAIL-Rl, shows no real overexpression in 
tumor cells versus normal cells. This is in contrast to, for example, the folate receptor 
(up to 6 fold higher expression in ovarian cancer), or the human epidermal growth 
factor receptor 2 (HER2) (up to 100 fold higher expression in breast cancer) (22,23). 
Because TRAIL-Rl shows no apparent overexpression, it can be anticipated that there 
is less driving force when compared with radiopharmaceuticals aimed at targets that 
show clear antigen overexpression, in terms of radiopharmaceutical accumulation. 
Because, in our study there is no clear correlation between immunohistochemically 
determined TRAIL-Rl expression and 111In-mapatumumab tumor uptake, other factors 
determining drug tumor uptake might be involved including vascular density and intra­
tumoral pressure. In addition, the tumor accumulation will be influenced by the rate of 
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TRAIL-Rl endocytosis upon mapatumumab antigen binding and renewal and recycling 
of the TRAIL-Rl membrane receptors (19). The current patient study shows much 
higher 1111n-mapatumumab tumor uptake in the two patients with metastatic 
melanoma than was seen in our animal study and higher than we anticipated. 
SPECT was used to monitor mapatumumab tumor uptake. In future studies, 
mapatumumab could also be radiolabeled with the positron emission tomography 
(PET) isotope 89Zr. The long-lived positron emitter 89Zr has ideal physical characteristics 
for antibody imaging, such as a half-life comparable to 1111n of 3.27 days. Interesting 
results were seen in a recent clinical trial of 89Zr-trastuzumab in patients with breast 
cancer and 89Zr-U36 in patients with head and neck cancer (24-26). PET imaging 
would have advantages over SPECT in terms of spatial resolution, signal to noise ratios 
and quantification. 
In conclusion, 1111n-mapatumumab tumor uptake in this group of patients was variable 
and the value of tumor imaging in upfront patient selection for mapatumumab-based 
treatment needs further evaluation. 
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Abstract 
Background: The extrinsic apoptotic pathway is activated in tumor cells after ligand 
binding to the death receptors TRAIL-Rl and/or TRAIL-R2. Mutations in these death 
receptors might play a role in insufficient apoptosis induction. Recently, the single 
nucleotide polymorphism (SNP) A683C in the TRAIL-Rl gene TNFRSFlOA was identified. 
Cancer cell lines with the 683C variant expressing the TRAIL-Rl Glu228Ala variant are 
less sensitive to rhTRAIL than the wild type carriers. We investigated this SNP in 
genomic DNA samples of patients treated with a regimen that contained a TRAIL-Rl 
targeting antibody, mapatumumab. 
Methods: DNA was isolated from plasma samples of patients with advanced solid 
tumors. Patients were treated with standard doses of gemcitabine and cisplatin, and 
escalating doses of mapatumumab and analyzed for SNP A683C (rs20576) in 
TNFRSFlOA. Association of the genotype data with clinical phenotypes including 
progression-free survival (PFS) and treatment related toxicity was studied in order to 
determine a possible predictive value of this SNP for response to a mapatumumab­
containing treatment. 
Results: TRAIL-Rl polymorphism A683C was analyzed in 44 patients, 33 expressed the 
683A variant, while 9 patients displayed 683A/C heterozygosity. Two patients were 
homozygous for the 683C variant. Patients heterozygous or homozygous for the 683C 
variant were analyzed as one group. PFS between 683A and 683C carriers did not 
differ. No difference was present between both groups with respect to baseline 
characteristics and treatment related hematological toxicity. 
Conclusion: In this first study exploring the effect of SNP TNFRSFlOA 683C on 
mapatumumab-containing treatment we found no difference in PFS or treatment 
related hematological toxicity. Given the small, exploratory nature of our study, an 
effect on disease outcome in the subgroup of patients carrying the TNFRSFlOA 683C 




Induction of apoptosis is an important factor in anticancer therapy. Chemotherapy and 
radiotherapy both induce apoptosis by activating the intrinsic, p53-dependent 
apoptotic pathway. In the past 15 years, research has focused on unraveling another 
apoptosis pathway, known as the extrinsic pathway. The extrinsic pathway can be 
activated upon binding of the naturally occurring tumor necrosis factor-related 
apoptosis inducing ligand (TRAIL) to the death receptors TRAIL-receptor 1 (TRAIL-R1; 
DR4) and TRAIL-R2 (DRS) (1). 
TRAIL-R targeting agents are currently in clinical development in a recombinant soluble 
human form (rhTRAIL/dulanermin) and as agonistic monoclonal antibodies specifically 
targeting TRAIL-R1 or TRAIL-R2. Mapatumumab is a fully human monoclonal antibody 
against the TRAIL-R1 and induces cell death in tumor cells in vitro and in preclinical 
vivo models, while sparing normal cells. Phase I and II clinical studies showed that 
mapatumumab can be safely administered both as single agent and in combination 
with chemotherapy (2-6). The precise role of mapatumumab as anticancer agent 
remains of course to be established in randomized phase 3 trials. However, as holds 
true for all anti-tumor regimens, one can expect that only a subset of cancer patients 
will benefit from this targeted therapy underlining the need for biomarkers allowing 
the selection of patients who are likely to benefit from mapatumumab-containing 
approaches. 
The gene encoding for the death receptor TRAIL-R1, TNFRSFlOA, is located on 
chromosome 8p21. Wolf et al. studied a single nucleotide polymorphism (SNP) in this 
gene (7). The A -> C nucleotide exchange on position 683 of the TNFRSFlOA sequence 
resulted in the amino acid substitution Glu228Ala in the cysteine-rich interaction 
domain 3 (CRD3) of the TRAIL-Rl. TNFRSFlOA 683C heterozygosity was more common 
in germline DNA of head and neck squamous cell carcinoma, chronic lymphocytic 
leukemia (CLL), bladder cancer, and prostate cancer patients compared to healthy 
controls. Moreover, CLL and prostate cancer cell lines carrying the Glu228Ala variant 
were less sensitive to rhTRAIL. Apoptosis signaling via TRAIL-R1 could be restored using 
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mutated TRAIL-like peptides, inducing caspase-8 activation and subsequently apoptosis 
{8). 
The higher incidence of various cancer types and the in vitro resistance to rhTRAIL in 
cells carrying the 683C variant is possibly caused by an insufficient complex formation 
due to reduced rhTRAIL binding and therefore less apoptosis (7,8). Whether cancer 
patients with the germline SNP A683C in TNFRSFWA are less sensitive to TRAIL-Rl 
targeting therapy such as rhTRAIL and agonistic TRAIL-Rl antibody is unknown. To our 
knowledge this is the first study evaluating the TRAIL-Rl polymorphism A683C in 
patients treated with TRAIL-Rl targeting therapy. For this purpose we performed a 
retrospective analysis of the TRAIL-Rl polymorphism A683C in relation to disease 
outcome and toxicity in patients treated with a mapatumumab-containing regimen in 
prospective clinical trials. 
Material and methods 
Study design and patients 
Patients were treated as reported earlier in the context of a phase 1 study and an 
imaging study {NTR2103) {6,9). In total 61 patients received standard doses of 
gemcitabine and cisplatin, and escalating doses of mapatumumab. Briefly, patients 
with advanced solid tumors received the combination treatment in 21-day cycles. 
Evaluation of response according to RECIST 1.0 was performed every second cycle in 
the phase 1 study and after every third cycle in the imaging study {10). After 6 cycles 
of chemotherapy and in absence of disease progression, patients could continue 
therapy with mapatumumab alone. Toxicity was carefully monitored using the 
National Cancer Institute Common Toxicity Criteria for Adverse Events {NCI-CTCAE) 
version 3.0. 
The Ethics Committee approved the study and all patients provided written informed 
consent for participation in the phase 1 study or imaging study. 
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DNA collection, amplification and genotyping 
Germline DNA was isolated from baseline plasma samples using the QIAamp DNA Mini 
Kit Spin Protocol for plasma samples (Qiagen GmbH) according to the protocol 
provided by the manufacturer, as has been previously described (11). 
Genomic DNA Fragments for TNFRSFlOA were amplified using Eurotaq Polymerase 
(BioCat) with primers (Biospring) as published previously (7). The nucleotide sequence 
of TNFRSFlOA was determined by cycle sequencing with Big Dye terminator chemistry 
(Applied Biosystems) followed by electrophoresis on a Perkin Elmer ABl-377 
automated sequencer. Variants of 683A/C were clearly visible as a double peak in the 
nucleotide sequence. 
Correlation study 
Patient characteristics used for assessing differences between TNFRSFlOA 683A wild 
type versus TNFRSFlOA 683C variant SNP carriers included gender, age, tumor type, 
dosing cohort of mapatumumab, number of cycles chemotherapy and mapatumumab 
administered, total cumulative doses mapatumumab, gemcitabine and cisplatin 
administered, best observed tumor response according to RECIST 1.0, percent change 
in the size of total tumor lesions, occurrence of grade 3 and/or grade 4 
thrombocytopenia, occurrence of grade 3 and/or grade 4 lymphocytopenia and 
progression-free survival (PFS). PFS was defined as the time elapsing from study 
inclusion until tumor progression or death, whatever came first. 
Statistics 
Homozygous and heterozygous variants were combined. Wild type and variant SNP 
carriers were compared for patient characteristics using the Chi-square test for 
categoric variables and the Mann-Whitney U test for continuous data. The association 
between PFS with genotypes was estimated using the Kaplan-Meier method and 
tested formally using the log-rank test. P < .05 was considered significant and reported 
values are two sided. SPSS v16.0 (SPSS Inc.) was used for all statistical analyses. 
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Results 
Patient characteristics are summarized in Table 1. Good quality DNA could be obtained 
of 44 patients. Thirty-three patients (75%) expressed the TNFRSFlOA 683A wild type 
and 9 patients were heterozygous for the TNFRSFlOA variant 683C. Two patients were 
homozygous for the TNFRSFlOA 683C variant. Patient characteristics did not differ 
between TNFRSFlOA 683A wild type carriers and TNFRSFlOA 683C variant carriers. No 
statistical difference was present between both groups with respect to PFS. Age, 
gender, best observed tumor response, tumor type, number of chemotherapy cycles 
administered, number of additional cycles monotherapy mapatumumab, and the 
dosing cohort mapatumumab did not differ. The occurrence of grade 3 and grade 4 
lymphocytopenia and thrombocytopenia was equal between both groups. No 
differences in cumulative doses gemcitabine, cisplatin or mapatumumab were found. 
Survival and polymorphism A683C. 
The Kaplan-Meier curve for PFS is shown in Figure 1. Log-rank testing shows no 
difference in PFS between genotypes (P = .451) . 
..... , ............... l 
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Figure 1. Kaplan-Meier estimate of progression-free survival (PFS) according to TNFRSF10A genotype. A/A, 
wild type; A/C heterozygous variant; C/C homozygous variant. 
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Median age, years (range) 
Gender (male/female) 












Head and neck cancer 
Other 
Median no. of cycles chemotherapy 
(range) 
Median no. of cycles monotherapy 
mapatumumab (range) 
Median duration of progression-free 
survival, weeks (range) 
Median change in sum of tumor 
diameter, percentage (range) 





Grade 3 and/or 4 lymphopenia 
Grade 3 and/or 4 thrombocytopenia 
Median cumulative mapatumumab 
dose, mg (range) 
Median cumulative gemcitabine dose, 
mg (range) 
Median cumulative cisplatin dose, mg 
(range) 
No. of patients (N = 44) 
A/A (N = 33) A/C and C/C {N = 11) 














4 (1-6) 6 (2-6) 
0 (0-55) 0 (0-12) 
16.9 (0.9-180.0) 26.5 (6.1-70.8) 







3430 (289-58320) 7740 (350-23882) 
14935 (1950-31200) 20400 (4475-30000) 
510 (130-1020) 687 (285-960) 

















Abbreviations: (A)CUP, (adeno)carcinoma of unknown primary; NSCLC, non-small cell lung carcinoma; NE, 
not evaluable; SD, stable disease; PR, partial response; PD, progressive disease. 
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Discussion 
We studied the association of the A -> C nucleotide exchange on position 683 of 
TNFRSF10A, resulting in the amino acid substitution Glu228Ala in the CRD3 of TRAIL­
Rl, with disease outcome and toxicity in patients with advanced solid tumors treated 
with gemcitabine, cisplatin and the TRAIL-Rl antibody mapatumumab. PFS did not 
differ between both groups. TNFRSF10A 683A and 683C carriers did not differ with 
respect to baseline patient characteristics, best observed tumor response and 
hematological toxicity. 
With the emerging development of tumor biology driven drugs there is a growing need 
for easy obtainable predictive biomarkers. These biomarkers would make it possible to 
select patients upfront, thereby preventing non-responders from unnecessary 
potential toxicity and time loss (12). Previous studies have demonstrated that the 
presence of the TNFRSF10A 683C variant is also associated with an increased risk for 
several cancer types (7,8,14-18). As a consequence of the presence of the TNFRSF10A 
683C variant, the negatively charged amino acid glutamate on position 228 of TRAIL-Rl 
is replaced by the uncharged amino acid alanine, which affects the TRAIL binding 
domain of TRAIL-Rl and therefore likely results in insufficient complex formation 
(7,8,14-18). After TRAIL binding, sufficient trimerization of the death receptors TRAIL­
Rl or TRAIL-R2 is needed in order to form the death inducing signaling complexes 
(DISCs), which then result in activation of initiator and downstream caspases (13). It 
was therefore expected that the presence of the TNFRSFlOA 683C variant would affect 
the severity of side effects, or, likely negatively, affect responses of tumors to 
mapatumumab. However, no effect on PFS or treatment toxicity was observed. The 
equal disease outcome between TNFRSF10A 683A/C and TNFRSF10A 683A carriers 
may point at a differential effect of the Glu228Ala substitution on monoclonal 
antibody binding and rhTRAIL binding to TRAIL-Rl and thus on apoptosis induction. 
The crystal structure of TRAIL-Rl interacting with rhTRAIL or mapatumumab is not 
available yet. The interaction sites of rhTRAIL in complex with TRAIL-R2 are supposed 
to be similar to those of rhTRAIL in complex with TRAIL-Rl. Therefore, the crystal 
structure of TRAIL-R2 in complex with either rhTRAIL or an agonistic TRAIL-R2 antibody 
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{PRO95780) may help to gain further insight into antibody and TRAIL binding to TRAIL­
Rl {19-21). Significant overlap in TRAIL-R2 binding modes was found for rhTRAIL and 
the TRAIL-R2 antibody. Both rhTRAIL and the TRAIL-R2 antibody bind to CRD3 of TRAIL­
R2, which shows conformational diversity and is supposed to be of major importance 
for TRAIL-R2 activation (21). Glu228 of TRAIL-Rl is located within a stretch of amino 
acids in the C-terminal part of CRD3 close to the transmembrane domain that is 
identical to a stretch of 15 amino acids of TRAIL-R2. No direct interaction between the 
TRAIL-R2 antibody and this part of TRAIL-R2 CDR3 was observed. These data suggest 
that the binding of mapatumumab in contrast to rhTRAIL will not be affected by the 
Glu228Ala substitution in the TRAIL-Rl variant. In line with this hypothesis, our clinical 
data show no difference between patient characteristics like PFS or treatment toxicity 
after mapatumumab-containing therapy between patients expressing wild type TRAIL­
Rl and patients expressing the TRAIL-Rl Glu228Ala variant. 
Given the small, exploratory nature of our study, an effect on disease outcome in the 
subgroup of patients carrying the TRAIL-Rl Glu228Ala variant can not be ruled out. 
larger prospective studies are needed to definite exclude an effect of the TRAIL-Rl 
Glu228Ala variant on activation of the extrinsic pathway in tumors. 
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Summary, general discussion and future perspectives 
In the past four decades, the mainstay of anticancer treatment has been surgery, 
radiotherapy, chemotherapy and hormonal systemic treatment. Despite improvement 
in these treatment modalities, still half of the cancer patients die as a consequence of 
metastatic disease. This is partly due to the development of resistance to the 
administered systemic treatment. Currently, much information is becoming available 
from tumor cell biology research, opening opportunities for the development of 
specifically tumor targeting agents. 
Chemotherapy-resistant tumor cells are characterized by an intrinsic or acquired 
incapability for going into apoptosis as a consequence of defects in the intrinsic 
apoptotic pathway. A strategy to overcome this resistance might be targeting the 
extrinsic apoptotic pathway. This pathway is activated by the endogenous occurring 
Tumor Necrosis Factor (TNF) Related Apoptosis-lnducing Ligand (TRAIL, or Apo2L). 
TRAIL binds to five different receptors, but induces apoptosis only after binding to its 
two death receptors, TRAIL-Rl (DR4) and TRAIL-R2 (DRS). The other three receptors, 
TRAIL-R3 (DcRl), TRAIL-R4 (DcR2) and the soluble osteoprotegerin (OPG), act as 
decoys. The discovery that TRAIL only induces apoptosis in several tumor cells and not 
in normal cells makes it a potentially attractive anticancer drug. Numerous preclinical 
studies showed synergy when combining these TRAIL-receptor targeting agents with 
chemotherapy. In addition, many chemotherapy-resistant cell lines as well as 
xenograft models could be sensitized by the addition of recombinant human (rh) 
TRAIL or one of the agonistic death receptor antibodies. RhTRAIL, targeting all TRAIL­
Rs, and monoclonal antibodies that target either TRAIL-Rl or TRAIL-R2 were entered 
into clinical trials and appeared to be safe as single agents in phase 1 and phase 2 
trials. 
Another approach to exploit a targeted therapy, is to treat malignancies by blocking 
angiogenesis, the formation of new blood vessels. Tumors require an adequate 
vascularization to obtain oxygen and nutrients, thereby enabling tumor growth and the 
development of metastases. An important proangiogenic protein is Vascular 
Endothelial Growth Factor (VEGF), known to be overexpressed by many tumor types. 
The binding of VEGF to the VEGF-receptors (VEGFR) can be prevented by drugs 
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blocking VEGF directly or by binding to the tyrosine kinase domain of the involved 
receptors. 
TRAIL-R targeting agents and angiogenesis inhibitors are examples of targeted 
therapies, i.e. drugs acting against a specific tumor cell characteristic. Anticancer 
drugs, and targeted therapies, may be beneficial for those patients, where the 
targeted mechanism is relevant for tumor growth and progression. Upfront patient 
selection before therapy is initiated or early after start of treatment would clearly help 
avoid useless treatment for non-responders and avoid unnecessary toxicity. 
The objective of this thesis was to study the safety, tolerability and pharmacokinetics 
of novel targeted agents and to concurrently develop predictive biomarkers for patient 
selection. 
In chapter 2, an overview of the TRAIL pathway is presented. The literature is 
summarized with respect to the physiological and pathophysiological role of TRAIL  and 
the potential exploitation of this pathway for drug treatment. Endogenous TRAIL  has 
anti-inflammatory capacities as well as a role in autoimmunity. Moreover, recent 
studies showed antitumor surveillance is another property of TRAIL and its receptors. 
TRAIL-R deficiency promotes primary tumor development and results in faster 
formation of metastases in mice. On the other hand, in rhTRAIL resistant preclinical 
models, prosurvival signaling was observed after rhTRAIL-induced death receptor 
activation resulting in reduced apoptosis and an increase in proliferation and 
subsequently tumor growth. 
RhTRAIL and agonistic antibodies targeting specifically TRAIL-Rl or TRAI L-R2 are in 
early clinical development and showed until now limited toxicity. Ongoing studies 
focus especially on combination of these agents with other targeted therapies or 
cytotoxic therapies. We summarized current knowledge on these agents and 
highlighted their potential role in the intrinsically chemotherapy-resistant 
glioblastomas. In addition, we discussed in more detail the mechanisms to sensitize 
tumors cells to rhTRAIL by combination with the proteasome inhibitor bortezomib. 
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In the phase 1 study described in chapter 3, we evaluated the safety, tolerability, 
pharmacokinetics, and antitumor activity of the agonistic TRAIL-Rl targeting 
monoclonal antibody mapatumumab in combination with standard combination 
regimen with gemcitabine and cisplatin. Patients with advanced solid tumors received 
gemcitabine 1250 mg/m2 intravenously (iv) on days 1 and 8 and cisplatin 80 mg/m2 iv 
on day 1 of each 21-day cycle. Escalating mapatumumab doses (iv) were administered 
every 21 days. Toxicity was closely monitored and pharmacokinetic analysis of plasma 
mapatumumab, gemcitabine, its metabolite 2-difluoro-2-deoxyuridine, and unbound 
and total platinum was performed. TRAIL-Rl expression on tumor material was 
determined by immunohistochemistry. 
In this study, 49 patients received mapatumumab (1 mg/kg, n = 4; 3 mg/kg, n = 7; 10 
mg/kg, n = 12; 20 mg/kg, n = 13; or 30 mg/kg, n = 13). A median of 6 cycles (range, 1-
48) was administered. The adverse events most commonly observed reflect the 
toxicity profile of gemcitabine and cisplatin. Dose-limiting toxicities were seen in 3 of 
12 patients at 10 mg/kg, consisting of grade 3 transaminitis, neutropenic fever, and 
grade 4 thrombocytopenia. At 20 mg/kg, 2 of 12 patients had dose-limiting toxicities, 
including grade 4 thrombocytopenia and grade 4 fatigue. The maximum tolerated dose 
was not reached. Pharmacokinetic interactions have not been observed. Twelve 
patients had a partial response, and 25 patients showed stable disease with a median 
duration of 6 months. In conclusion, mapatumumab in combination with gemcitabine 
and cisplatin is safe and well tolerated at doses up to 30 mg/kg. Further studies on this 
combination are therefore warranted. 
Increasingly the critical role of the microenvironment in tumor development, migration 
and metastasis is acknowledged. A crucial role in the microenvironment is played by 
angiogenic factors. Tivozanib is an orally available VEGF-Rl, VEGF-R2 and VEGF-R3 
tyrosine kinase inhibitor that showed potent anticancer activity in vitro and in 
preclinical in vivo models. Tivozanib appeared to be safe as single agent in advanced 
solid tumor patients and synergistic effects were observed when combined with 
chemotherapy in preclinical models. 
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Encouraged by these data we have performed the, still ongoing, phase 1 study for 
which prleliminary data are reported in chapter 4. In this dose escalation study, 
tivozanib was combined with fluorouracil, oxaliplatin and leucovorin (FOLFOX6-
regimen). Eligible were patients with advanced gastrointestinal malignancies. Tivozanib 
was administered orally once daily for 21 days in 28-day cycles. Planned daily dose 
levels of tivozanib were 0.5 mg, 1.0 mg, and 1.5 mg. Standard FOLFOX6 was 
administered every 14 days. Patients were allowed to continue tivozanib following 
discontinuation of FOLFOX6 in the absence of disease progression. The safety of 
administering this combination was observed and pharmacokinetic interactions were 
studied. 
In this ongoing study, 30 patients with a median age of 58 years (range, 40-75 years), 
were evaluated in the following cohorts of tivozanib: 0.5 mg (n = 9), 1.0 mg (n = 3) and 
1.5 mg (n = 18). Dose-limiting toxicities consisted of one episode of reversible grade 4 
AST and ALT elevations and 1 reversible grade 3 diarrhea at tivozanib 0.5 mg, no dose 
limiting toxicities occurred at tivozanib 1.0 mg. At tivozanib 1.5 mg/day dose limiting 
toxicities consisted of one episode of grade 3 vertigo and one episode of grade 3 
epileptic seizure during cycle 2. Other grade 3/4 adverse events across dose levels 
included hypertension (n = 11) , neutropenia (n = 6) and fatigue (n = 4). There was no 
indication that drug related adverse events of this combination were more frequent or 
severe than those observed with FOLFOX6 or tivozanib alone. No PK interactions have 
been observed. Of the 30 evaluable patients, 1 patient had a complete response, 8 
patients received a partial response and 12 experienced stable disease Responses 
occurred in patients with oesophageal cancer (n = 4), pancreatic cancer (n = 2), 
colorectal cancer (n = 1), gastric cancer (n = 1) and small bowel cancer (n = 1). 
The combination of tivozanib and FOLFOX6 appears feasible and safe, with drug 
related AEs of the combination that were not more frequent or severe than those 
known to occur with FOLFOX6 or tivozanib alone The recommended dose for future 
studies is 1.5 mg/day. Observed clinical activity merits further exploration in 
gastrointestinal tumors of different origins. 
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Targeted therapies have in common that they act against a specific feature of tumor 
cells. Tumor heterogeneity is commonly present, even in patients with the same tumor 
type, and the target is not always expressed. It is a major challenge to select patients 
upfront or early during treatment who will benefit from these treatments, while 
correctly withholding it from the other patients. Identification of, preferably easy 
obtainable, predictive biomarkers might facilitate this strategy. An attempt to pursue 
such a strategy is described in the second part of this thesis. 
In chapter 5, we clarified the confusing terminology "prognostic and predictive 
biomarkers". A prognostic biomarker provides information about the patient's overall 
cancer outcome, regardless of therapy, while a predictive biomarker gives information 
about the effect of a therapeutic intervention. A predictive biomarker can be a target 
for therapy. We discussed several examples of clinically relevant genes like estrogen 
receptor (ER), progesterone receptor (PR) and HER2/neu in breast cancer and EGFRl 
mutations in non-small cell lung cancer (NSCLC). ER and PR expression are both 
examples of independent prognostic biomarkers as well as predictive factors for 
response to endocrine therapy in patients with breast cancer. HER2/neu gene 
amplification results in overexpression of this receptor on the cell membrane and is 
also of prognostic and predictive value in breast cancer patients. However, in contrast 
to ER and/or PR overexpression, HER2/neu amplification is a negative prognostic 
factor. The worse prognosis of patients overexpressing HER2/neu is "neutralized" by 
adding trastuzumab to chemotherapy in the adjuvant setting compared to HER2/neu 
negative patients. We also discussed that different tumor types can be treated by 
blocking the same pathway, like for example EGFR inhibition in colorectal cancer and 
NSCLC. Predictive biomarkers may be shared between tumor types, like the negative 
predictive value of K-ras mutations in colorectal cancer and NSCLC for the effect of 
EGFR inhibition. However, on the other hand, EGFR mutations do predict benefit from 
anti-EGFR therapy in NSCLC where they do not in colorectal cancer. Identification of 
predictive biomarkers is important in our effort to develop patient-tailored treatment. 
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This is an additional argument that biomarker studies should be incorporated into 
clinical trials. 
Approximately 5-10% of the colorectal cancer patients comprise the well-characterized 
hereditary forms, hereditary nonpolyposis colorectal cancer {HNPCC, or Lynch 
syndrome) and familial adenomatous polyposis {FAP). Since most of these patients 
develop colorectal cancer during their life, treatment strategies are sought to prevent 
tumor development. The non-steroidal anti-inflammatory drug {NSAID) sulindac 
reduces colorectal cancer risk in FAP patients, where its role in HNPCC is still under 
debate. The molecular mechanisms underlying these effects are incompletely 
understood. Many studies suggest an important role for the induction of apoptosis 
involving the mitochondrial pathway and the death receptor pathway. Alternatively, 
mechanisms involving the Wingless-int {Wnt) pathway have been suggested, possibly 
mediated by p21. The Wnt signaling pathway plays an important role in colorectal 
carcinogenesis. Mutations in the adenomatous polyposis coli {APC} or 6-catenin gene 
lead to cytoplasmic accumulation and increased translocation to the nucleus of '3-
catenin. This results in activation of T-cell factor 4 and subsequently activation of a 
genetic program responsible for adenoma formation. Active Wnt-signaling also 
reduces p21 levels, allowing cells to proliferate instead of differentiate. Sulindac 
metabolites showed to decrease '3-catenin expression in colon cancer cells. In addition, 
sulindac induced p21 expression in vitro and in a mouse model. 
In the biomarker study described in chapter 6 we have tried to provide more insight in 
the chemopreventive mechanisms of sulindac. Biopsies of normal-appearing colonic 
mucosa obtained during two previously published studies before and after sulindac 
treatment were analyzed for the presence of apoptotic cells and the expression of 
TRAIL-Rl, TRAIL-R2, p21 and '3-catenin by immunohistochemistry. Patients {n = 18) 
with HNPCC received 150 mg sulindac two times daily for 4 weeks in a placebo­
controlled crossover design. Patients {n = 6) with FAP received 150 mg sulindac twice a 
day for 6 months. Apoptosis was assessed by M30 staining and expression patterns of 
TRAIL-Rl, TRAIL-R2, (3-catenin, and p21 were studied immunohistochemically. In 
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HNPCC patients, apoptotic indices were similar following placebo and sulindac. Also in 
FAP patients, apoptotic indices were not different after sulindac compared with 
pretreatment values. Expression of TRAIL-Rl and TRAIL-R2 was observed in all samples 
with no consistent differences between placebo/baseline and sulindac. Intensity of 
membranous �-catenin staining was lower in HNPCC samples following sulindac 
compared with placebo (p < 0.001). Similar results were obtained in FAP samples (p < 
0.01). P21 expression before and after sulindac treatment were similar in both patient 
groups. We concluded that sulindac inhibits �-catenin expression in normal colorectal 
epithelium from HNPCC and FAP patients without affecting apoptotic indices and 
TRAIL-Rl, TRAIL-R2, and p21 expression. We, therefore, have no evidence for a role of 
the TRAIL-R pathway in sulindac-induced chemoprevention. However, our data provide 
further support for inhibition of the Wnt signaling as a contributing mechanism of 
chemoprevention by sulindac. 
It is unknown whether the TRAIL-Rl targeting monoclonal antibody mapatumumab 
actually reaches the tumor cells within a patient's tumor to display its anticancer 
efficacy. Upregulation of TRAIL-Rl after chemotherapy was seen in mice bearing 
human colorectal cancer tumor xenografts. However the effect of chemotherapy on 
mapatumumab tumor binding is not clear. In chapter 7 we described the tumor 
uptake, pharmacokinetics and biodistribution of 111 In-mapatumumab in patients with 
advanced solid tumors, at the start and during treatment with gemcitabine, cisplatin 
and mapatumumab. Patients were eligible for the study if they met the inclusion 
criteria of the preceding phase I study outlined in chapter 3 and were treated 
accordingly. Patients received 150 MBq 111In-mapatumumab i.v. 1.5 hours following 
the start of the mapatumumab infusion in cycle 1. The protocol provided the 
possibility that, if tumor lesions were not clearly visualized after 4 patients, the tracer 
was administered 7 days before the mapatumumab infusion in cycle 1. On day 2, cycle 
3, 150 MBq 111 In-mapatumumab was administered 30 minutes before the end of the 
therapeutic mapatumumab dose. Planar whole body imaging and single-photon 
emission computed tomography (SPECT) was performed at 0.5, 24, 72, and 144 hours 
after tracer injection. Venous blood samples were obtained up to 312 hours following 
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111In-mapatumumab injection. TRAIL-Rl expression was determined 
immunohistochemically in archival tumor tissue. In 5 of the 12 patients included, 11 
out of 18 tumor lesions known by CT were visualized with 111In-mapatumumab SPECT, 
but a large heterogeneity was seen in 111In-mapatumumab uptake between these 5 
patients. Two melanoma patients showed remarkable intense tracer uptake. In 3 
patients all lesions were visualized. SPECT results in cycle 3 were comparable to the 
first SPECT series. Three of the 4 patients having positive 111In-mapatumumab 
scintigraphy and tumor tissue available showed at least low cytoplasmic TRAIL-Rl 
expression. Intensity of staining did not correlate with positive 111In-mapatumumab 
scintigraphy or tumor response to treatment. In conclusion, 111In-mapatumumab 
tumor uptake in this group of patients was variable and the value of tumor imaging in 
upfront patient selection for mapatumumab-based treatment needs further 
evaluation. 
The extrinsic apoptotic pathway is activated after ligand binding to TRAIL-Rl and/or 
TRAIL-R2. Mutations in death receptors or in downstream proteins might play a role in 
insufficient apoptosis induction. Recently, the single nucleotide polymorphism (SNP) 
A683C in the TNFRSF10A gene encoding TRAIL-Rl was identified. Cancer cell lines 
expressing the variant appeared to be less sensitive to rhTRAIL compared to the wild 
type carriers. In chapter 8 we analyzed the effect of SNP A683C in germline DNA 
samples of patients treated with gemcitabine, cisplatin and the TRAIL-Rl targeting 
antibody mapatumumab in the two previously performed studies described in chapter 
3 and chapter 7. For this purpose we performed an analysis of the TRAIL-Rl 
polymorphism A683C in relation to outcome and toxicity. Genomic DNA of 44 patients 
was successfully analyzed for the TNFRSF10A polymorphism A683C. In total, 33 of the 
44 patients were carrier of the wild type A683, while 9 patients were heterozygous and 
2 patients were homozygous for the variant A683C. The patients with either 
heterozygous or homozygous variants were combined and analyzed as one group. 
Progression-free survival between 683A and 683C carriers did not differ. No difference 
was present between both groups with respect to baseline characteristics and 
treatment related hematological toxicity. Given the small, exploratory nature of our 
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study, an effect on disease outcome in the subgroup of patients carrying the 
TNFRSFlOA 683C variant can not be ruled out. Larger prospective studies are 
therefore needed. 
In conclusion, we describe in this thesis two phase 1 studies with novel targeted 
therapies that could be safely combined with chemotherapy. Furthermore, we 
explored the chemopreventive mechanism of the NSAID sulindac in colorectal cancer 
and investigated potential predictive biomarkers for mapatumumab-containing 
treatment. Both the new targeted therapies as well as the biomarkers studied could 
potentially be implemented in future anticancer treatment strategies. 
General discussion and future perspectives 
In chapters 3 and 4, we have shown that both the TRAIL-Rl targeting monoclonal 
antibody mapatumumab, as well as the VEGF-Rl, 2 and 3 tyrosine kinase inhibitor 
tivozanib, could be safely combined with chemotherapy. Data on antitumor activity of 
these compounds needs of course to be established in phase 2 and phase 3 trials. 
Chemotherapy is still the basis of most systemic anticancer treatment strategies. 
However, more and more insight in the molecular and oncogenetic characteristics of 
tumors points towards interesting highly specific targeting agents. Mapatumumab 
induces apoptosis by ligation of TRAIL-Rl and results in a cascade of caspase 
activations eventually resulting in apoptosis. More downstream of the apoptotic 
pathway, apoptosis can be prevented by inhibitor of apoptosis (IAP) proteins, like X­
linked IAP (XIAP). IAP inhibitors are currently in early clinical development (1). 
However, single agent activity seems to be modest. Recently, it was shown that small 
molecule XIAP inhibitors profoundly enhanced mapatumumab-induced apoptosis in 
pancreatic carcinoma cell lines (2). A next step in targeting the apoptotic pathway in 




Tumor cell apoptosis can also be achieved by activating the p53-dependent intrinsic 
pathway. MDM2 is a negative regulator of p53 and results in proteasomal degradation 
of p53 after complex formation. Nutlin is a small-molecule that binds MDM2, thereby 
preventing its interaction with p53 (3). Our group showed enhanced apoptosis 
induction after combining the MDM2 antagonist Nutlin-3 with TRAIL-R targeting 
agents (4). Although an interesting concept, the safety results of the currently ongoing 
single agent phase 1 studies with MDM2 targeting drugs should of course be awaited 
(NCT01143740, NCT01462175) before combining a MDM2 antagonist with TRAIL-R 
targeting agents even can be considered. 
Mapatumumab and tivozanib target different, but both biological important pathways, 
each representing a hallmark of cancer as defined by Hanahan and Weinberg (5). As 
most malignancies are not dependent of one pathway for tumor growth and 
progression, one can envision that future therapy lies in combinations specifically 
targeting several pathways, instead of several drugs targeting the same pathway, 
would be more effective. 
Combining new targeted therapies with radiotherapy might be another approach for 
improving cancer outcome. For example in patients with locally advanced cervical 
cancer, where the standard treatment consists of radiotherapy and concomitant 
cisplatin-based chemotherapy. This treatment schedule results in a 5-year overall 
survival of 66-79%, illustrating that there is ample room for improvement (6). The 
toxicity profile of radiotherapy and chemotherapy hardly permit dose escalation of 
current drugs or irradiation. Therefore, the combination with targeted therapies might 
open a new venue. In cervical cancer cell lines and xenografts, mapatumumab in 
combination with irradiation resulted in synergistic apoptosis induction (unpublished 
results, de Jong) (7). We have shown in the phase I trial, described in chapter 3, that 
the addition of mapatumumab to cisplatin did not augment side effects. Currently we 
are evaluating the combination of mapatumumab with cisplatin and radiotherapy as a 
first line therapy in patients with advanced cervical cancer in a phase lb study 
(NCT01088347). 
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Reducing cancer mortality can also be achieved by prevention of tumor formation. In 
chapter 6 we have shown that inhibition of Wnt signaling might be a contributing 
mechanism of sulindac-induced chemoprevention in colorectal cancer. No effect was 
seen on TRAIL-R expression. Recently, our group demonstrated that sulindac 
effectively sensitized colon adenoma cell lines to rhTRAIL induced apoptosis, also 
without affecting TRAIL-R expression. Moreover, this effect was only seen in cells with 
active Wnt signaling (8). Given the favorable toxicity profiles of both NSAIDs and TRAIL­
R targeting agents, it would be of interest to combine both drugs in colorectal cancer 
chemoprevention strategies, especially in the genetic susceptible population. 
Characteristics of tumors and metastatic lesions will be increasingly leading to the 
optimal systemic therapy of choice in individual patients. Non-invasive biomarkers that 
can predict the patients' tumor response before start of treatment are therefore 
needed. We explored 111 1n-mapatumumab scintigraphy (chapter 7) and TRAIL-Rl 683C 
variant (chapter 8) as candidate biomarkers. Both are of potential clinical relevance in 
selecting patients for mapatumumab-containing treatment, although they need of 
course validation in larger, prospective trials. 
Phase 1 studies in general include patients with advanced cancer for whom no 
standard treatment is available. In the current era, where new developmental drugs 
mostly consist of targeted therapies, it would be of interest to select patients in whom 
the target is available. This will give probably a more reliable safety profile, including 
specific on-target toxicity, of the drug tested. Next to this, it would be important to put 
even more effort than is currently done to, prospectively, incorporate analysis of 
potential biomarkers in early clinical studies. This might not only result in a putative 
increase in response rates in the selected patient group but also spare the other 
patients toxic site effects of a non-effective treatment. Furthermore, this might 
accelerate drug development and will limit the amount of patients needed. Such an 
approach will eventually lead to personalized treatment based on the molecular profile 
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Samenvatting, algemene discussie en toekomstperspectieven 
De afgelopen veertig jaar zijn chirurgie, radiotherapie en systeemtherapie de pijlers 
van kankerbehandeling geweest. Ondanks gestage uitbreiding van deze therapeutische 
mogelijkheden overlijdt nag steeds de helft van de kankerpatienten aan de gevolgen 
van gemetastaseerde ziekte. Dit is ten dele toe te schrijven aan het ontwikkelen van 
tumorcelresistentie tegen de toegediende systeemtherapie. Door een verbeterd 
inzicht in de tumorcelbiologie heeft de ontwikkeling van specifieke, doelgerichte 
medicijnen op grand van tumoreigenschappen zich de laatste jaren sterk uitgebreid. 
Tumorcellen die resistent zijn voor bijvoorbeeld chemotherapie hebben als gevolg van 
een defecte intrinsieke apoptoseroute een intrinsieke of verworven onvermogen om in 
apoptose te gaan. Deze resistentie zou potentieel omzeild kunnen warden door 
activatie van de extrinsieke apoptoseroute. De extrinsieke route wordt geactiveerd 
door het lichaamseigen Tumor Necrosis Factor (TNF) Related Apoptosis-lnducing 
Ligand (TRAIL, of Apo2L). TRAIL kan aan vijf verschillende receptoren binden, maar 
induceert slechts apoptose na binding aan TRAIL-Rl (DR4) of TRAIL-R2 (DRS). De 
andere drie receptoren, TRAIL-R3 (DcR1), TRAIL-R4 (DcR2) en het oplosbare 
osteoprotegerine (OPG), fungeren als zogenaamde decoys. De ontdekking dat TRAIL 
alleen apoptose in tumorcellen induceert en niet in de meeste normale cellen, maakt 
het een potentieel aantrekkelijk antikankermiddel. Vele preklinische studies hebben 
synergie laten zien indien TRAIL-Rl/2 activerende stoffen warden gecombineerd met 
chemotherapie. Daarnaast worden veel chemotherapieresistente cellijnen en 
xenograftmodellen opnieuw gevoelig voor het betreffende chemotherapeuticum na 
toevoeging van recombinant humaan (rh) TRAIL of een van de antilichamen gericht 
tegen de pro-apoptotische TRAIL-Rl/2. RhTRAIL, dat aan alle TRAIL receptoren bindt 
en monoclonale antilichamen die of TRAIL-Rl of TRAIL-R2 binden, zijn inmiddels in fase 
1 en fase 2 studies getest en lijken veilig te zijn. 
Een andere benadering om resultaten van oncologische behandelingen mogelijk te 
verbeteren, is het blokkeren van angiogenese, de vorming van nieuwe bloedvaten. 
Tumorcellen hebben een adequate bloedvatvoorziening nodig om voorzien te warden 
van voldoende zuurstof en voedingsstoffen. Hierdoor is de tumor in staat te groeien en 
te metastaseren. Een belangrijk pro-angiogeen eiwit is Vascular Endothelial Growth 
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Factor (VEGF), dat door vele tumoren tot overexpressie komt en door die tumoren 
geseceneerd wordt. De binding van  het door de tumor geproduceerde VEGF aan de  
VEGF-receptoren (VEGFR) op endotheelcellen kan  voorkomen worden door medicijnen 
die VEGF direct blokkeren of de tyrosinekinase-activiteit van de betrokken receptor 
remmen. 
TRAIL-Rl/2 activerende middelen en angiogeneseremmers zijn voorbeelden van 
doelgerichte medicijnen. Deze medicijnen zijn gericht tegen een specifiek kenmerk van 
een eel .  Oncologische behandel ingen, inclusief doelgerichte medicijnen, werken 
vanzelfsprekend alleen a ls het mechanisme dat geattaqueerd wordt een belangrijke rot 
speelt in tumorgroei van de betreffende patient. Het kunnen selecteren van patienten 
vooraf of kort na start van de therapie is van groot belang om onnodige behandel ing 
van en toxiciteit bij patienten te voorkomen. 
Het doel van dit proefschrift was enerzijds het bestuderen van de vei l igheid, 
verdraagbaarheid en farmacokinetiek van nieuwe doelgerichte middelen en anderzijds 
paral lel daaraan het ontwikkelen van predictieve biomarkers voor betere 
patientenselectie. 
Na een korte inleiding in hoofdstuk 1 wordt in hoofdstuk 2 een overzicht van de 
TRAI L/TRAIL-R apoptoseroute gegeven. De literatuur met betrekking tot de 
fysiologische en pathofysiologische rot van TRAIL wordt samengevat, evenals de 
potentiele rot voor behandeling met medicatie. Endogeen TRAIL heeft a nti­
inflammatoire eigenschappen en speelt een rol in autoimmuniteit. Daarnaast werd 
recent aangetoond dat TRAIL/TRAIL-R antitumorcapaciteiten bezit. TRAIL-R deficientie 
zet aan tot ontwikkeling van primaire tumoren en zorgt in muizen voor snel lere 
vorming van metastasen. Er werd echter ook een pro-survival signaal geobserveerd in 
rhTRAIL resistente, preklinische model len. Na activatie van TRAIL-Rl/2 door rhTRAIL 
was er namelijk  afname van apoptose en juist toename van prol iferatie en tumorgroei .  
RhTRAIL  en anti l ichamen specifiek gericht tegen TRAIL-Rl of TRAIL-R2 zijn in vroeg­
kl inische ontwikkel ing en laten tot nu toe weinig toxiciteit zien. Lopende studies zij n  
met name gericht o p  combinaties van deze nieuwe middelen met andere doelgerichte 
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medicijnen of chemotherapie. De kennis van rhTRAIL en TRAIL-Rl/2 antilichamen is 
samengevat en hun potentiele rol in de intrinsiek chemotherapieresistente 
gliobastomen is extra belicht. Daarnaast zijn er verschillende mechanismen 
bediscussieerd om tumorcellen gevoeliger te maken voor rhTRAIL, zoals bijvoorbeeld 
door combinatie met de proteasoomremmer bortezemib 
In de fase-1 studie beschreven in hoofdstuk 3 werd de veiligheid, verdraagbaarheid, 
farmacokinetiek en antitumoreffectiviteit van het tegen TRAIL-Rl gerichte 
monoclonale antilichaam mapatumumab in combinatie met standaarddoseringen 
gemcitabine en cisplatine bestudeerd. Patienten met vergevorderde solide tumoren 
kregen gemcitabine 1250 mg/m2 intraveneus (iv) op dag 1 en 8 en cisplatine 80 mg/m2 
iv op dag 1 van elke 3-weekse cyclus. Opklimmende doseringen mapatumumab 
werden elke 3 weken iv toegediend. Toxiciteit werd nauwgezet bijgehouden en 
farmacokinetische analyse van plasma concentraties mapatumumab, gemcitabine, de 
metaboliet 2-difluoro-2-deoxyuridine en ongebonden en totaal platinum vond plaats. 
Expressie van TRAIL-Rl in de tumor werd bepaald middels immunohistochemie. 
49 patienten kregen mapatumumab (1 mg/kg, n = 4; 3 mg/kg, n = 7; 10 mg/kg, n = 12; 
20 mg/kg, n = 13; of 30 mg/kg, n = 13) eenmaal per 3 weken. Mediaan werden 6 kuren 
{range, 1-48) gegeven. De meest geobserveerde bijwerkingen kwamen overeen met 
het bijwerkingenprofiel van gemcitabine en cisplatine. Dosislimiterende toxiciteit werd 
gezien bij 3 van de 12 patienten op de dosisstap van 10 mg/kg en bestond uit: graad 3 
stijging van ASAT en ALAT, neutropene koorts en graad 4 trombocytopenie. Bij 20 
mg/kg hadden 2 van de 12 patienten dosislimiterende toxiciteit bestaande uit graad 4 
trombocytopenie en graad 4 vermoeidheid. De maximaal getolereerde dosis werd niet 
overschreden. Er werden geen farmacokinetische interacties gezien. Twaalf patienten 
hadden een partiele tumorrespons en 25 patienten stabiele ziekte met een mediane 
duur van 6 maanden. 
Concluderend kan gesteld warden dat mapatumumab in combinatie met gemcitabine 
en cisplatine veilig is en goed verdragen wordt bij doseringen tot en met 30 mg/kg elke 
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3 weken. Vervolgstudies om deze combinatie verder te evalueren zijn daarom 
aangewezen. 
In toenemende mate wordt het cruciale belang van de micro-omgeving voor 
ontwikkeling van tumoren, migratie en metastasering duidelijk. Angiogene factoren 
spelen hierbij een belangrijke rol. Tivozanib is een oraal beschikbare VEGF-Rl, -R2 en -
R3 tyrosine kinase remmer die zowel in vitro als in preklinische in vivo modellen sterke 
antitumoractiviteit liet zien. Tivozanib blijkt veilig als monotherapie bij patienten met 
gemetastaseerde solide tumoren en laat synergistische antitumor effecten zien in 
combinatie met chemotherapie in preklinische modellen. Aangemoedigd door deze 
data, hebben we de in hoofdstuk 4 gerapporteerde studie opgezet en uitgevoerd. De 
resultaten gepresenteerd in dit hoofdstuk zijn voorlopig, aangezien de studie nog 
voortduurt. In deze dosisescalatie studie werd tivozanib gecombineerd met 
fluorouracil, oxaliplatin en leucovorin {FOLFOX6). Patienten met vergevorderde 
gastrointestinale maligniteiten kwamen in aanmerking voor deze studie. Tivozanib 
werd in tabletvorm gedurende de eerste 21 dagen van elke 28 dagen durende cyclus 
gegeven. Geplande doseringen van tivozanib waren 0,5 mg, 1,0 mg en 1,5 mg per dag. 
Standaard kuren FOLFOX6 werden elke 14 dagen gegeven. Patienten mochten 
doorgaan met tivozanib na het staken van FOLFOX6, mits er geen sprake was van 
progressieve ziekte. De veiligheid van deze combinatie werd nauwgezet geobserveerd 
en farmacokinetische interacties werden bestudeerd. 
In deze nog lopende studie werden 30 patienten met een leeftijd van mediaan 58 jaar 
{range, 40-75 jaar) geevalueerd in de volgende cohorten tivozanib: 0,5 mg {n = 9), 1,0 
mg {n = 3) en 1,5 mg {n = 18). Dosislimiterende toxiciteit met tivozanib 0,5 mg bestond 
uit 1 episode reversibele graad 4 ASAT en ALAT stijging en 1 patient met reversibele 
graad 3 diarree. Er was geen sprake van dosislimiterende toxiciteit met tivozanib 1,0 
mg. Met tivozanib 1,5 mg bestond de dosislimiterende toxiciteit uit een episode graad 
3 duizeligheid en een patient met een graad 3 epileptisch insult in de tweede kuur. 
Andere graad 3/4 bijwerkingen gedurende de studie bestonden tot nu toe met name 
uit hypertensie {n = 11), neutropenie {n = 6) en vermoeidheid {n = 4). Er waren geen 
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aanwijzingen dat studiemedicatie-gerelateerde bijwerkingen van deze combinatie 
meer voorkwamen of ernstiger waren dan de bijwerkingen die werden gezien bij 
alleen FOLFOX6 of alleen tivozanib. Er werden geen farmacokinetische interacties 
gezien. Van de 30 evalueerbare patienten had er 1 een complete tumorrespons, 8 
hadden een partiele tumorrespons en 12 patienten hadden stabiele ziekte. 
Tumorresponsen werden gezien in patienten met oesofaguscarcinoom (n = 4}, 
pancreascarcinoom (n = 2), colorectaal carcinoom (n = 1}, maagcarcinoom (n = 1} en 
dunne darm carcinoom (n = 1}. 
Het combineren van tivozanib met FOLFOX6 lijkt op basis van deze gegevens haalbaar 
en veilig. De aanbevolen dosis tivozanib voor vervolgstudies is 1,5 mg per dag. De 
geobserveerde klinische activiteit rechtvaardigt nader onderzoek bij verschillende 
types gastrointestinale maligniteiten. 
Doelgerichte middelen hebben als gemeenschappelijk eigenschap dat ze gericht zijn op 
een specifiek tumorkenmerk. Heterogeniteit in mate van aanwezigheid van het 
specifieke tumorkenmerk tussen tumoren komt veel voor, maar kan ook varieren in 
een patient met een bepaalde tumortype. Daarnaast is het specifieke tumorkenmerk 
ook niet altijd aanwezig. Het is een uitdaging die patienten te selecteren vooraf aan of 
vroegtijdig tijdens behandeling, die daadwerkelijk baat hebben bij deze behandelingen 
en deze niet te geven aan de overige patienten. Het identificeren van, bij voorkeur 
makkelijk te verkrijgen, predictieve biomarkers zou dit proces kunnen 
vergemakkelijken. Een paging hiertoe is beschreven in het tweede deel van dit 
proefschrift. 
In hoofdstuk 5 hebben we een poging gedaan de verwarrende terminologie van 
"prognostische en predictieve biomarkers" te verhelderen. Een prognostische 
biomarker geeft informatie over de prognose van de patient, onafhankelijk van een al 
dan niet gegeven behandeling. Een predictieve biomarker geeft informatie over het 
effect van een therapeutische interventie. Een predictieve biomarker kan een doelwit 
van de behandeling zijn. We bespraken verschillende voorbeelden van klinisch 
relevante genen, zoals de oestrogeenreceptor (ER}, progesteronreceptor (PR) en 
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HER2/neu bij mammacarcinomen en EGFRl mutaties bij het niet-kleincellig 
longcarcinoom (NSCLC). ER en PR expressie zijn beide voorbeelden van onafhankelijke 
prognostische markers en daarnaast predictieve factoren voor respons op endocriene 
therapie bij patienten met mammacarcinoom. HER2/neu genamplificatie resulteert in 
overexpressie van deze receptor op de celmembraan en is oak van zowel predictieve 
als prognostische waarde bij borstkankerpatienten. Echter, in tegenstelling tot ER 
en/of PR overexpressie, is HER2/neu amplificatie een negatieve prognostische factor. 
De slechtere prognose van patienten met HER2/neu overexpressie vergeleken met 
HER2/neu negatieve patienten wordt "geneutraliseerd" door trastuzumab toe te 
voegen aan chemotherapie in de adjuvante setting. Daarnaast lieten we zien dat 
verschillende tumortypes behandeld kunnen warden door hetzelfde signaalpad te 
blokkeren, zoals bijvoorbeeld EGFR remming bij colorectaalcarcinoom en NSCLC. 
Dezelfde predictieve biomarkers kunnen ook aanwezig zijn in verschillende 
tumortypes, zoals de negatieve predictieve waarde van K-ras mutaties voor het effect 
van EGFR remming bij het colorectaalcarcinoom en bij NSCLC. Echter, EGFR mutaties 
zijn voorspellend voor respons op anti-EGFR therapie in NSCLC, maar niet bij het 
colorectaalcarcinoom. ldentificatie van predictieve biomarkers is van belang voor onze 
inspanningen patientspecifieke therapie op maat te ontwikkelen. Dit is een extra 
argument om zoveel mogelijk studies naar biomarkers te incorporeren in klinische 
studies. 
Ongeveer 5-10% van de patienten met colorectaalcarcinoom hebben een van de twee 
erfelijke vormen, hereditair nonpolyposis colorectaalcarcinoom (HNPCC) of familiaire 
adenomateuze polyposis (FAP). Aangezien bijna alle patienten met deze aandoeningen 
colorectaalcarcinoom ontwikkelen gedurende hun leven, wordt naarstig gezocht naar 
strategieen om tumorontwikkeling te voorkomen. Het non-steroidale anti­
inflammatoire medicijn (NSAID) sulindac reduceert het risico op colorectaalcarcinoom 
in FAP patienten en het effect bij HNPCC patienten is nog onderwerp van onderzoek. 
Het moleculaire mechanisme dat ten grondslag ligt aan dit effect is nag niet compleet 
opgehelderd. Veel studies suggereren een belangrijke rol voor apoptose-inductie via 
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de intrinsieke of de extrinsieke route. Daarnaast zou de Wingless-int (Wnt) route van 
invloed zijn, al dan niet gemedieerd door p21. De Wnt route speelt een belangrijke rol 
in de colorectale carcinogenese. Mutaties in het adenomateuze polyposis coli {APC)­
gen of het f3-cateninegen leiden tot cytoplasmatische accumulatie en toegenomen 
translocatie van f3-catenine naar de celkern. Dit resulteert in activatie van T-cel factor 4 
en aansluitend activatie van een genetisch programma verantwoordelijk voor de 
vorming van adenomen. Actieve Wnt-signalering resulteert daarnaast in verlaging van 
de hoeveelheid p21, waardoor cellen kunnen prolifereren in plaats van differentieren. 
Sulindac metabolieten zorgen voor verminderde f3-catenine-expressie in colorectale 
carcinoomcellen. Bovenal induceert sulindac p21 expressie in een in vitro 
muizenmodel. Met deze achtergrond hebben we in de biomarkerstudie, beschreven in 
hoofdstuk 6, geprobeerd meer inzicht te geven in de chemopreventieve mechanismen 
van sulindac. In biopten van normaal uitziend colonslijmvlies, verkregen bij twee 
eerder gepubliceerde studies, voor en na behandeling met sulindac, werd 
immunohistochemisch gekeken naar de aanwezigheid van apoptotische cellen en naar 
de expressie van TRAIL-Rl, TRAI L-R2, p21 en f3-catenine. Patienten (n = 18) met HNPCC 
kregen twee maal daags 150 mg sulindac gedurende 4 weken in een 
placebogecontroleerde crossover studie. Patienten (n = 6) met FAP kregen tweemaal 
daags 150 mg sulindac gedurende 6 maanden. Apoptotische cellen werden geteld na 
immunohistochemische aankleuring van de apoptosemarker M30 en 
expressiepatronen van TRAIL-Rl, TRAIL-R2, p21 en f3-catenine werden beoordeeld 
middels immunohistochemie. Zowel bij de HNPCC als de FAP patienten was er geen 
verschil in apoptose na behandeling met sulindac. Expressie van TRAIL-Rl en TRAIL-R2 
werd gezien in alle coupes, zonder consistent verschil tussen de placebo/sulindac 
na"ieve groep en het aan sulindac blootgestelde weefsel. De intensiteit van 
membraneuze f3-catenine kleuring was lager in de biopten van HNPCC-patienten 
behandeld met sulindac vergeleken met de placebogroep (p < 0.001). Vergelijkbare 
resultaten werden verkregen in de FAP groep (p < 0.01). P21 expressie voor en na 
sulindac was vergelijkbaar in beide patientengroepen. Sulindac lijkt dus f3-catenine 
expressie te remmen in normaal uitziend colorectaalepitheel van HNPCC en FAP 
154 
Chapter 10 
patienten zonder een effect op apoptose of op de expressie van TRAIL-Rl, TRAIL-R2 en 
p21. We hebben derhalve geen bewijs kunnen vinden voor een bijdrage van de TRAIL­
R route in sulindac-ge"induceerde chemopreventie. Remming van Wnt-signalering lijkt 
echter wel een rol te spelen in het chemopreventieve mechanisme van sulindac. 
Het is niet bekend of het TRAIL-Rl activerende monoklonale antilichaam 
mapatumumab daadwerkelijk tumorcellen bereikt na toediening aan patienten. 
Opregulatie van TRAIL-Rl na chemotherapie werd gezien in humane colorectale 
tumoren dragende muizen. Het effect van chemotherapie op binding van 
mapatumumab aan tumoren is echter niet duidelijk. In hoofdstuk 7 beschreven we de 
opname in tumoren, farmacokinetiek en biodistributie van 111In-gelabeld 
mapatumumab bij patienten met vergevorderde solide tumoren na start en gedurende 
behandeling met gemcitabine, cisplatine en mapatumumab. Patienten mochten 
deelnemen aan deze studie als ze voldeden aan de inclusiecriteria van de hieraan 
voorafgegane fase 1 studie zoals die beschreven is in hoofdstuk 3. Ook de behandeling 
was gelijk aan deze studie. Patienten kregen 150 MBq 111In-mapatumumab iv 1,5 uur 
na start van het mapatumumabinfuus in de 1 e cyclus. Het protocol liet de mogelijkheid 
open, indien tumorlaesies niet duidelijk zichtbaar waren na inclusie van 4 patienten, 
om de tracer 7 dagen voor start van het mapatumumabinfuus in de 1 e cyclus toe te 
dienen. Op de tweede dag van de 3e kuur kregen patienten, 30 minuten voor het einde 
van de therapeutische dosis mapatumumab, opnieuw 150 MBq 111In-mapatumumab 
toegediend. Na 30 minuten en op dag 1, 3 en 6 na injectie van de tracer werden 
planaire scans van het gehele lichaam en single-photon emission computed 
tomography (SPECT) scans gemaakt. Veneus bloed werd afgenomen op verschillende 
tijdstippen tot 312 uur na elke 111In-mapatumumab injectie. TRAIL-Rl expressie in 
tumorweefsel werd bepaald middels immunohistochemie. In 5 van de 12 patienten 
werden 11 van de 18 tumorlaesies, vooraf vastgesteld middels CT, teruggezien op de 
111In-mapatumumab SPECT scans. Er was echter een grate mate van heterogeniteit in 
de tumoropname van 111In-mapatumumab bij deze 5 patienten. Twee 
melanoompatienten lieten opmerkelijk sterke traceropname zien. In 3 van de 5 
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patienten werden alle bekende tumorlaesies gevisualiseerd. De SPECT resultaten van 
de 3e cyclus waren vergelijkbaar met die van de 1 e cyclus. Van 4 patienten met 1111n­
mapatumumab tumoropname was tumorweefsel beschikbaar, waarin bij 3 patienten 
lage cytoplasmatische TRAIL-Rl expressie werd gezien. De intensiteit van aankleuring 
was niet gecorreleerd met 111 1n-mapatumumabopname of tumorrespons op de 
behandeling. 
Concluderend was de tumoropname van 111 1n-mapatumumab in de onderzochte 
patientengroep variabel. De waarde van tumorbeeldvorming bij de selectie van 
patienten voor start van behandeling met mapatumumab dient daarom nader 
geevalueerd te warden. 
De extrinsieke apoptoseroute wordt geactiveerd na binding van een ligand aan TRAIL­
Rl en/of TRAIL-R2. Mutaties in deze receptoren of in andere eiwitten lager uit de 
apoptosecascade spelen mogelijk een rol in insufficiente apoptose-inductie. Recent 
werd het mononucleotide polymorfisme (SNP) A683C in het TNFRSF10A gen, coderend 
voor TRAIIL-Rl, ge"identificeerd. Kankercellijnen die deze variant tot expressie brengen 
bleken minder gevoelig voor rhTRAIL vergeleken met de wild types. In hoofdstuk 8 
hebben we het effect van SNP A683C geanalyseerd in kiembaan DNA materiaal van 
patienten, behandeld met gemcitabine, cisplatine en mapatumumab, uit de eerder in 
hoofdstuk 3 en hoofdstuk 7 beschreven studies. Het effect van het TRAIL-Rl 
polymorfisme A683C in relatie tot toxiciteit en ziektevrije overleving werd hiervoor 
bestudeerd. Genomisch DNA van 44 patienten werd succesvol onderzocht op het 
polymorfisme A683C. Van deze patienten bleken 33 wild type, 9 patienten 
heterozygoot en 2 patienten homozygoot te zijn voor de variant A683C. De hetero- en 
homozygote varianten werden gecombineerd en geanalyseerd als een groep. 
Progressievrije overleving tussen 683A en 683C dragers was niet verschillend. Er 
bestond geen verschil tussen beide groepen in uitgangskarakteristieken en aan de 
behandeling gerelateerde toxiciteit. Gezien het kleine, explorerende karakter van deze 
studie kan een effect op ziekte uitkomst in de subgroep patienten met SNP 683C niet 
worden uitgesloten. Daarvoor zijn grotere, prospectieve studies noodzakelijk. 
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Samenvattend worden in dit proefschrift twee fase 1 studies beschreven met nieuwe, 
doelgerichte medicijnen die veilig gecombineerd kunnen worden met chemotherapie. 
Daarnaast hebben we geprobeerd het chemopreventieve mechanisme van het NSAID 
sulindac bij het colorectaal carcinoom verder te exploreren. Tot slot hebben we 
potentiele predictieve biomarkers voor mapatumumab-bevattende behandeling 
onderzocht. Beide nieuwe, doelgerichte middelen en de onderzochte biomarkers 
zouden potentieel wellicht kunnen worden ge"implementeerd in nieuwe 
behandelstrategieen tegen kanker. 
Algemene discussie en toekomstperspectieven 
In hoofdstuk 3 en 4 hebben we laten zien dat zowel het monoclonale antilichaam 
mapatumumab, gericht tegen TRAIL-Rl en de VEGF-Rl, -R2 en -R3 
tyrosinekinaseremmer tivozanib veilig gecombineerd kunnen worden met 
chemotherapie. Antitumoractiviteit van deze middelen moet uiteraard nog worden 
vastgesteld in fase 2 en fase 3 studies. 
Chemotherapie is nog steeds de basis van de meeste systemische 
antikankerbehandelingen. Met de toenemende kennis over de moleculaire en 
oncogenetische kenmerken van tumoren vindt er echter een verschuiving plaats naar 
doelgerichte middelen, specifiek gericht tegen een bepaald tumorkenmerk. 
Mapatumumab bindt aan TRAIL-Rl en resulteert, via het activeren van een cascade 
van caspases, uiteindelijk in apoptose. Lager in deze apoptoseroute, kan celdood nog 
steeds warden voorkomen door zogenaamde remmers van apoptose {IAP) eiwitten, 
zoals X-gebonden IAP {XIAP). IAP-remmers warden momenteel getest in fase 1 en fase 
2 studies (1). Uit de eerste resultaten blijkt dat het monotherapie-effect maar matig is. 
Recent werd echter duidelijk dat XIAP-remmers het effect van mapatumumab­
ge"induceerde apoptose in pancreascarcinoomcellijnen aanmerkelijk versterken (2). 
Combinatie van beide apoptose-inducerende middelen zou daarom een logische 
volgende stap zijn om verder onderzocht te warden in een klinische studie bij 
kankerpatienten. 
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Apoptose van tumorcellen kan ook warden bereikt door activeren van de p53-
afhankelijke, intrinsieke apoptoseroute. MDM2 is een negatieve regulator van p53 en 
resulteert na complexformatie in proteasomale afbraak van p53. Nutlin-3 is een klein 
molecuul dat bindt aan MDM2, waardoor het de interactie van MDM2 met p53 
tegengaat (3). Onze onderzoeksgroep heeft de MDM2 antagonist Nutlin-3 
gecombineerd met een TRAIL-Rl agonist, wat een duidelijk versterkt apoptosesignaal 
tot gevolg had (4). Alhoewel conceptueel interessant, moeten de veiligheidsresultaten 
van de op dit moment lopende monotherapie fase 1 studies met MDM2 antagonisten 
(NCT01143740, NCT01462175) natuurlijk warden afgewacht, voordat overwogen kan 
warden een MDM2 antagonist te combineren met een TRAIL-Rl agonist. 
Mapatumumab en tivozanib attaqueren verschillende, maar biologisch belangrijke 
routes in kankercellen (5). De meeste maligniteiten zijn niet afhankelijk van een route 
voor tumorgroei en progressie. Voor nieuwe antikankerbehandelingen zullen we dan 
waarschijnlijk zo rationeel mogelijk middelen moeten blijven combineren die op 
verschillende routes aangrijpen. 
Een andere aanpak voor het verbeteren van tumorbehandeling zou kunnen zijn het 
combineren van nieuwe, doelgerichte middelen met radiotherapie. Bijvoorbeeld bij 
patienten met lokaal uitgebreid cervixcarcinoom, waarbij de standaardbehandeling 
bestaat uit radiotherapie en tegelijkertijd cisplatine bevattende chemotherapie. Dit 
behandelschema resulteert in een 5-jaarsoverleving van 66-79%, met nog voldoende 
ruimte voor verbetering (6). De aanzienlijke toxiciteit van deze gecombineerde 
behandeling laat geen ruimte meer voor dosisescalatie van de chemotherapeutica of 
radiotherapie. Derhalve zou toevoegen van doelgerichte medicatie wellicht een optie 
zijn. In cervixcarcinoomcellijnen en -xenografts, resulteerde mapatumumab in 
combinatie met irradiatie in synergistische apoptose-inductie (ongepubliceerde 
resultaten, de Jong) (7). We hebben in de fase 1 studie beschreven in hoofdstuk 3 al 
laten zien, dat toevoegen van mapatumumab aan cisplatine niet leidt tot meer 
bijwerkingen. Op dit moment evalueren we de combinatie van mapatumumab met 
cisplatine en radiotherapie als eerstelijns behandeling bij patienten met uitgebreid 
cervixcarcinoom in een fase lb studie (NCT01088347). 
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Verminderen van mortaliteit ten gevolge van kanker kan ook worden bereikt door 
preventie van de ontwikkel ing van mal igniteiten.  In hoofdstuk 6 hebben we laten zien 
dat de Wnt route een van de onderliggende mechanismen zou kunnen zijn waa rdoor 
sulindac zorgt voor chemopreventie van colorectaalca rcinoom. Er werd geen effect 
gezien op TRAIL-Rl expressie. Recent heeft onze onderzoeksgroep laten zien dat 
sulindac colonadenoomcellen gevoelig maakt voor rhTRAIL-ge"induceerde apoptose. 
Oak hierbij werd geen effect gezien op TRAIL-Rl expressie. Bovendien werd d it effect 
a l leen waargenomen bij cellen met geactiveerde Wnt-signalering (8}. Gezien het milde 
bijwerkingenprofiel van zowel NSAIDs a ls TRAI L-Rl agonisten, zou het interessant zijn 
beide middelen te combineren in chemopreventiestudies voor colorectaalcarcinoom 
en dan met name in de genetisch belaste populatie. 
Kenmerken van zowel tumoren als metastasen zul len in toenemende mate bepalen 
wat de meest optimale systeemtherapeutische behandeling voor de individuele 
patient zal zijn. N iet-invasieve biomarkers, d ie een eventuele tumorrespons reeds voor 
start van deze behandeling kunnen voorspellen, zijn daarvoor zeer welkom.  We 
hebben 1111 n-mapatumumab scintigrafie (hoofdstuk 7} en de TRAIL-Rl 683C variant 
(hoofdstuk 8} onderzocht als potentiele biomarkers. Beide zijn van potentieel kl in ische 
betekenis, a lhoewel ze natuurlijk nog gevalideerd moeten worden in grotere, 
prospectieve studies. 
In fase 1 studies worden patienten ge"includeerd met vergevorderde tumoren 
waarvoor geen standaard behandel ing (meer} beschikbaar is .  Met de huidige 
ontwikkelingen van met name doelgerichte therapieen, zal men steeds meer patienten 
selecteren bij wie het doel voor het medicijn in de tumor oak daadwerkelijk  aanwezig 
is, om zo de kans op het ontwikkelen van nieuwe effectievere (combinatie}therapieen 
te vergroten. Er is a l  een toenemend streven ook in fase 1 studies prospectief, 
potentiele biomarkers te testen. U ite indel ijk zou zo het responspercentage in de 
geselecteerde patientengroep kunnen toenemen en wordt eventuele toxiciteit van een 
niet-effectieve behandeling bij de andere patienten voorkomen. Hopelijk  zal de 
ontwikkeling van op het individu toegespitste behandelingen, gebaseerd op het 
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Samenvatting, algemene discussie en toekomstperspectieven 
moleculaire tumorprofiel van de betreffende patient, uiteindelijk leiden tot een 
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afronden naast de specialistenopleiding is lastig, maar het is gelukt ! Om mijn studies 
goed te laten verlopen, was nauwe samenwerking met tal van mensen een vereiste. lk 
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Mijn promotoren prof. dr. J.A. Gietema, prof. dr. E.G.E. de Vries en prof. dr. S. de Jong. 
Beste Jourik, Liesbeth en Steven. lk wil jullie heel hartelijk danken voor de mogelijkheid 
die jullie me hebben gegeven binnen jullie groep onderzoek te doen. Het voelde als 
een voorrecht in zo'n motiverende, bruisende omgeving te werken. 
Jourik, heel veel dank voor alles. Onder andere voor wat je me hebt geleerd over -de 
specifieke- fase-1 patientenzorg. Daarnaast confronteerde je nauwkeurigheid bij het 
uitoefenen van de wetenschap in z'n voile omvang me regelmatig met mijn eigen kort­
door-de-bocht-zijn. Het heeft mijn denken genuanceerd en de manuscripten werden 
er altijd beter van. 
Liesbeth, vele malen kwam ik met een, in mijn ogen, probleem bij je binnen. Er was 
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richtinggevende aanwijzing of oplossing. Het is slechts een van de aspecten die je 
snelheid en overzicht kenmerken. Je bent een enorme drive voor mijn promotie 
geweest. Bedankt voor alles. 
Steven, je onuitputtelijke biologische kennis deed me regelmatig duizelen, maar ik heb 
er erg veel van geleerd. Terwijl ik af en toe voorzichtig over het translationele muurtje 
richting laboratorium keek, vertaalde jij moeiteloos de laboratoriumresultaten naar de 
kliniek. Dat maakt het voor een dokter prettig samenwerken met jou. Heel erg veel 
dank daarvoor. 
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Heel veel dank ben ik verschuldigd aan a lle patienten die hebben meegewerkt aan 
onze onderzoeken. In waarschijn l ijk de moeilijkste fase van hun leven gaven ze 
toestemming voor deelname in een van de studies en zo hebben ze bijgedragen de 
kenn is over kankerbehandelingen verder te vergroten. 
Fase-1 stud ies in Groningen doe je samen met Rotterdam. Prof. dr. J. Verweij, prof. d r. 
S. Sleijfer, dr. F.A.L.M.  Eskens, dr. W.J . Loos, beste Jaap, Stefan, Ferry en Walter, dank 
voor de prettige samenwerking. 
Dr. C.H. Mom, beste Stijn .  M ijn promotietraject began met het overnemen van jouw 
studies. Het begin was daardoor flitsend, ik sprang op een rijdende trein. Heel erg 
bedankt daarvoor. 
Beste Martine (den Hollander). lk heb mijn studies vol vertrouwen aan je over kunnen 
dragen. lk  wens je heel veel succes met het afronden van jouw boekje. 
Beste Gerry (Sie l ing) . Zander jouw ondersteuning bij (onder andere) het kinetieken 
was het moei l ijk geworden al le buisjes bloed op tijd af te nemen, laat staan op 
vakantie te kunnen. Heel erg bedankt voor al les. 
Alie co-auteurs, bedankt voor de altijd goed verlopende, efficiente samenwerking. 
Dr. E.C.F. Dijkers, beste Eli. Bedankt voor de prettige samenwerking tijdens ans 
mapatumumab-imaging project. Het was een uitdaging de vele data overzichte l ijk  te 
duiden en op te schrijven, maar het resultaat mag er zijn ! 
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